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Abstract
Abstract
The pure anti-oestrogen faslodex presents a valuable therapeutic option for post-menopausal 
women with endocrine-sensitive advanced breast cancer. However, emergence of resistance 
following long-term treatment constitutes a major clinical problem as faslodex-refractory 
disease is associated with poor prognosis. Consequently, elucidation of the mechanisms 
underlying resistance is imperative. An in vitro MCF-7 cell model of acquired resistance to 
faslodex (FAS-R) has been developed in our laboratory. Previous studies using this model 
revealed endocrine insensitivity to be accompanied by development of an invasive phenotype. 
Since proteolytic degradation of extracellular matrix components by matrix metalloproteinases 
(MMPs) is a prerequisite for tumour invasion and metastasis, the objective of this project was 
to explore the role of these proteases and tissue inhibitors of matrix metalloproteinases 
(TIMPs) in die aggressive behaviour of faslodex-resistant breast cancer cells. Additional 
studies were performed to identify the dominant growth factor signalling pathway regulating 
these pro-invasive events.
MMP and TIMP mRNA expression in FAS-R cells was variable. MMP-2 mRNA was 
increased in FAS-R cells compared with WTMCF-7 cells. Significantly, treatment with a 
broad-spectrum MMP inhibitor significandy reduced the invasive behaviour of FAS-R cells 
suggesting a central role for. MMPs in FAS-R invasion. Importantly, FAS-R cells were found 
to overexpress c-Met receptor tyrosine kinase which, when activated by HGF/SF, induced 
latent MMP-9 protein expression and considerably augmented the motile, migratory and 
invasive capacities of these cells. Both ERK1/2 and PI3K/AKT pathways were activated by 
HGF/SF, and signalling through both resulted in increased secretion of latent MMP-9 protein. 
However, HGF/SF-enhanced FAS-R cell invasion was only suppressed by inhibition of the 
P13K/AKT pathway or following treatment with the MMP inhibitor.
Collectively, these data suggest that in FAS-R cells HGF/SF/c-Met signalling enhances 
aggressive behaviour via PI3K-mediated MMP-9 secretion. c-Met may therefore present a 
therapeutic target in faslodex resistance.
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Chapter One
Introduction
“N o problem  can stand the assault o f  sustained thinking. ” 
Francis M arie Arouet de Voltaire (1694-1778)
Chapter One -  Introduction
1 Introduction
1.1 Breast Cancer Incidence and Mortality Rates
The past decade has witnessed a sustainable decline in breast cancer mortality 
rates in Western Europe, Australia and North and South America; a development 
which is primarily due to the introduction of routine mammographic screening, 
more precise diagnosis and appropriate treatment regimes which notably 
includes extensive use of tamoxifen (Veronesi et al., 2005, Boyle, 2005, Peto 
and Mack, 2000). In the UK, breast cancer mortality rates have declined 
steadily; and it is estimated that 8 out of 10 patients survive beyond five years as 
opposed to only 5 out of 10 in the 1970s (http://info.cancerresearchuk.org/ 
cancerstats/types/breast/).
In contrast, the rates for breast cancer incidence have been rising steadily. 
Worldwide, more than 1 million women are diagnosed with breast cancer every 
year. The highest incidence rate is found in the USA (Jemal et al., 2008). In the 
UK, over 45,500 women were diagnosed in 2006, which equals to about 125 
women a day. (http://info.cancerresearchuk.org/cancerstats/types/breast/).
Breast cancer is now the most common female cancer in the UK. 1 in 9 women 
will contract the disease at some point in their lifetime (Quinn et al., 2008) with 
approximately 80% of cases occuring in post-menopausal women. Furthermore, 
breast cancer is the second most common cause of death from cancer in women, 
second only to lung carcinoma, (http://info.cancerresearchuk.org/cancerstats/ 
types/breast/).
As these statistics clearly demonstrate, breast cancer continues to constitute a 
major global health issue despite the not insubstantial advancement in terms of 
disease control. The failure to prevent incidence rates from rising is 
predominantly due to a failure to understand the underlying mechanisms of 
breast carcinogenesis and illustrates that breast cancer remains a complex
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disease with an aetiology that is only poorly understood.
1.2 Risk Factors
Several risk factors thought to contribute to the development of breast cancer 
have been identified (table 1.1), however, many remain ill-defined and further 
epidemiological studies are needed to clarify their role. One of the most well- 
established risk factors is familial history of the disease, especially if linked with 
mutations in high penetrance breast cancer susceptibility genes such as BRCA1, 
BRCA2 and the tumour suppressor p53 (Collaborative Group on Hormonal 
Factors in Breast Cancer, 2001). However, this genetic predisposition accounts 
for only a small percentage of all cases. The majority of breast tumours are 
caused by hormonal factors; and prolonged exposure to oestrogens, caused by 
early menarche, late first full-term pregnancy and late menopause or the use of 
exogenous hormones such as hormone replacement therapy and oral 
contraceptives have been identified as key risk factors (Beral, 2003; Berkey et 
al., 1999; Hankinson et al., 2004; Medina, 2004). The single greatest risk factor, 
however, is age; with the relative risk of developing the disease increasing 
significantly after the menopause (McPherson et al., 2000; Veronesi et a l , 
2005). Another established risk determinant is geographic location; as 
demonstrated by epidemiological studies that showed breast cancer to be more 
prevalent in Western populations such as the US and the UK as opposed to in 
countries such as India, Japan and China (McPherson et al., 2000; Morton et al., 
2002; Parkin & Fernandez, 2006). Interestingly, studies of migrants who moved 
from low-incidence countries to high-incidence countries revealed that the rate 
of incidence of the host country was assumed within just one or two generations 
(Parkin, 2004; Ziegler et al., 1993). Such findings emphasise that socio­
economic status along with environmental and life-style factors such as weight, 
poor diet, increased alcohol consumption and lack of physical exercise also 
contribute to the risk of developing breast cancer (Boyle, 2005; Dumitrescu & 
Cotarla, 2005).
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Risk factors Relative risk
Family history, e.g. BRCA1 and BRCA2 gene 
mutations
> 2
Menarche before age 11 3
First full term pregnancy after age 40 3
Relative risk falls by 4.3% for every
Nulliparity or absence o f  breastfeeding 12 months o f  breastfeeding in 
addition to 
a 7% reduction for every birth
Onset o f  menopause after age 54 2
Use o f  hormone replacement therapy 1.66
Use o f  oral contraception 1.2
Age Relative risk increases significantly
after menopause
Geographic location, i.e. living in developed 5
countries
Diet 1.5
Postmenopausal body weight, e.g. body mass
2
index >35
Alcohol consumption 1.07
Table 1.1 Established and probable risk factors for breast cancer developm ent.
(Adapted from Veronesi et a l., 2005 and McPherson et a l., 2000).
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13 Endocrine Therapy in the Treatment of ER-positive Breast 
Cancer
The functional link between oestrogens and breast cancer was first established 
by Albert Schinzinger who had observed that cessation in ovarian function 
resulted in atrophy of the breast (Schinzinger et al., 1889). In 1896, George 
Beatson demonstrated mammary tumour regression following oophorectomy 
and thus introduced the first successful endocrine manipulation of advanced 
breast cancer (Beatson, 1896). It was the work of these two pioneers that 
established the concept of manipulation of the endocrine system as a treatment 
for breast cancer. In 1936, this hypothesis was further developed by Antoine 
Lacassagne who reasoned that, if breast cancer was due to an inherent sensitivity 
to oestrogen, the disease could be prevented through the use of agents that would 
antagonise the effects of oestrogen (Lacassagne, 1936). This essentially presents 
the rationale for present-day anti-oestrogen therapy which will be delineated in 
more detail in section 1.3.3. However, first an overview of oestrogens and their 
receptor and signalling functions in breast cancer is required before the mode of 
action of anti-hormone agents can be fully appreciated.
13.1 Breast Cancer and Oestrogens
Oestrogens are a group of sex steroid hormones synthesized from cholesterol 
and secreted by the ovaries and, to a lesser extent, by adrenal glands, adipose 
tissue and placenta. They occur naturally in several structurally related forms, 
the predominant intracellular oestrogen being 17p-estradiol (E2) (figure 1.1) 
(Lewis & Jordan, 2005).
5
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Figure 1.1 Structure o f 17/f-estradiol.
(from Nicholson and Johnston, 2005)
E2 is secreted primarily by the ovaries and its synthesis is controlled by the 
pituitary gonadotrophins follicle-stimulating hormone (FSH) and luteinising 
hormone (LH) (Ali & Coombes, 2002). Despite the many beneficial effects 
oestrogens have on womens’ health including cardiovascular protection and 
maintenance o f bone mineral density, there is a wealth o f evidence that supports 
an important role for E2 , in particular, in the stimulation and progression of 
malignant cancer o f the breast (Morris & Wakeling, 2002). Oestrogens mediate 
most, if not all, o f their functions via two receptors, ERa and ERp (Gustafsson, 
2000; Toft et al., 1967), which belong to the nuclear receptor gene superfamily 
and function as ligand-activated transcription factors (Weinberg et al., 2005). 
Whilst ERa (henceforth referred to as ER) is considered to be the predominant 
regulator o f oestrogen-induced genes in breast cancer (Fuqua et al., 2003), the 
role o f ERp in oestrogen-signalling is currently ill-defined and will therefore not 
be considered further in this thesis.
1.3.2 ER Structure and Signalling
Briefly, ER is a modular protein, consisting o f 6 distinct functional domains, 
designated A-F, which are depicted in figure 1.2 (Tsai & O'Malley, 1994). The 
A/B domain refers to the N-terminus and encodes a hormone-independent 
transcriptional activation function (AF-1), which is involved in transcriptional 
activation o f target gene expression. Domain C corresponds to the highly 
conserved DNA binding domain (DBD). The DBD consists o f two functionally 
distinct zinc-finger motifs which are responsible for the recognition and binding 
o f oestrogen-response-elements (EREs) located in the promoter sequences of
6
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oestrogen-regulated genes (Schwabe et al., 1993). Domain D, the hinge region, 
separates the DBD from the ligand-binding domain (LBD). The flexibility 
resulting from this structure is thought to allow the conformational changes that 
occur in the receptor during its activation and is also important in receptor 
dimerisation. Domain E/F at the C-terminus o f the ER molecule encodes the 
LBD, a hydrophobic pocket responsible for E2 binding (Brzozowski et al., 
1997). The LBD additionally harbours a second transcriptional activation 
function (AF-2) which is hormone-dependent and activates target gene 
transcription in response to E2 by recruiting and tethering co-activators to the 
ER.
N
AF-1 DBD Hinge
•ERE site re8 ion 
recognition 
•DNA binding
AF-2 and LBD 
•hormone binding 
•chaperone protein binding 
•co-regulator binding 
•dimerisation
Figure 1.2 O estrogen receptor domain structure.
Schematic diagram depicting the 6 domains o f  the ER and their respective functions.
ER signalling mechanisms are more complex than initially supposed with three 
distinct modes identified so far (Lewis & Jordan, 2005; Nicholson & Johnston, 
2005; Osborne & Schiff, 2005); these are briefly outlined below.
1.3.2.1 ‘Classical' Genomic ER Signalling
In the classical mechanism of ER action, E2 diffuses through the cell membrane 
and into the nucleus where it binds to the LBD of the ER which is associated 
with the molecular chaperone heat shock protein90 (hsp90). The binding of E2 to 
the LBD induces a conformational change in the receptor which results in hsp90 
dissociation, ER phosphorylation and dimerisation. The stable E2 :ER dimer
7
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complex then binds the EREs located in the 5’-promoter regions of oestrogen- 
responsive genes. Once bound to the EREs, the ligand-occupied receptor 
complex recruits additional proteins, i.e. nuclear receptor co-activators and co- 
repressors, which respectively promote or repress oestrogen-regulated gene 
transcription. Whilst binding of E2 leads to co-activator recruitment such as 
A1B1 (amplified in breast cancer 1), binding of Selective Estrogen Receptor 
Modulators (SERMS) typically results in co-repressor recruitment such as 
NCoRl, NCoR 2 and SMRT (silencing mediator for retinoid and thyroid 
receptor), and consequently in the inhibition of transcription of genes that 
regulate cell-cycle progression, proliferation and apoptosis. It is thought that the 
ratio of co-activator to co-repressor is one of the many factors that impact on the 
resistance of some breast cancers to therapy with SERMs (Schiff et al.y 2003).
1.3.2.2 ‘Non-Classical’ Genomic ER Signalling
Interestingly, approximately one third of genes regulated by the ER do not 
contain ERE-like sequences (Weinberg et al., 2005), with the ER modulating 
gene expression at alternative regulatory sites such as AP-1 (activator protein 1), 
SP-1 (specificity protein 1) and other poorly defined non-ERE sites (Kushner et 
al., 2000; Safe, 2001; Saville et al., 2000). In these instances, ERs do not bind to 
the DNA directly and function as transcription factors but instead act as co­
activators themselves, stabilising the tethering of transcription factors such as the 
AP-1 complex Fos/Jun and SP-1 to the DNA and recruiting other co-activators 
to the binding site. Several genes essential to growth factor signalling, including 
the genes encoding insulin-like growth factor 1, cyclin Dl, myc and the 
antiapoptotic factor Bcl-2, are regulated in this manner and it is thought that 
these alternative signalling pathways may play a contributory role in the 
development of resistance to therapy with SERMs.
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1.3.2.3 Non-Genomic ER Signalling
In addition to nuclear or genomic ER signalling, E2 can also result in very rapid 
effects that occur too quickly to involve transcriptional mechanisms; this 
phenomenon is referred to as ‘non-genomic’ ER signalling or membrane- 
initiated steroid signalling (MISS) and is mediated by extranuclear cytoplasmic 
or plasma membrane-associated ER (Kelly & Levin, 2001), which directly binds 
to growth factor signalling elements such as HER-2, EGFR, IGFR1, the p85 
subunit of phosphatidyl inositol 3 kinase (PI3K), Src and She. This leads to 
AKT/PKB and MAPK pathway activation resulting in powerful survival and 
proliferation responses.
Importantly, this cross-talk between the ER and growth factor receptors operates 
in both directions; hence growth factor and intracellular kinase pathways can in 
turn enhance ER signalling. This bi-directional molecular communication is also 
thought to be involved in the development of resistance against SERMs (refer to 
section 1.4).
1 3 3  Antihormonal Agents
Prior to endocrine therapy initiation, the hormone receptor status of the tumour 
needs to be established. ER and progesterone receptor (PR) presence is an 
important predictor of response to endocrine therapy (McGuire & Clark, 1992), 
and is usually associated with a lower rate of cell proliferation, evidence of 
tumour differentiation and consequently more favourable prognosis (Platet et al., 
2004; Weinberg et al., 2005). Approximately 70% of breast cancers are ER- 
positive at diagnosis. In contrast, ER-negativity is a significant clinical feature 
present in 30% of breast cancer patients at presentation and also in some 
previously ER-positive tumours at the point of tamoxifen relapse (Gee et al., 
2005). Negative receptor status is generally linked to poor prognosis, precluding 
response to endocrine therapy and resulting in a more proliferative and 
aggressive phenotype (Kinne et al., 1987; Kuukasjarvi et al., 1996; Maynard et 
al., 1978; Nicholson et al., 2005; Pari et al., 1984; Putti et al., 2005). Since the
9
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initial recognition of breast cancer as an oestrogen-dependent disease, three main 
strategies have been developed to block the action of oestrogen on tumour cells:
• Inhibition of oestrogen binding to the ER by using Selective Estrogen 
Receptor Modulators (SERMs) such as tamoxifen (Lewis & Jordan, 
2005)
• Prevention of oestrogen synthesis using the aromatase inhibitors (AIs) 
anastrozole, letrozole and exemestane (Coombes et al., 2003)
• Downregulation of cellular ER levels using the Selective Estrogen 
Receptor Downregulator (SERD) fulvestrant (Johnston, 2004).
These three avenues of oestrogen signalling inhibition are further explored 
below.
1.3.3.1 Tamoxifen (Nolvadex™)
The non-steroidal triphenylethylene derivative tamoxifen (Nolvadex™, 
AstraZeneca Pharmaceuticals Ltd.) (figure 13) was the first anti-oestrogen to be 
developed.
Figure 13 Structure of the SERM tamoxifen.
(from Nicholson and Johnston, 2005).
It is classed as a ‘SERM’ based on its ability to act as both an ER agonist and 
antagonist (Lewis & Jordan, 2005). Tamoxifen achieves its antineoplastic effect 
by competition for binding to the ER with endogenous circulating oestrogen. As 
opposed to E2, which facilitates interaction of the ER with nuclear co-activators, 
tamoxifen induces a conformational change in the ER which prevents co­
activator recruitment and leads to the recruitment of co-repressors
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instead, thus inhibiting transcription of oestrogen-responsive genes (Lewis & 
Jordan, 2005). However, tamoxifen impairs only AF-2, and as a consequence 
AF-1 activation, ER dimerisation and nuclear translocation of the tamoxifen-ER 
complex to the EREs of target genes still occur, resulting in incomplete 
inactivation o f ER-regulated transcription (Adamo et al., 2007). This partial 
agonist effect is thought to explain the serious adverse events often associated 
with tamoxifen therapy such as endometrial cancer, thromboembolic events and 
gynaecological complications (Nicholson & Johnston, 2005).
1.3.3.2 Aromatase Inhibitors
While tamoxifen has been the gold standard adjuvant treatment for 
postmenopausal women following primary surgery, this unfavourable side effect 
profile as well as de novo and acquired resistance necessitated the development 
o f alternative therapeutic agents.
In postmenopausal women, conversion o f androgens to oestrogens occurs 
through the action o f the cytochrome P450 enzyme aromatase in peripheral 
tissues such as adipose tissue and muscle, as detailed in figure 1.4 below.
Arom atase 17pH SDl
Androstenedione Oestrone 17p-estradiol
Arom atase
Testosterone — 17p-estradiol
Figure 1.4 Arom atase-m ediated conversion o f androgens to oestrogens.
The androgens androstenedione and testosterone are converted into the oestrogens oestrone and 
17fLestradiol through the actions o f  the enzymes aromatase and 17p-hydroxy steroid 
dehydrogenase type 1 (17pH S D l) (Suzuki et al., 2008).
Therefore, AIs have been developed to suppress cytochrome P450 enzyme 
aromatase activity which results in reduced circulating 17p-estradiol levels. This 
in turn inhibits oestrogen-regulated gene transcription via nuclear and non­
nuclear pathways and thus removes the growth stimulus for ER-positive breast
11
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carcinomas (Adamo et al., 2007; Smith & Dowsett, 2003). Third generation AIs 
can be divided into two groups, the nonsteroidal AIs anastrozole (Arimidex®, 
AstraZeneca Pharmaceuticals Ltd.) and letrozole (Femara®, Novartis 
Pharmaceuticals Corp.), and the steroidal Al exemestane (Aromasin®, 
Pharmacia Corp.). They can be further subclassified according to their mode of 
action. While anastrozole and letrozole bind the aromatase cytochrome P450 
moiety reversibly, exemestane has an irreversible action on the enzyme 
(Lonning, 2004). AIs possess both favourable efficacy and tolerability profiles. 
Moreover, due to the lack of cross-resistance between non-steroidal and steroidal 
AIs, these agents can be used sequentially which results in prolonged clinical 
benefit for the patient (Bertelli, 2005).
Recently, large, randomised trials such as the ATAC (Anastrozole, Tamoxifen 
Alone or in Combination), BIG 1-98 (Breast International Group 1-98) and 
MA.17 trials have demonstrated that therapy with third generation AIs leads to 
superior results compared to five years of therapy with tamoxifen, and AIs are 
now challenging the 25-year reign of tamoxifen as the first-line adjuvant of 
choice in early breast cancer. As a consequence, third-generation AIs are now an 
important therapeutic option for the adjuvant treatment of ER-positive early 
breast cancer in postmenopausal women, and are recommended as the preferred 
therapy by ASCO (American Society for Clinical Oncology), St. Gallen 
International Expert Consensus and NICE (National Institute for Health and 
Clinical Excellence) guidelines (Goldhirsch et al., 2005; Winer et al., 2002). 
Where tamoxifen is given as first-line treatment, treatment with this agent is 
routinely discontinued after five years, as recommended by the National Cancer 
Institute guidelines. However, the optimal treatment schedule for the sequential 
use of tamoxifen and AIs in the adjuvant setting is yet to be established; and 
whilst the overall tolerability of AIs is similar to that of tamoxifen, further safety 
studies are required to assess the long-term toxicities associated with Al therapy.
12
Chapter One -  Introduction
1.3.3.3 Fulvestrant (Faslodex™)
Both resistance to existing antihormonal agents and the partial agonist action of 
tamoxifen made necessary the development o f novel ER antagonists that lack 
partial agonist properties, leading to the synthesis o f fulvestrant (7a-[9- 
(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]estra-l,3,5-(10)-triene-3,17, /?-diol), 
a steroidal 7a-alkylsulphinyl analogue of 17/?-estradiol (Howell et al., 2000). 
Like tamoxifen, fulvestrant (Faslodex™, AstraZeneca Pharmaceuticals Ltd.) 
(figure 1.5) competitively inhibits binding o f 17/?-estradiol to the ER.
Figure 1.5 Structure o f  the SERD fulvestrant.
(from Nicholson and Johnston, 2005).
However, fulvestrant has a much stronger affinity for the ER than tamoxifen. 
While tamoxifen binds to the ER with a binding affinity which is only 2.5% that 
o f 17/?-estradiol, fulvestrant displays an ER-binding affinity o f 98% (Wakeling 
& Bowler, 1987; Wakeling et al., 1991). In terms o f chemical structure, 
fulvestrant is distinctly different from the non-steroidal tamoxifen, raloxifene 
and other SERMs. Due to the steric hindrance caused by its long alkylsulphinyl 
side chain, fulvestrant induces a different conformational shape in the ER to that 
achieved by SERMs (Johnston, 2004). This results in inhibition o f ER 
dimerisation (Parker, 1993), reduced nuclear localisation of the drug-receptor 
complex (Dauvois et al., 1993; Fawell et al., 1990) and subsequent prevention of 
ER binding to EREs in the promoters o f oestrogen-responsive genes (Gibson et 
al., 1991; Osborne et al., 1995). Additionally, any fulvestrant-ER complex that 
does enter the nucleus is transcriptionally inactive as fulvestrant disables both 
transcriptional activation functions, AF-1 and AF-2, which results in complete 
abrogation o f oestrogen-sensitive gene transcription. Furthermore, the drug-ER
OH
HO (CH2)9SO(CH2)3CF2CF3
13
Chapter One -  Introduction
complex is unstable which leads to accelerated degradation of the ER protein 
and downregulation of cellular ER levels (Dauvois et al., 1992; Fawell et al., 
1990; Nicholson et al., 1995); this downregulation of cellular ER protein occurs 
without reduction in ER mRNA levels (Osborne et al., 2004). Thus, fulvestrant 
binds, blocks and accelerates degradation of the ER, resulting in pure anti- 
oestrogenic action (Carlson, 2005; Wardley, 2002); fulvestrant is hence referred 
to as a ‘pure’ anti-oestrogen and classed as a ‘selective oestrogen receptor 
downregulator’ (SERD) (Howell et al., 2000).
Following the development of fulvestrant, numerous Phase II and Phase III 
clinical trials were initiated to establish clinical efficacy and appropriate 
positioning within the endocrine sequence cascade. A brief overview of the 
largest and most significant trials is given below.
The efficacy of fulvestrant in tamoxifen-resistant advanced breast cancer was 
demonstrated in two Phase III clinical trials, trials 0020 and 0021, which 
compared the tolerability and efficacy of fulvestrant with those of anastrozole 
(Howell et al., 2002; Osborne et al., 2002). A prospectively planned combined 
analysis of the data from both trials showed fulvestrant to be at least as effective 
as anastrozole in terms of time to progression (TTP); moreover, objective 
response (OR), clinical benefit (CB) and median duration of response were also 
similar. A subsequent combined analysis of survival data found that there was no 
significant difference in the median overall survival between tamoxifen and 
fulvestrant treatment (Howell & Buzdar, 2005). Based on these findings, 
fulvestrant received regulatory approval as second-line treatment for 
postmenopausal women with hormone-sensitive advanced breast cancer after 
progression or relapse on tamoxifen therapy in several countries.
A double-blind, randomized Phase III trial, trial 0025, subsequently compared 
fulvestrant with tamoxifen as first-line treatment for postmenopausal women 
with ABC (Howell et al., 2004). However, although fulvestrant is at least as 
effective as anastrozole in the second-line setting (Robertson et al., 2003), the
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pure anti-oestrogen did not meet the criteria for non-inferiority to tamoxifen in 
the intent-to-treat population.
New Phase II and III clinical trials investigating additional roles for fulvestrant 
following prior non-steroidal Al treatment or as first line-therapy in combination 
with monoclonal antibodies or small molecule inhibitors are currently in 
progress or have already yielded results (Robertson, 2007) (see table 1.2). In 
addition, various loading-dose (LD) and high-dose (HD) regimens of fulvestrant 
are being evaluated in order to establish an optimum treatment plan.
15
Population Phase
Fulvestrant + bevacizumab MBC, post-AI II
Fulvestrant + trastuzumab ER+ and/or PR+, HER2-overexpressing stage IV BC II
Fulvestrant ± lapatinib ditosylate Stage III or IV HER2-expressing hormone-receptor-positive BC III
Fulvestrant + gefitinib ER+ and/or PR+ ABC or MBC II
Fulvestrant + tipifamib ER+ and/or PR+, inoperable LABC or MBC progressing after prior first-line endocrine therapy II
Table 1.2 Details of current trials o f fulvestrant plus monoclonal antibodies and small molecule inhibitors.
(Adapted from Adamo et al., 2007).
MBC, metastatic breast cancer; BC, breast cancer; ABC, advanced breast cancer; LABC, locally advanced breast cancer.
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Two randomised, controlled Phase III trials, EFECT (Evaluation of Faslodex™ 
and Exemestane Clinical Trial) and SoFEA (Study of Faslodex with or without 
concomitant Arimidex vs Exemestane following progression on non-steroidal 
Aromatase inhibitors), compared the tolerability and efficacy of fulvestrant vs 
exemestane in postmenopausal women who showed disease progression or 
recurrence following prior non-steroidal Al therapy (table 13). The EFECT trial 
is now closed and the results show fulvestrant LD and exemestane to be equally 
active and well-tolerated in a meaningful proportion of postmenopausal women 
with ABC who have experienced progression or recurrence during treatment 
with a nonsteroidal Al (Chia & Gradishar, 2008; Chia et al., 2008). The SoFEA 
trial, in contrast, is currently on-going and recruiting participants; trial results are 
awaited with great interest (http://www.clinicaltrials.gov/ct2/show/record/ 
NCT00253422; (Dodwell et al., 2008; Robertson, 2007).
Two additional trials, FACT (Fulvestrant and Anastrozole Clinical Trial) and 
SWOG 226 (Southwest Oncology Group 226), to compare the efficacy of 
fulvestrant plus anastrozole with anastrozole alone as first-line therapy are 
currently on-going (table 13). Both clinical trials are presently recruiting 
patients, and trial outcomes are eagerly anticipated (http://www.clinicaltrials. 
gov/ct2/show/record/NCT00075764).
17
■■ Phase Population Treatment regime Patients Status
EFECT III Post-nonsteroidal Al Fulvestrant LD 250mg vs exemestane 660 Closed
SoFEA ■■ III Post-nonsteroidal Al Fulvestrant LD 250mg ± anastrozole vs exemestane 750 Currently recruiting
SWOG 226 III First-line Fulvestrant 250mg + anastrozole vs anastrozole 690 Currently recruiting
Table 1.3 Details o f trials o f fulvestrant in comparison with AIs and of fulvestrant plus an Al in comparison to Al monotherapy. (Adapted from Johnston et al., 2004). 
EFECT, Evaluation o f  Faslodex and Exemestane Trial; SoFEA, Study o f  Faslodex without or without concomitant arimidex vs Exemestane following progression on non­
steroidal Aromatase inhibitors; SWOG 226, Southwest Oncology Group 226.
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In summary, while not quite as effective in hormone-receptor-positive advanced 
breast cancer as tamoxifen, fulvestrant showed the same efficacy as anastrozole 
as second-line therapy and also the same efficacy as exemestane following 
progression on first-line non-steroidal Al therapy. Furthermore, when comparing 
the side effects of fulvestrant with those of tamoxifen and anastrozole 
respectively, fulvestrant was found to be well tolerated and associated with a 
lower incidence of joint disorders (Vergote & Abram, 2006). Importantly, it has 
also been demonstrated that sensitivity to further endocrine therapy following 
progression on first-line or second-line fulvestrant therapy is retained due to its 
lack of cross-resistance with existing endocrine agents (Buzdar, 2004). This 
observation is of particular importance as it allows flexible positioning of 
fulvestrant within the sequential endocrine agent cascade. This in turn will 
enable clinicians to achieve the aim of extending effective duration of well- 
tolerated treatment and will also allow patients to derive maximum benefit 
before cytotoxic chemotherapy with all its associated side effects becomes 
necessary (Carlson, 2002). As these data illustrate, fulvestrant is a versatile new 
treatment option for post-menopausal women with advanced or metastatic breast 
cancer who have progressed on prior endocrine therapy.
1.4 Resistance to Endocrine Therapy
Resistance to anti-oestrogen therapy is classified as ‘intrinsic’, also known as de 
novo, or ‘acquired’. De novo resistant tumours are either ER-negative or do not 
respond to therapy despite positive ER status. Acquired resistance, in contrast, 
describes a state in which initially responsive ER-positive disease ceases to 
respond to antihormonal treatment after long-term therapy. While only 50% of 
all ER-positive tumours are responsive to endocrine agents such as tamoxifen at 
first presentation, in the metastatic setting most initially responsive tumours 
eventually become non-responsive; this results in rapid disease progression and 
high patient mortality (Osborne, 1998). Clearly, both resistant states severely 
limit the effectiveness of endocrine agents and therefore present a major
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therapeutic challenge in the clinical management of breast cancer (Gee, 2006; 
Nicholson & Johnston, 2005).
While the causative mechanisms for endocrine resistance are multi-factorial and 
so far only partially comprehended, co-activator to co-repressor ratio in the 
tumour cell milieu (refer to section 1.3.2.1) and bi-directional cross-talk between 
oestrogen and growth factor signalling (refer to section 1.3.2.3) have been 
identified as important contributory factors that induce and sustain non­
responsiveness to anti-hormone therapy (Nicholson et al., 2005; Nicholson et al., 
2007; Osborne & Schiff, 2003; Schiff et al., 2003). Interestingly, it is envisaged 
that increased growth-factor-driven kinase activity does not only directly 
promote cell proliferation but also efficiently phosphorylates key serine residues 
within the AF-1 domain of the ER. Phosphorylation of these serine residues, in 
particular serine 118 which presents a target for MAPK, re-activates ligand- 
independent ER signalling which results in re-expression of oestrogen-regulated 
genes and consequently in continued growth in the presence of anti-oestrogens 
(Bunone et al., 1996; Kato et al., 1995). Also, growth factor signalling pathways 
can promote ER co-activator phosphorylation which again results in the re­
expression of oestrogen-regulated genes and continued proliferation (Font de 
Mora & Brown, 2000). Furthermore, as delineated in section 1.3.2.3, non- 
genomic ER signalling links the ER to growth factor receptors which also leads 
to sustained cell survival and proliferation.
As with tamoxifen, patients unfortunately do eventually progress on fulvestrant, 
and with increased use, fulvestrant resistance will pose a considerable clinical 
problem, potentially limiting the benefits of this novel ER antagonist (Buzdar, 
2004; Cheung et al.9 2006; Robertson et al.9 2005).
In order to investigate the mechanisms underlying such acquired resistance, 
several in vitro breast cancer models displaying acquired resistance to 
antihormones have been established at the Tenovus Centre for Cancer Research 
(TCCR); these include tamoxifen-resistant, tamoxifen- and gefitinib-resistant 
and faslodex-resistant MCF-7 cells (TAM-R, TAM-/TKI-R and FAS-R cells,
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respectively). Significantly, characterisation studies carried out on these cell 
lines have demonstrated that inappropriate activation of growth factor signalling 
cascades is one of the key factors in antihormone resistance (Jones et al., 2005; 
Knowlden et al., 2003), with resistant cells displaying remarkable flexibility in 
recruiting alternative signalling pathways to circumnavigate the need for 
oestrogen for continued growth.
Intriguingly, while the role of altered growth factor signalling in endocrine 
resistance has been firmly established, more recent in-house studies on the 
TAM-R model have demonstrated that such drug-resistant growth in these cells 
is associated with a gain in migratory and invasive behaviour, driving a very 
aggressive phenotype (Hiscox et al.9 2004; Hiscox et al., 2006). Furthermore, 
endocrine refractory disease in the clinic invariably results in rapid disease 
progression and is associated with a poor prognosis (Nicholson et al., 2007), 
mirroring these in vitro observations.
Collectively, these findings illustrate the role of aberrant growth factor signalling 
in anti-hormone failure and concomitant enhanced metastatic potential and 
hence emphasize the urgent need for the delineation of the underlying molecular 
basis which will permit the development of successful combined targeting 
strategies to prevent, delay or overcome the resistant state and thereby 
significantly improve breast cancer survival.
1.5 Invasion and Metastasis
The ability of tumour cells to invade, colonise and impair the function of distant 
organs was first recognised by Jean-Claude Recamier in 1829. He termed this 
phenomenon ‘metastasis’. This multi-step process involves a series of 
sequential, obligatory events termed the ‘metastatic cascade’ (figure 1.6).
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Figure 1.6 M etastatic cascade.
Diagram depicting the stages primary cancer cells must go through to successfully establish 
themselves at a metastatic site. (Adapted from Geho et a l., 2005).
Extravasation 
into stroma
Proliferation 
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Angiogenesis 
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site
First, cancer cells detach from neighbouring cells and penetrate the basement 
membrane and the interstitial stroma by way of enzymatic activity of 
strategically secreted proteases. They then invade both blood and lymphatic 
vessels, thereby gaining access to the circulatory system in a process known as 
‘intravasation'. Circulating tumour cells that successfully evade both anoikis and 
immunogenic surveillance attach to platelets and leukocytes forming emboli that 
are eventually arrested in the microcirculation o f the target organ; furthermore 
they can also be arrested on the basis o f their physical size or even directly 
interact with vessel walls. Finally, metastatic cells extravasate, i.e. they exit 
blood and lymph vessels where, after resuming proliferation, they can undergo 
local expansion in the parenchyma of distant organs (Geho et al., 2005; Guo & 
Giancotti, 2004).
Thus, metastasis is an intricate interplay between altered cell adhesion, localised 
proteolysis at the invasive front, migration, lymph- and angiogenesis, evasion of 
immune surveillance and apoptosis, and homing on target organs involving 
profound changes in the adhesive, motile and invasive properties of primary 
tumour cells.
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Breast carcinomas preferentially metastasise to bone, lung and liver (Weigelt et 
al., 2005); and the presence of metastatic disease remains the primary cause of 
mortality in breast cancer patients.
In spite of the obvious clinical relevance of metastases, the inherently occult 
nature of these processes unfortunately means they are a challenging subject 
matter to study. Nonetheless, technological advances such as microarray 
expression profiling to identify new molecular markers and ‘poor prognosis 
signatures’ predictive of metastatic disease (Duffy, 2005; Minn et al., 2005; van 
't Veer et al., 2003; van de Vijver et al., 2002) and in vivo video microscopy to 
follow the fate of cancer cells inside the body (Chambers et al., 2002) have 
furthered our knowledge. Whilst the traditional models of metastasis based on 
the work of Leighton (Leighton, 1965) and Fidler (Fidler, 1973) consider 
metastatic capacity to be a late, acquired event in tumourigenesis, new research 
challenges these long-held tenets suggesting that breast cancer is an inherently 
systemic disease with metastasis being an intrinsic capacity of all primary breast 
cancer cells (Bernards & Weinberg, 2002).
Regrettably, despite these findings, the prognosis for patients with advanced 
invasive and metastatic disease remains exceedingly poor, highlighting the 
pressing need for ongoing research and development of novel and effective anti- 
invasive treatments to overcome this impasse.
1.6 Matrix Metalloproteinases
The sheer complexity of proteolytic systems operating in human tissues is 
challenging, with human genome sequencing having revealed over five hundred 
protease-like proteins, many of which are associated with cancer dissemination 
(Puente & Lopez-Otin, 2004). However, among all the proteases linked to 
metastatic spread, matrix metalloproteinases (MMPs) are considered the most 
influential (Folgueras et al., 2004). MMPs are a family of zinc- and calcium- 
dependent endopeptidases collectively capable of degrading essentially all 
components of the extracellular matrix (ECM) (Westermarck & Kahari, 1999)
23
Chapter One -  Introduction
and therefore associated with a variety of processes that involve matrix 
degradation and remodelling. They were first discovered when Gross and 
Lapiere described collagenolytic activity in tadpole tail resorption during 
metamorphosis (Gross & Lapiere, 1962). The structure, regulation and 
multifunctional roles of these proteases are delineated below, current inhibition 
strategies also being considered.
1.6.1 Domain Structure and Function
The availability of the complete human genome sequence and recent genomic 
studies have permitted identification and structural analysis of the entire set of 
24 MMPs produced in human tissues. Based on their domain structure, MMPs 
can be divided into six groups: collagenases (MMP-1, MMP-8 and MMP-13), 
gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3 and MMP-10), 
matrilysins (MMP-7 and MMP-26), membrane-type MMPs (MT1-MMP to 
MT6-MMP) and other MMPs (figure 1.7) (Lemaitre & D'Armiento, 2006; Visse 
& Nagase, 2003). All family members with the exception of membrane-type 
MMPs contain an N-terminal signal peptide which directs the proenzyme for 
secretion. This predomain is followed by a prodomain which contains a 
conserved sequence in which a cysteine residue forms a covalent bond with a 
catalytic zinc ion located in the active site; this so-called cysteine switch 
maintains the latency of pro-MMPs. The catalytic domain contains the highly 
conserved zinc-binding site in which the zinc ion is coordinated by three 
histidine residues. A proline-rich hinge region links the catalytic domain to the 
hemopexin domain which mediates multiple protein interactions. It is involved 
in MMP activation and determines the substrate specificity (Pavlaki & Zucker, 
2003).
Six distinct membrane-type MMPs have been identified; and localisation at the 
cell surface is achieved through a C-terminal type I transmembrane domain 
(MT1-, MT2-, MT3- and MT5-MMP) or by a glycosylphsophatidylinositol 
anchor (MT4- and MT6-MMP) (Zucker et a!., 2003).
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Figure 1.7 Schem atic diagram o f M M P domain structure.
Diagram showing domain structure o f  each o f  the 6 MMP groups, with complexity and size 
decreasing in descending order (adapted from Folgueras et a l 2004). Zn2+, catalytic zinc ion; 
TM-I, transmembrane-I; GPI, glycosylphosphatidyl.
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1.6.2 Regulation of MMP Activity
Whilst MMPs are essential for physiological tissue turnover and homeostasis, 
uncontrolled proteolytic activity has clearly been shown to contribute to a 
plethora of pathologies such as arthritis, cardiovascular disease and cancer. 
Precise regulation of protease activity is therefore crucial in order to avoid the 
potentially devastating consequences of excessive tissue degradation. Not 
surprisingly, MMP expression and activity is tightly controlled at the level of 
gene transcription, proenzyme activation and enzyme inhibition (Clark et al., 
2008; Folgueras et al., 2004; Overall & Lopez-Otin, 2002).
1.6.2.1 Gene transcription
In general, levels of MMP expression in unstimulated cells in vitro and intact 
tissue in vivo are low and only induced when ECM remodelling is required 
(Curran & Murray, 2000; Vihinen et al., 2005). Expression of certain MMPs is 
induced by a wide variety of stimuli ranging from growth factors and cytokines 
to cell-cell and cell-matrix interactions (Benbow & Brinckerhoff, 1997; 
Westermarck & Kahari, 1999). The promoter regions of these inducible MMP 
genes (MMP-1, MMP-3, MMP-7, MMP-9, MMP-10, MMP-12 and MMP-13) 
contain an activator protein-1 (AP-1) binding site (Benbow & Brinckerhoff, 
1997; Pendas et al., 1997). In addition, polyoma enhancer A binding protein-3 
(PEA3) sites have been identified in the promoters of MMP-1, MMP-3 and 
MMP-9 (Crawford et al., 2001; Westermarck & Kahari, 1999). The cytokines 
and growth factors that activate MMP expression typically act via the MAPK 
pathway which comprises the ERK1/2, JNK/SAPK1/2 and p38 proteins and 
include EGF (Epidermal Growth Factor), TGF-a (Transforming Growth Factor 
a) and HGF/SF (Hepatocyte growth Factor/Scatter Factor) (Bjorklund & 
Koivunen, 2005). In contrast, the promoters of the non-inducible, constitutively 
expressed MMP family members MMP-2, MMP-11 and MT-l-MMP do not 
contain AP-1 binding sites. More recently, further characterisation studies have 
revealed Spl, Tcf/Lef-1, NFkB and RARE to be additional cis-acting elements
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in MMP promoter regions (Clark et al., 2008). Overall, control of MMP gene 
transcription is cell and tissue-specific, temporally variable and complex.
1.6.2.2 Proenzyme activation
MMPs are synthesised as inactive zymogens (pro-MMPs) (Harper et al., 1971; 
Okada et al., 1988). As outlined previously, latency is achieved through the 
interaction of the cysteine residue in the prodomain with the zinc ion bound to 
the catalytic site (‘cysteine switch’) (Windsor et al., 1991); and activation 
requires proteolytic removal of the prodomain (Van Wart & Birkedal-Hansen, 
1990). While the majority of MMPs in vivo are activated extracellularly or on 
the cell surface by other MMPs or serine proteases, intracellular activation by 
furin-like serine proteases has been described for the MT-MMPs, MMP-11, 
MMP-23 and MMP-28 (Pei & Weiss, 1995; Yana & Weiss, 2000). In vitro, 
several non-proteolydc agents such as thiol-modifying agents and SDS as well 
as heat and low pH result in zymogen activation through disturbance of the zinc- 
cysteine interaction of the cysteine switch (Van Wart & Birkedal-Hansen, 1990).
1.6.2.3 Enzyme inhibition
MMP activity is blocked by general inhibitors such as a2-macroglobulin as well 
as by specific endogenous inhibitors, tissue inhibitors of metalloproteases 
(TIMPs), which non-covalently bind to the zinc-binding site in the catalytic 
domain of active MMPs (Willenbrock & Murphy, 1994). Four homologous 
TIMPs (TIMP-1 to TIMP-4) have been identified (Brew et al., 2000). With the 
exception of TIMP-3, which is anchored in the ECM, these cysteine-rich 
proteins are secreted. They share a conserved structure which consists of an N- 
terminal domain, a C-terminal domain and three disulfide bonds (Williamson et 
al., 1990). The inhibitory activity of these proteins suggests that the net balance 
between the MMPs and their tissue-specific inhibitors is the primary determinant 
of the proteolytic potential of a tumour. This concept has been supported by 
several studies demonstrating that while TIMP overexpression results in reduced 
experimental metastasis (DeClerck & Imren, 1994), low TIMP levels correlate
27
Chapter One -  Introduction
with tumourigenesis (Khokha & Denhardt, 1989). However, more recent studies 
ascribing angiogenic and tumour-promoting functions to these proteins suggest 
more complex and even paradoxical roles for TIMPs in cancer (Jiang et al., 
2002)).
1.63 MMP Functions
While MMPs were initially characterised as matrix-degrading proteases, more 
recent identification of numerous novel substrates has forced us to revise our 
perhaps overly simplistic view of MMP proteolytic activity. By way of their 
ability to process additional substrates such as growth factors and their receptors, 
cell adhesion molecules, chemokines, cytokines, apoptotic ligands and 
angiogenic factors MMPs are now recognised as signalling molecules rather than 
just ordinary ‘weapons of mass destruction’. It is this substrate diversity which 
reflects the varied and sometimes even paradoxical functions that are now 
attributed to this protease family. Specific examples of the myriad of cellular 
processes controlled by MMPs are given below.
1.6.3.1 Apoptosis
Evasion of apoptosis permits cancer progression by allowing cell survival in the 
presence of low oxygen and nutrient levels, attack from the immune system and, 
most importantly, after detachment from the ECM - a prerequisite for invasion 
and metastasis (Reed, 1999). Due to the proteolytic activity MMPs have on 
various biologically active molecules, MMPs can positively or negatively 
regulate cell survival in a context-dependent manner (Hojilla et al., 2003). 
MMP-3, MMP-7, MMP-9 and MMP-11 have been shown to regulate apoptosis 
(Egeblad & Werb, 2002). MMP-7, for example, releases membrane-bound Fas 
ligand which triggers apoptosis upon binding the Fas receptor (Powell et al., 
1999). Conversely, MMP-7 can also inhibit apoptosis by generation of mature 
heparin-binding epidermal growth factor (HB-EGF) which promotes survival by 
stimulating the ERBB4 tyrosine kinase receptor (Yu et al., 2002).
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1.6.3.2 Angiogenesis
Angiogenesis is a prerequisite for continued tumour growth as the newly formed 
blood vessels function as conduits for gas exchange and nutrient supply (Chang 
& Werb, 2001). MMPs are regarded as essential regulators of angiogenesis 
because of their ability to stimulate endothelial cell proliferation and migration 
through mobilisation of latent growth factors and receptor shedding. MMPs 
promote angiogenesis by increasing the bioavailability of vascular endothelial 
growth factor (VEGF), fibroblast growth factor 2 (FGF-2) and transforming 
growth factor-p (TGF-P). However, MMPs also act anti-angiogenically through 
the cleavage of plasminogen and collagen XVIII which results in the generation 
of the angiogenesis inhibitors angiostatin and endostatin (Egeblad & Werb, 
2002; Mott & Werb, 2004).
1.6.3.3 Escape from immune surveillance
While the immune system functions to recognise and eliminate tumour cells, the 
latter have developed several strategies to escape this immune surveillance by 
utilising MMPs. Sheu et al. (2001) showed that MMPs cleave the interleukin-2- 
receptor-a on T-lymphocytes thereby blocking T-cell proliferation while Gorelik 
et al (2001) reported MMP-mediated TGF-p liberation, resulting in suppression 
of T-cell reactions against cancer cells. Cleavage of various members of the CC 
and CXC chemokine families blocks leukocyte attraction and thus assists the 
tumour cells in circumventing the host anti-tumour defense systems (McQuibban 
et al., 2000).
1.6.3.4 Cell growth and proliferation
Cell proliferation is primarily controlled through the interaction of growth- 
promoting or growth-suppressing factors with their respective cell-surface 
receptors; and MMPs facilitate this interaction via several mechanisms. One 
such mechanism is the cleavage of matrix components bound to growth factors. 
Growth factors such as FGF preferentially bind to certain matrix components so
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that cleavage o f these matrix molecules leads to liberation of the associated 
growth factor. MMP-1 and MMP-3 - mediated cleavage of the proteoglycan 
perlecan, for example, releases FGF (Whitelock et al., 1996). In addition to their 
proteolytic action on ECM components, MMPs also cleave non-matrix 
substrates which again results in the release o f growth factors. Proteolysis o f the 
Insulin Like Growth Factor-Binding Protein (IGF-BP), for example, results in 
the generation of active IGF ligand (Fowlkes et al., 1994). Finally, MMPs also 
directly cleave and thereby activate growth factors; MMP-2 and MMP-9- 
mediated processing o f TGF-p, for example, results in active ligand generation 
(Yu & Stamenkovic, 2000).
1.6.3.5 Cell migration
Coordinated regulation o f cell-cell attachment, cell-matrix attachment and 
matrix remodelling is a prerequisite for cell migration. The diverse nature of 
their substrates has made the proteolytic action of MMPs seemingly 
indispensable to all aspects o f the migration process (see figure 1.8).
Migration direction
Invading cell
►Matrix degradation
►Disruption o f  cell-cell interactions
►Disruption o f  cell-matrix adhesion
►Exposure o f  cryptic migration-promoting sites
►Liberation o f  matrix-associated growth factors and
cytokines
Breached basement membrane
Cell surface-associated MMPs localised at the invasive front
Figure 1.8 The functions o f  M M Ps in cell m igration.
(Adapted from BjOrklund and Koivunen, 2005).
For example, MMPs function in the direct modulation o f cell-matrix adhesion by 
both removing adhesion sites and exposing binding sites. MMP-2-mediated 
cleavage o f laminin-5 results in the release o f the y-chain o f this basement 
component and the exposure o f a cryptic promigratory site (Giannelli et al., 
1997). MMPs can furthermore modulate attachment and migration through 
direct cleavage of cell-cell or cell-matrix receptors; examples are MMP-7-
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mediated cleavage of p4integrin (von Bredow et al., 1997) and MMP-3 and 
MMP-7-mediated proteolysis of the cell adhesion molecule E-cadherin (Noe et 
a l, 2001).
1.6.4 Implication of MMPs in Invasion and Metastasis 
As mentioned earlier, cancer cells must dissociate from their primary tumour and 
traverse several tissue barriers in order to metastasize. By way of their ability to 
process ECM and non-ECM substrates, to induce angiogenesis and cell 
migration and to promote evasion of apoptosis and host defense systems, MMPs 
are considered to be vital for tumour progression.
The concept that proteolytic activity could be critical for cell matrix degradation 
and the subsequent invasion of tumour cells into the surrounding stroma was 
pioneered several decades ago (Fisher, 1946). Individual proteases began to be 
identified in the 1970s, and in 1980 Liotta et al demonstrated that the metastatic 
potential of various tumours correlated directly with the ability of cancer cells to 
degrade basement membrane collagen (Liotta et al., 1980). Since then, countless 
in vivo and in vitro studies have suggested a role of MMPs in tumour cell 
dissemination. Importantly, many MMPs including MMP-9 and MMP-2 were 
originally cloned from cancer cell lines or tumours (Curran & Murray, 2000). 
Enhanced MMP expression has been observed in many solid tumours, including 
cancers of the breast, and is usually accompanied by acquisition of an invasive 
phenotype, advanced stage metastatic disease and decreased overall survival 
(Fingleton, 2008; Mannello et a l , 2005).
Recent mouse model and patient transcriptome studies validated by in vitro data 
further highlight the pivotal roles of MMPs in metastasis. In a ‘poor prognosis’ 
signature of primary breast carcinomas, two of the 70 genes associated with 
short interval to distant metastasis were MMP-1 and MMP-9 (van ft Veer et al, 
2003; van de Vijver et a l, 2002) while in another ‘poor prognosis’ signature of 
95 genes which mediate breast cancer metastasis to the lung the second most 
important gene was MMP-1 (Minn et a l, 2005).
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Overall, the evidence for a role of MMPs in metastasis is compelling; and it is 
this prevailing view of proteases promoting tumour progression that prompted 
the development of synthetic MMP inhibitors.
1.6.5 MMPs as Therapeutic Targets
Currently, MMP inhibitors belong to five categories: peptidomimetics, non- 
peptidomimetics, chemically modified tetracyclines (CMTs), bisphosphonates 
and natural inhibitors (see table 1.4).
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M M P Inhibitor Com pany Structure Specificity
Batimastat British Biotech Peptidomimetic Broad spectrum 
(B B -94) ^
llomastat
(G M -6001)
Gly corned Peptidomimetic Broad spectrum
Marimastat British Biotech; Peptidomimetic Broad spectrum
BB-2516) Schering-Plough
Tanomastat 
(B ay-12-9566)
Bayer Non-peptidomimetic
Higher specificity 
towards 
MMP-2, MMP-3 and 
M M P-9
Prinomastat Agouron; Pfizer Non-peptidomimetic Broad spectrum 
(A G -3340)
BM S-275291
Bristol-Myers 
Squibb; Celltech
Non-peptidomimetic Broad spectrum
CGS27023A Novartis Non-peptidomimetic Broad spectrum
Broad spectrum;
Metastat Collagenex CMT higher
(COL-3) specificity towards
MMP-2 and MMP-9
Neovastat Sterna
Natural MMP inhibitor 
(shark cartilage extract)
Broad spectrum
T able 1.4 M M P inhibitors along with their structures and specificities.
Overview o f  the most important MMP inhibitors most o f  which have undergone clinical 
development which has been halted due to disappointing outcomes (Konstantinopoulos et al., 
2008; Overall and Kleifeld, 2006).
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In retrospect, the development of MMP inhibitors was problematic from the very 
beginning. Administration of endogenous MMP inhibitors was the first attempt 
at therapeutic MMP inhibition after several studies had demonstrated the ability 
of TIMPs to inhibit tumour growth in transgenic mouse models (Kruger et al., 
1997; Martin et al., 1999). However, difficulties with administration and poor 
pharmacokinetics further compounded by the paradoxical effects of these 
multifunctional proteins severely limited the feasibility of using TIMPs in cancer 
therapy (Folgueras et al., 2004), thus highlighting the need for synthetic MMP 
inhibitors.
Over the past twenty-five years, the pharmaceutical industry has made an 
impressive effort to develop and establish specific, well-tolerated small molecule 
inhibitors as new anticancer agents. The first generation of MMP inhibitors to be 
developed were the peptidomimetics, pseudopeptide derivatives synthesised to 
mimic the structure of collagen at the site that binds to the catalytic domain of 
MMPs. Both Batimastat (BB-94) and its successor Marimastat (BB-2516) are 
examples of these early MMPIs that feature a hydroxamic acid zinc-chelating 
group which binds competitively and reversibly to the catalytic site of their 
target (Pavlaki & Zucker, 2003). Improved oral bioavailability as well as more 
acceptable pharmacokinetics were obtained through the subsequent design of 
non-peptidomimetic inhibitors such as Tanomastat (BAY12-9566) and 
Prinomastat (AG3340) which were synthesised on the basis of the 3-dimensional 
conformation of the MMP zinc-binding site (Mannello et al., 2005; Vihinen et 
al., 2005). However, despite extremely promising activity in a plethora of 
preclinical models, these compounds failed to demonstrate a statistically 
significant survival advantage in Phase III clinical trials for most human 
malignancies (Fingleton, 2003; Fingleton, 2008; Overall & Lopez-Otin, 2002), 
and a consequence, most MMP inhibitor development programs have been 
halted. So far, the only MMP inhibitor approved for clinical use is the 
collagenase inhibitor Periostat (AG-3340) in the treatment of adult periodontitis 
(Peterson, 2004).
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In hindsight, the lack of efficacy of MMP inhibitors is not surprising. Both drugs 
and trials were designed at a time when knowledge of MMPs was still 
fragmentary, in terms of family members and their pleiotropic role in tumour 
progression. Since then, multiple etiologies have been proposed for the poor 
clinical performance of MMP inhibitors. Clearly, the utility of animal models to 
predict clinical outcome in humans was limited (Fingleton, 2008). Moreover, 
Phase III evaluation involved advanced stage cancers whereas patients with 
earlier stage disease might have derived more benefit (Bramshall et al., 2002). 
Lack of a validated surrogate marker for effective inhibition meant that it was 
impossible to determine whether the optimal biologic dose had been achieved; 
and some trial results further revealed MMP inhibitors to have a very narrow 
therapeutic index as patients who derived the greatest benefit concomitantly 
developed musculoskeletal toxicities (King et al., 2003). However, the most 
fundamental cause for the failure of Phase III trials was the inadvertent 
inhibition of beneficial protease activity which effectively counterbalanced the 
benefits of drug target inhibition. Indeed, at its inception, the idea of targeting 
proteolytic activity was inextricably linked to the basic assumption that all MMP 
activity was detrimental and that therefore indiscriminate inhibition would be 
desirable. However, more recent studies with mouse models of gain and loss of 
MMP function have shown certain MMPs to display host-protective functions 
(Balbin et al., 2003; Hamano et al.9 2003; Pozzi et al., 2002). As a consequence, 
MMP family members are currently being categorised into drug ‘targets’ and 
‘anti-targets’ (Overall & Dean, 2006; Overall & Kleifeld, 2006) (see figure 1.9).
35
Chapter One  -  Introduction
MMPs in Carcinogenesis
‘T A R G E T S’ 
MMPs that promote 
cancer
MMP-1
MMP-2
MMP-7
ECM degradation
Angiogenesis promotion
Tumour growth stimulation
Anti-apoptotic effect
osteoclast activation and bone 
resorption
MMPs that demonstrate both 
pro-tumourigenic and anti­
tumour effects
MMP-3
MMP-9
Chemical carcinogenesis 
protection
Angiogenesis promotion
Malignant transformation 
promotion
‘A NTITARG ETS’
MMPs with anti­
tumour effects
I
MMP-8 
MMP-12 
M MP-14
Tumour growth inhibition 
angiogenesis inhibition 
innate immunity against cancer 
tumour metastasis inhibition
Figure 1.9 Target and Anti-target status o f  MM Ps.
While som e MMPs exert clear cancer-promoting or anti-cancer targets, some MMPs play a dual role 
in carcinogenesis (Konstantinopoulus et a l 2007; Overall and Kleifeld, 2006).
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MMP-1, MMP-2 and MMP-7 have been confirmed as valid drug targets whilst 
MMP-8, MMP-12 and MMP-14 have been designated anti-target status as they 
seem to exert only anticancer effects (Konstantinopoulos et al., 2008). Even this 
classification is not without caveats, since studies have revealed MMPs to exert 
both positive and disease-promoting functions in the same disease, contributing 
to the pathology at early stages but being host-protective in advanced disease 
setting (Fingleton, 2008). Target and anti-target status is also likely to vary 
between individual cancer types and patients, further emphasizing the 
complexity of the MMP proteolytic system in cancer. What is becoming 
increasingly apparent with time is that precise identification of target MMPs for 
each disease setting and innovative chemistries that permit the synthesis of lead 
compounds that spare anti-targets over MMP targets are an absolute prerequisite 
if the third generation of MMP inhibitors are to form part of the drug armament 
against cancer in the future. However, despite these obstacles, the quest for 
specific and well-tolerated molecular therapeutics for MMP inhibition remains 
an exciting area of cancer research, and as recent reports on novel compounds in 
the chemical literature prove, there is a continued effort and sustained interest in 
meeting this goal.
1.7 HGF/SF and c-Met
Deregulated receptor tyrosine kinase (RTK) activity is a common feature of 
many human malignancies and is often associated with the acquisition of an 
invasive phenotype. While HGF/SF/c-Met-signalling-induced cellular responses 
are usually tightly regulated and required for many normal physiological 
processes such as wound healing and during embryogenesis, aberrant c-Met 
activation has been implicated in most types of solid tumours. Deregulated c- 
Met signalling is furthermore often associated with metastatic disease and has 
hence been recognised as a powerful expedient for cancer dissemination. The 
structure and function of HGF/SF and c-Met as well as current therapeutic 
strategies aimed at targeting this ligand-receptor complex are delineated below.
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1.7.1 HGF/SF Structure and Regulation
HGF/SF is a pleiotropic cytokine so named due to its discovery both as a potent 
mitogen for hepatocytes (Nakamura et al., 1984; Nakamura et al., 1989) and as a 
fibroblast-derived factor which promotes cell motility or ‘scattering’ (Stoker & 
Perryman, 1985). The protein was subsequently purified as a disulfide-linked 
heterodimer consisting o f a 69-kDa a-chain and a 34-kDa p-chain (Nakamura et 
al., 1989) (figure 1.10).
a-chain p-chain
  n n n n  R V ________
SP HL K1 K2 K3 K4 I—  S-----S—^
Signal peptide (SP)
Hairpin loop (HL)
Kringle (K) domain
D isu lp h id e bond  
Arg494 
Val495
Figure 1.10 Schem atic diagram  o f the structure o f  HGF/SF.
The a-chain consists of an N-terminal hairpin loop followed by four canonical 
kringle domains which are 80 amino acid double-looped structures stabilised by 
three internal disulfide bridges (Comoglio, 1993). The high-affinity binding site 
for its receptor, the receptor tyrosine kinase c-Met, is located in the first kringle 
domain, while the hairpin loop and the second kringle domain form a low- 
affinity binding site for membrane-associated heparin sulphate proteoglycans. 
The p-chain contains a serine proteinase homology domain but lacks enzymatic 
activity as a result o f amino acid substitutions in the catalytic site (Maulik et al., 
2002). HGF/SF is synthesised and secreted by mesenchymal cells as a single­
chain, inactive precursor (pro-HGF/SF) which is subsequently proteolytically 
converted into an active disulfide-linked a-p-chain heterodimer by serine
3 8
n
S-S
R
V
Chapter One  -  Introduction
proteinases such as urokinase-type Plasminogen Activator (uPA) and tissue 
Plasminogen Activator (tPA), coagulation factors X, XI and XIII and HGF 
activator (HGFA) (Mars et al., 1993; Parr et al., 2004), (Naldini et al., 1992). 
Factors that regulate the expression and secretion of HGF/SF include 
interleukins, injurin and glucocorticoids (Jiang et al., 2005). The immediate 
HGF/SF regulatory system consists of its main activator HGFA and the two 
HGFA inhibitors, HAI-1 and HAI-2 (Parr et al., 2004).
1.7.2 c-Met Structure and Function
The Met oncogene was originally isolated from a human osteogenic sarcoma cell 
line that had been chemically mutagenised in vitro (Cooper et al., 1984). A 
translocated promoter region locus (TPR) from chromosome 1 was placed 
upstream of a portion of the Met gene on chromosome 7, and the resultant TPR- 
MET fusion protein displayed constitutively active Met kinase activity (Park et 
al., 1986). Whilst HGF/SF is produced by surrounding mesenchymal cells, c- 
Met is predominantly expressed in epithelial cells.
The HGF/SF receptor is a transmembrane protein encoded by the MET proto­
oncogene (Bottaro et al., 1991). Its precursor protein is synthesized as single 
polypeptide chain which is then proteolytically processed into a mature, 
disulphide-linked 185kDa Met heterodimer (Migliore & Giordano, 2008). This 
heterodimer comprises an entirely extracellular a-subunit linked to a p-subunit 
which consists of a large extracellular region involved in ligand-binding, a 
transmembrane domain, a j uxta-membrane domain, a tyrosine kinase domain 
and C-terminal docking site (Gao & Vande Woude, 2005; Maulik et al., 2002). 
The extracellular segment of the c-Met receptor is subdivided into a Serna 
domain, a PSI domain (originally found in plexins, semaphorins and integrins) 
and four IPT domains (related to immunoglobulin-like domains present in 
plexins and transcription factors) (figure 1.11) (Comoglio et al., 2008).
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Sema domains
3-subunit PSI domain
IPT domain
a-subunit
Cj> Ig4
Figure 1.11 Schem atic diagram  o f the m odular structure o f  the extracellular domain o f the c- 
Met receptor.
IG, immunoglobulin-like domain; PSI, plexin-semaphorin-integrin; IPT, immunoglobulin-like 
domain in plexins and transcription factors.
Upon activation by its ligand HGF/SF, c-Met undergoes autophosphorylation o f 
specific tyrosine residues within its intracellular domain. Y1234 and Y1235 are 
located in the activation loop o f the tyrosine kinase domain (figure 1.11) 
(Ferracini et a l 1991). When inactive, this activation loop is in a ‘closed’ 
conformation and therefore inaccessible to substrates and ATP (Gentile & 
Comoglio, 2004). Upon ligand binding, the Met-Met dimers stabilise, and the 
activation loop is unlocked by trans-autophosphorylation o f Y 1234 and Y1235 
(Longati et al., 1994). Thus the phosphorylation o f these tyrosine residues 
positively modulates the intrinsic kinase activity of the receptor (Naldini et al., 
1991a; Naldini et al., 1991b) while negative regulation is achieved through 
phosphorylation of a serine residue (S985) in the juxta-membrane segment 
(Gandino et al., 1994).
Once activated, the Met-Met dimers induce intramolecular phosphorylation of 
the tyrosine residues Y1349 and Y1356 located in the C-terminal (Gentile & 
Comoglio, 2004). These residues, along with the adjacent amino acids, constitute
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the so-called multi-substrate docking site. Upon phosphorylation, this 
promiscuous motif mediates interactions with multiple SH2-domain-containing 
adaptors and signal transducers. Gab-1, an adaptor protein unique to c-Met, 
mediates most of the complex cellular responses to c-Met activation (Sachs et 
al., 2000; Weidner et al., 1996). Upon binding, Gab-1 is phosphorylated at 
several tyrosine residues which are required for recruiting downstream signalling 
molecules such as the non-receptor tyrosine kinase src (Ponzetto et al., 1994), 
the lipid kinase PI3K (Ponzetto et al., 1994) and the transcription factor STAT3 
(Boccaccio et al., 1998).
1.73 HGF/SF/c-Met Signalling in Invasion and Metastasis
As the name suggests, HGF/SF induces a potent scattering response in epithelial 
cells (Stoker & Perryman, 1985). Scattering involves cell spreading, cell-cell 
dissociation and cell migration. Attenuation or dissolution of cell-cell adhesions 
is achieved by HGF/SF-mediated p-catenin phosphorylation (Hiscox & Jiang, 
1999a), cadherin-shedding (Davies et al., 2001) and redistribution of E-cadherin 
(Hiscox & Jiang, 1999b). This, however, is just one of the pleiotropic responses 
c-Met activation evokes. The full complement of c-Met induced changes has 
been termed ‘invasive growth’ (Corso et al., 2005); and the main signalling 
aspects of this genetic program are outlined below.
As briefly mentioned before, activation of c-Met results in the recruitment of 
scaffolding proteins such as Gabl and Grb2, which in turn activate Shp2, Ras 
and ERK/MAPK (Birchmeier et al., 2003). This alters gene expression of cell- 
cycle regulators such as pRB, Cdk6 and p27 which promotes cell cycle 
progression and proliferation, increases synthesis and secretion of extracellular 
matrix proteinases such as MMPs and uPA which facilitate invasion, and also 
modifies the cytoskeletal functions which results in enhanced proliferation, 
migration and invasion (figure 1.12) (Birchmeier et al., 2003).
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Figure 1.12 Diagram o f c-M et phosphorylation and substrate-binding sites.
Diagram detailing the downstream signalling molecules bound by Y1349 and Y1356 and the 
pleiotropic cellular responses elicited. The negative regulatory site (Serine 985) and the 
tyrosine residues o f  the kinase domain, Y1234 and Y 1235, are also shown. To the far right the 
5 main domains o f  c-Met are indicated. (Modified from Birchmeier et al., 2003)
G abl, growth-factor-receptor-bound protein 2 (Grb2)-associated binder 1; PI3K, 
phosphatidylinositol 3-kinase; PLCy, phospholipase Cy; She, Src-homology-2 (SH2)-domain- 
containing; Shp2, SH2-domain-containing protein tyrosine phosphatase 2; Grb2 and GrblO, 
growth-factor-receptor-bound protein 2 and 10; Ship, SH2-domain-containing inositol-5- 
phosphatase; p85 refers to the regulatory subunit o f  P13K.
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Moreover, Gab-1-mediated activation of PI3K-AKT/PKB promotes cell survival 
through inhibition of caspase-9 and Bad (Xiao et al., 2001). Overall, the 
regulation of cell motility, cell dissociation, cell adhesion and invasion 
downstream of Gab-1 was shown to be dependent on both ERK 1/2 and PI3K 
pathways as demonstrated in experiments utilising specific pharmacological 
inhibitors (Potempa & Ridley, 1998). Finally, c-Met signalling has also been 
shown to evoke a powerful angiogenic response (Rosen et al., 1993). In 
summary, the c-Met pathway activates a program of cell dissociation and 
motility coupled with increased protease secretion, promotion of angiogenesis 
and evasion of apoptosis which results in tumour invasion and metastatic 
progression.
Not surprisingly, c-Met and HGF/SF signalling activities have emerged as a 
crucial feature of virtually all human malignancies including breast cancer 
(Knudsen & Vande Woude, 2008; Peruzzi & Bottaro, 2006). Furthermore, 
aberrant c-Met activation, mostly due to transcriptional upregulation in the 
absence of gene amplification, is often linked to high tumour grade and poor 
prognosis (Jeffers et al.9 1996). By way of promoting proliferation, angiogenesis, 
survival and invasion inappropriate HGF/SF/c-Met signalling participates in all 
stages of malignant progression, and thus represents a promising drug target for 
molecular cancer therapy.
With the exception of c-Met receptor transactivation, ligand binding must occur 
before c-Met receptor dimerisation and autophosphorylation can take place. 
Therefore, activation of this signalling complex can be inhibited by interfering 
either with HGF/SF or c-Met directly, or both components simultaneously. Our 
present understanding of c-Met oncogenic signalling supports three main 
avenues for c-Met inhibition: (i) HGF/SF/c-Met competitors, (ii) anti-HGF or 
anti-c-Met antibodies and (iii) c-Met kinase inhibitors. Potent and selective drug 
candidates have been developed using these three strategies, and Phase I and II 
clinical trials for many of these compounds are now under way (table 1.5).
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Com pound Stage o f developm ent Additional inform ation
H G F/c-M et biological antagonists
NK4 Preclinical Competitively inhibits HGF/SF 
binding to c-Met
DecoyMet Preclinical Inhibits HGF/SF binding and 
c-Met dimerisation
Antibodies against H G F/SF
L2G7 (Galaxy Biotech) Preclinical Blocks binding o f  HGF/SF to c-Met
AM G102 (Am gen) Phase I/ll trial
Antibodies against c-M et
O A-5D5 (Genentech) Phase I trial ‘one-armed’ antibody
DN30 (Metheresis) Preclinical
—
Small m olecule c-M et inhibitors
ARQ197 (ArQule) Phase I/II trial
Non ATP competitive, c-Met- 
specific inhibitor
XL184 (Exelixis) Phase I/II/III trials
ATP competitive, broad spectrum 
kinase inhibitor
Table 1.5 Typical exam ples o f  types o f  c-M et signal transduction inhibitors currently  
undergoing pre-clinical and clinical evaluation.
(Com oglio et al., 2008; Eder et al., 2009).
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1.8 Aims
As mentioned previously in section 1.4, resistance to fulvestrant therapy presents 
a problem in the pharmacotherapeutic management of breast cancer (Buzdar, 
2004; Cheung et al., 2006; Robertson et al., 2005), with most patients who 
progress on fulvestrant ultimately developing distant metastases, the primary 
cause of mortality in cancer.
As outlined before in section 1.4, cells resistant to endocrine therapy circumvent 
the need for oestrogen stimulation for growth by switching to growth factor 
signalling pathways to drive proliferation (Nicholson et al., 1999). Preliminary 
in-house studies with our fulvestrant-resistant cell model have shown that 
development of resistance to the pure anti-oestrogen is accompanied by the 
acquisition of an in vitro aggressive cell phenotype, characterised by enhanced 
motile, migratory and invasive capabilities. Since proteolytic degradation of 
ECM barriers is a prerequisite for tumour invasion and metastasis, aberrant 
MMP/TIMP expression regulated by a growth factor signalling pathway 
significantly upregulated in FAS-R cells may be one of the factors contributing 
to their aggressive invasive phenotype. In order to test this hypothesis, the 
present study aims to:
• fully characterise the FAS-R cell phenotype with respect to its in vitro 
aggressive behaviour;
• establish the roles of MMP and TIMPs in this context;
• attempt to identify the dominant growth factor signalling pathway that 
promotes this aggressive behaviour.
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“If we knew what we were doing, it wouldn't be called research,
would it?”
Albert Einstein (1879-1955)
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2 Material and Methods
2.1 Materials
The materials used throughout this study along with their suppliers are detailed 
in table 2.1.
Table 2.1 List of materials and suppliers.
Material Supplier
Fisher Scientific UK Ltd., Loughborough,
Acetic acid
UK
Acrylamide/bis-acrylamide (30% solution
Sigma-Aldrich, Poole, Dorset, UK
(v/v), 29:1 ratio)
Agarose Bioline Ltd, London, UK
Alexa-488 fluorescent dye Sigma-Aldrich, Poole, Dorset, UK
Ammonium persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK
Amphotericin B (Fungizone) Invitrogen, Paisely, UK
Ampicillin Sigma-Aldrich, Poole, Dorset, UK
Antibiotics Invitrogen, Paisely, UK
Anti-mouse horseradish-peroxidase-linked
Amersham, Little Chalfont, UK
IgG (source: sheep)
Anti-rabbit horseradish-peroxidase-linked IgG
Amersham, Little Chalfont, UK
(source: donkey)
Aprotinin Sigma-Aldrich, Poole, Dorset, UK
Bio-Rad Dc Protein Assaay Bio-Rad Laboratories Ltd, HERTS, UK
Bovine serum albumin (BSA) Sigma-Aldrich, Poole, Dorset, UK
47
Chapter Two -  Materials and Methods
Bromophenol blue (BPB) BDH Chemicals Ltd, Poole, UK
Casein Sigma-Aldrich, Poole, Dorset, UK
Cell culture medium : RPMI 1640 and Phenol-
Invitrogen, Paisely, UK
red-free RPMI 1640
Cell culture medium: Phenol-red-free DCCM Biological Industries, Ltd, Israel
Cell scrapers Greiner Bio-One Ltd, Gloucestershire, UK
Chemiluminescent Supersignal® West HRP
Pierce and Warmer Ltd, Cheshire, UK
Substrate (Pico, Dura and Femto)
Coming Standard Transwell® inserts (8pm Fisher Scientific UK Ltd, Loughborough,
pore size, 6.5mm diameter) UK
Sarstedt AG and Co., Nflmbrecht,
Coulter counter counting vials and lids
Germany
Crystal violet Sigma-Aldrich, Poole, Dorset, UK
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Poole, Dorset, UK
Fisher Scientific UK Ltd., Loughborough,
Disposable cuvettes
UK
Di-thiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK
dNTPs (dGTP, dCTP, dATP, dTTP; lOOmM) Amersham, Little Chalfont, UK
Ethidium Bromide Sigma-Aldrich, Poole, Dorset, UK
Ethylene glycol -bis(2-aminoethyl ether )-
Sigma-Aldrich, Poole, Dorset, UK
N,N,N',N’ -tetraacetic acid (EGTA)
Ethylene diamine tetraacetic acid (EDTA) Sigma-Aldrich, Poole, Dorset, UK
Faslodex (Fulvestrant)
AstraZeneca Pharmaceuticals, 
Macclesfield, Cheshire, UK
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Fibronectin (source: human plasma; 1 mg/ml 
in 0.05M TBS: pH 7.5)
Sigma-Aldrich, Poole, Dorset, UK
Filter paper grade 3 Whatman, Maidstone, UK
Foetal Calf Serum (FCS) Invitrogen, Paisley, UK
Gelatine Sigma-Aldrich, Poole, Dorset, UK
General laboratory glass- and plasticware
Fisher Scientific UK Ltd., Loughborough, 
UK
Glacial Acetic Acid
Fisher Scientific UK Ltd., Loughborough, 
UK
Glass coverslips
Fisher Scientific UK Ltd., Loughborough, 
UK
Glass microscopy slides
Fisher Scientific UK Ltd., Loughborough, 
UK
Glycerol
Fisher Scientific UK Ltd., Loughborough, 
UK
Glycine Sigma-Aldrich, Poole, Dorset, UK
Hepatocyte growth factor/ Scatter factor 
(HGF/SF)
R&D Systems Europe Ltd. 
Abingdon, UK
Hyperladder™ IV Bioline Ltd, London, UK
Isoton® II azide-free balanced electrolyte 
solution
Beckmann Coulter Ltd, High Wycombe, 
UK
Kodak MXB Autoradiography film (blue 
sensitive, 18cm x 24cm)
Genetic Research Instrumentation (GRI), 
Rayne, UK
Leupeptin Sigma-Aldrich, Poole, Dorset, UK
L-glutamine Invitrogen, Paisley, UK
Lower buffer for SDS-PAGE gels (Tris 1.5M, 
pH 8.8)
Bio-Rad Laboratories Ltd, HERTS, UK
LY294002 (selective PI3K inhibitor) Sigma-Aldrich, Poole, Dorset, UK
Magnesium Chloride (MgCl2) Sigma-Aldrich, Poole, Dorset, UK
Matrigel™ Basement Membrane Matrix BD Biosciences, Oxford, UK
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Micro-centrifuge tubes (0.5 and 1.5ml) Elkay Laboratory Products, Basingstoke, 
UK
MMP2/9 Immunoblotting Standard 
(Biomol®) Biomol® International, LP, Exeter, UK
MMP Inhibitor III (Calbiochem®) Merck Chemicals Ltd., Nottingham, UK
Moloney Murine Leukaemia Virus (MMLV) 
reverse transcriptase
Invitrogen, Paisely, UK
N,N,N',N'-Tetramethylethylenediamine
(TEMED)
Sigma-Aldrich, Poole, Dorset, UK
Nitrocellulose transfer membrane (Protran® 
BA85; 0.45 pm pore size)
Schleicher and Schuell, Dassell, Germany
PCR oligonucleotide primers Invitrogen, Paisely, UK
PD98059 (specific MEK-inhibitor) Alexis Corporation Ltd., Nottingham, UK
Phalloidin-594 fluorescent dye Sigma-Aldrich, Poole, Dorset, UK
PhastBlue® tablet GE Healthcare, Chalfont St. Giles, UK
pH buffer calibration tablets (ph 4,7 and 10)
Fisher Scientific UK Ltd., Loughborough, 
UK
Phenylarsine oxide Sigma-Aldrich, Poole, Dorset, UK
phenylmethylsuiphonyl fluoride (PMSF) Sigma-Aldrich, Poole, Dorset, UK
Pipette tips Greiner Bio-One Ltd, Gloucestershire, UK
polyoxyethylene sorbitan monoiaurate 
(Tween-20)
Sigma-Aldrich, Poole, Dorset, UK
Ponceau S solution (0.1% (w/v) in 5% acetic 
acid)
Sigma-Aldrich, Poole, Dorset, UK
Potassium Chloride (KCL)
Precision Plus Protein™ All Blue Standards 
(10-250kDa)
Sigma-Aldrich, Poole, Dorset, UK
Bio-Rad Laboratories Ltd, HERTS, UK
Random hexamers (RH) Amersham, Little Chalfont, UK
RNase-free H20 Sigma-Aldrich, Poole, Dorset, UK
RNAsin™ ribonuclease inhibitor Promega, Southampton, UK
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Sodium azide Sigma-Aldrich, Poole, Dorset, UK
Sodium chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, Poole, Dorset, UK
Sodium fluoride (NaFl) Sigma-Aldrich, Poole, Dorset, UK
Fisher Scientific UK Ltd., Loughborough,
Sodium hydroxide (NaOH; 5M)
UK
Sodium molybdate (Na2Mo04) Sigma-Aldrich, Poole, Dorset, UK
Sodium orthovanadate (Na3V04) Sigma-Aldrich, Poole, Dorset, UK
Solvents (acetone, chloroform, ethanol, Fisher Scientific UK Ltd., Loughborough,
formaldehyde, isopropanol and methanol) UK
Sterile bijou vials (5ml) Bibby Sterilin Ltd, Stone, UK
Sterile cell culture plasticware (i.e. culture
Nunc Int., Roskilde, Denmark
dishes, flasks, 12-and 24-well plates)
Sarstedt AG and Co., NOmbrecht,
Sterile Falcon tubes (15 and 50ml)
Germany
Sterile phosphate buffered saline (PBS) Invitrogen, Paisley, UK
Sterile syringe needles (BD Becton Dickinson (BD) UK Ltd, Oxford,
MicrobalanceTM3; 25G x 5/8”) UK
Becton Dickinson (BD) UK Ltd, Oxford,
Sterile syringes (BD Plastipak™; 1ml)
UK
Sterile universal containers (30ml) Greiner Bio-One Ltd, Gloucestershire, UK
Sterile, disposable serological pipettes (1ml, Sarstedt AG and Co., NUmbrecht,
5ml, 10ml and 25ml) Germany
Taq DNA polyemerase (BioTaq™; 5U/pl) Bioline Ltd, London, UK
TRI® Reagent RNA Isolation Reagent Sigma-Aldrich, Poole Dorset, UK
Tris HCI Sigma-Aldrich, Poole, Dorset, UK
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK
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Trizma (Tris) base Sigma-Aldrich, Poole, Dorset, UK
Trypsin/EDTA lOx solution
Upper buffer for SDS-PAGE gels (Tris 0.5M, 
pH 6.8)
Invitrogen, Paisely, UK
Bio-Rad Laboratories Ltd, HERTS, UK
VectorShield® hard-set mounting medium Vector Laboratories, Inc., Peterborough,
containing DAPI nuclear stain UK
Western Blocking Reagent Roche Diagnostics, Mannheim, Germany
X-ray film developer solution (X-O-dev) X-O-graph Imaging Sytem, Tetbury, UK
X-ray film fixative solution (X-O-fix) X-O-graph Imaging Sytem, Tetbury, UK
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2.2 Cell Culture
2.2.1 Routine Cell Culture
The hormone-sensitive human mammary carcinoma wild-type cell line MCF-7 
(WTMCF-7) was kindly donated to TCCR by AstraZeneca Pharmaceuticals 
(Macclesfield, Cheshire, UK) and had originally been obtained from the 
American Type Culture Collection (ATCC® Number HTB-22™). WTMCF-7 
cells were removed from liquid nitrogen storage and routinely cultured in 
RPMI 1640 medium containing the pH indicator phenol-red (rRPMI) 
supplemented with 5% foetal calf serum (FCS), antibiotics (penicillin 
lOOunits/ml and streptomycin lOOpg/ml) and an antifungal agent 
(amphotericin B; 2.5pg/ml).
Cultures were maintained as monolayers in 75 cm2 flasks (T-75) at 37°C in a 
humidified 5% CO2 atmosphere in a Sanyo MCO-17AIC incubator (Sanyo 
E&E Europe BV, Loughborough, UK); culture medium was replaced every 3-4 
days. Cell confluency and viability were monitored by phase-contrast 
microscopy (Nikon Eclipse TE200 (Nikon UK Ltd, Kingston-upon-Thames, 
UK)). Cells were routinely passaged upon reaching 90% confluency and 
seeded in a 1:10 dilution (see section 2.2.3 for details of procedure). All cell 
culture was performed in MDH Class II laminar-flow safety cabinets 
(BIOQUELL UK Ltd, Andover, UK) using sterile technique and sterile plastic 
ware. Routine cell culture equipment was autoclaved at 119°C in a Denley 
BA852 autoclave (Thermoquest Ltd, Basingstoke, UK).
2.2.2 Experimental Cell Culture
24 hours prior to experiments, WTMCF-7 cells were washed 3 times with 
Dulbecco’s phosphate- buffered saline (PBS) and transferred to phenol-red-free 
RPMI 1640 (wRPMI) supplemented with 5% charcoal-stripped foetal calf 
serum (SFCS), L-glutamine (200mM) and antibiotics and antifungal as detailed 
above; thereby eliminating any oestrogenic effects arising from the ph indicator
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or the steroid hormones of full serum. This experimental cell culture medium 
will be referred to as ‘EM’.
2.23 Cell Passaging
First, cultured medium was replaced with 10ml trypsin (0.05%)/EDTA (0.02%) 
in PBS and the flasks were returned to the incubator for approximately 5 
minutes until the cells had detached. Then, 10ml of serum-containing medium 
was added to the trypsinised cells to neutralise trypsin/EDTA action and the 
resultant cell suspension centrifuged (Jouan C312 (Thermo Fisher Scientific 
Inc., MA, USA); lOOOrpm, 5 min). The supernatant was discarded and the cell 
pellets carefully resuspended in 1ml culture medium until a uniform suspension 
was obtained. 1/10 of this cell suspension was then added to 15ml medium in a 
T-75 which was then cultured as described above until required.
Upon reaching the maximum number of 25 cell passages, cryopreserved 
original stocks were resuscitated thereby eliminating the cell line character 
changes that are induced by high passage numbers.
2.2.4 Cell Number Determination Prior to Experimental Analysis 
To ensure seeding of cells at specific densities and equivalent cell numbers in 
duplicate flasks cell number determination using Coulter counter analysis 
(Coulter™ Multisizer II (Beckmann Coulter UK Ltd, High Wycombe, UK)) 
was carried out. Cells were harvested by trypsinisation as described above and 
the resultant cell suspension passed through a 25G syringe three times to obtain 
a single-cell suspension. lOOpl of this cell suspension were then added to 10ml 
of Isoton® II solution and cell counts performed in triplicate. In order to obtain 
the total number of cells present in the flask the average of the above cell 
counts was multiplied by a factor of 200. An appropriate volume of cell culture 
medium was then added to the remaining cell suspension and cells seeded onto 
new flasks at the desired density; the latter being governed by the cell line used 
and experimental design.
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2.2.5 Establishment of a Faslodex (ICI 182,780) - resistant cell line 
(FAS-R)
The faslodex-resistant MCF-7 cell line (FAS-R) was established in-house by 
McClelland et al. (2001). WTMCF-7 cells were removed from liquid nitrogen 
storage and maintained and subcultured in EM as described in sections 2.2.1 
and 2.2.3 for 2 weeks. After this period of routine maintenance, WTMCF-7 
monolayers were washed with PBS and transferred to EM supplemented with 
faslodex (10'7M final concentration); and from this point onwards, the cells 
were continuously exposed to the anti-oestrogen. In the initial phase, cell 
growth was drastically reduced by the drug rendering passaging unnecessary 
while the culture medium was still being replaced every 3-4 days. After 3 
months of culture in the continuous presence of faslodex, cell growth rates 
began to increase again and stabilise, suggesting the cells had developed 
resistance to the growth-inhibitory properties of the drug; and the resultant cell 
line was therefore designated FAS-R. The resistant cells were cultured for an 
additional 4 months before the commencement of characterisation studies. 
FAS-R cells were routinely maintained in EM supplemented with faslodex (10' 
7M).
2.2.6 Treatments
Many experiments in this study required treatment of cells with anti- 
oestrogens, growth factors and signal transduction inhibitors (see table 2.2). 
24h prior to all treatments, cells were serum-starved in phenol-red-free DCCM 
supplemented with L-glutamine and antibiotic/antifungal agents (as above). 
Detailed information on compound concentration and treatment duration can 
be found in the relevant sections of the results chapters.
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Table 2.2 Treatments used in cell culture experiments.
Treatments Classification Target Protein Final concentration used Supplier
4-hydroxytamoxifen anti-hormone ER lOOnM Sigma-Aldrich, Poole, Dorset, UK
Faslodex™ anti-hormone ER lOOnM AstraZeneca Pharmaceuticals, Cheshire, UK
TGF-a growth factor EGFR lOng/ml Sigma-Aldrich, Poole, Dorset, UK
EGF growth factor EGFR lOng/ml Sigma-Aldrich, Poole, Dorset, UK
IGF-II growth factor IGF-1R lOng/ml Sigma-Aldrich, Poole, Dorset, UK
TPA growth factor PKC lOOnM Sigma-Aldrich, Poole, Dorset, UK
HGF/SF growth factor c-Met 20ng/ml R&D Systems Europe Ltd., Abingdon, UK
MMP inhibitor III 
(Calbiochem®) inhibitor MMPs 40pM
Merck Chemicals Ltd., Nottingham, UK
PD98059 inhibitor ERK1/2 50pM Alexis Corporation Ltd., Nottingham, UK
LY294002 inhibitor PI3K 10|iM Sigma-Aldrich, Poole, Dorset, UK
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2.3 Cell Counting Assay
Cell growth was assessed by cell counting experiments using Coulter counter 
analysis. Cells were harvested by trypsinisation as described previously and 
seeded into a 24-well-plate in EM ± Faslodex (10'7M) at a density of 
4xl04cells/well. Cells were allowed to attach for 24h prior to the addition of 
treatments. Following treatment, the plate was incubated at 37°C in a 
humidified 5% CO2 atmosphere for 15 days; medium changes took place every 
3-4 days. On day 15, medium was replaced with trypsin/EDTA (1 ml/well) and 
the plate returned to the incubator for approximately 5 minutes until the cells 
had detached. The resultant cell suspension was passed through a 25G syringe 
three times to obtain a single-cell suspension and then drawn into the syringe. 
Wells were subsequently rinsed with fresh Isoton II solution (1 ml/well) three 
times and this volume was also drawn into the syringe each time to give a final 
volume of 4ml in the syringe. These 4ml of suspension were then added to a 
counting cup containing 6 ml of Isoton II solution to give a total volume of 
10ml in the cup and cell counts performed in triplicate. In order to obtain the 
total number of cells present in each well the average of the above cell counts 
was multiplied by a factor of 20.
2.4 Cell Morphology Assessment
Representative images of live cells were captured by differential interference 
microscopy using a Leica DM-IRE2 inverted microscope (Leica Microsystems 
Imaging Solutions Ltd, Cambridge, UK) connected to a Hamamatsu C4742-96 
digital camera (Hamamatsu Photonics UK Ltd, HERTS, UK) and a 
PowerMAC G5 computer (Apple Computer Inc., CA, USA) running 
Improvision® OpenLab V4.04 software (Improvision®, Coventry, UK).
2.5 Gene Expression Analysis
Gene expression in WTMCF-7 and FAS-R cell lines was analysed using semi- 
quantitative reverse transcription-polymerase chain reaction (RT-PCR)
57
Chapter Two -  Materials and Methods
(Saiki et al.> 1985, Mullis et al., 1986, Mullis and Faloona, 1987), a technique 
for enzymatic DNA amplification. RT-PCR was first employed to establish 
basal gene expression levels and subsequently to determine the effect of 
growth factor and inhibitor treatment on the expression levels of some of the 
above genes. All reactions were set up in a Labonco Purifier PCR Enclosure 
(GRI, Rayne, UK) using sterile pipette tips and microcentrifuge tubes. 
Equipment and work surfaces were cleaned with 70% ethanol to remove 
contaminating RNAse and DNAse enzymes.
2.5.1 Total RNA isolation
Cells were seeded into 60mm culture dishes at a density of 5xlOscells/dish and 
cultured until log-phase growth; at this point treatments were added for the 
desired duration where appropriate. Total RNA was extracted from cell 
monolayers using TRI® Reagent RNA Isolation Reagent (Chomczynski, 
1993).
Culture medium was aspirated and monolayers washed twice with PBS prior to 
the addition of TRI® Reagent (1ml per 10cm2 area of culture dish at RT). After 
5 minutes lysates were collected using a cell scraper, homogenised by pipetting 
and transferred to sterile 1.5ml microcentrifuge tubes. Phase separation into 
aqueous (RNA), interphase (DNA) and organic phase (protein) was achieved 
by adding chloroform (0.2ml chloroform per 1ml TRI reagent) to the lysates. 
Samples were gently shaken for 15 seconds and incubated for 15 minutes at 
RT. Following centrifugation (IEC Micromax RF microcentrifuge (Thermo 
Electron Corporation, Hampshire, UK); ll,3000rpm, 15 minutes, 4°C), the 
aqueous upper phase was transferred to fresh 1.5ml microcentrifuge tubes. 
After the addition of isopropanol (0.5ml isopropanol per 1ml TRI® Reagent) 
samples were gently shaken and incubated for 10 minutes at RT and 
subsequently centrifuged (ll,300rpm, 10 minutes, 4°C). The resulting RNA 
pellets were washed with ethanol (75% in H2O, 1ml per pellet), vortexed and 
centrifuged (9000rpm, 5 minutes, 4°C). Following a second ethanol wash, 
ethanol was removed and RNA pellets allowed to dry briefly before
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resuspension in RNAse-free sterile H20  (20pl per pellet). RNA samples were 
stored at -80°C until required.
2.5.2 Total RNA Quantitation
RNA concentration (pg/ml) was determined by diluting lpl RNA in 499pl 
RNAse-free H20  and measuring the absorbance at 260nm (A26o) on a 
spectrophotometer (Cecil CE2041 spectrophotometer (Cecil Instruments, 
Cambridge, UK)) based on the following formula:
(RNA) = A26o x 40 x Dilution Factor
2.5.3 Total RNA Qualitation and Agarose Gel Electrophoresis
RNA qualitation was carried out by measuring the absorbance at 280nm (A2so) 
and calculating the A26o/A28o ratio (a ratio of 1.8-2.0 being indicative of good- 
quality RNA) and by electrophoresing RNA.
RNA samples were resolved on a 2% (w/v) agarose gel in Tris-Acetate-EDTA 
buffer (TAE, pH 8.3; see buffer appendix) containing ethidium bromide (lpl of 
a lOmg/ml solution per 100ml agarose gel). Gels were cast and electrophoresed 
using the Sub-cell® Agarose Electrophoresis System linked to a Powerpac 
1000 power pack (both Bio-Rad Laboratories Ltd, HERTS, UK) following 
manufacturer’s instructions. 500ng RNA per sample were combined with 
sample loading buffer (5pi; see buffer appendix) and loaded into the wells of 
the gel. TAE buffer was added to the electrophoresis tank and the gel 
electrophoresed at 80V constant voltage for 1 hour. Gels were subsequently 
visualised under UV light using a FOTODYNE 3-3002 UV trans-illuminator 
and photographed using a Polaroid GelCam camera (both GRI, Rayne, UK). 
Strong 28S and 18S ribosomal bands with the 28S band appearing twice as 
strong as the 18S band were indicative of good-quality RNA.
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2.5.4 Reverse Transcription (RT)
Complementary DNA (cDNA) was generated by reverse transcribing RNA 
using the Moloney Murine Leukaemia Virus (MMLV) reverse transcriptase 
enzyme.
lpg of total RNA (made up to a total volume of 6pl with RNAse-free H2O) 
was added to 6pl of master mix comprising 2pl random hexamer 
oligonucleotides (lOOpM) and 4pl dNTP mix (0.625mM of dGTP, dCTP, 
dATP and dTTP) to make up a final volume 12jil. Samples were then placed in 
a PTC-100 thermocycler (MJ Research Ltd, Massachusetts, USA), denatured at 
65°C for 5 minutes and cooled on ice. 8pl of RT master mix comprising 4pl 
First Strand Buffer (5x), 2pl dithiothreitol (DTT, 0.1M), lpl RNasin™ RNase 
inhibitor (40U/pl) and lpl MMLV-reverse transcriptase (200U/pl) were added 
to each denatured sample. Samples were incubated at 37C° for 50 minutes, 
inactivated by heating to 70C° for 15 minutes and then cooled at 4C°. The 
resulting cDNA samples were aliquotted and stored at -20C° until required.
2.5.5 Primer design
The oligonucleotide primers employed were either based on published 
sequences or designed using the software program ‘Primer3’ 
(http://frodo.wi.mit.edu/), using gene sequences that had been obtained from 
the NCBI online database nittp://www.ncbi.nlm.nih.gov/sites/entrez?db= 
nuccore&itool=toolbar) (see table 23  for primer sequences).
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Table 2.4 General guidelines used for PCR primer design.
Parameter Optimum
Length 18-22 nucleotides
G/C content 40-60%
Melting temperature
Forward and reverse primers should have similar melting 
temperatures.
Tm = (number of A+T) x 2° C + (number of G+C) x 4°C 
(Suggs et al. , 1981)
Sequence
Primer sequence should span a region towards middle of gene 
sequence to avoid potential partial RNA degradation
Avoid complementarity at 3’ ends to avoid primer dimer 
formation
Avoid 3 G or C nucleotides in a row near the 3’ end
Aim for high G/C content at 3’ end as this is where RNA 
polymerase enzyme binds_______________________
Table 2.5 Expected product sizes of PCR primers.
Primer pair Expected product size (bp)
MMP-1 1030
MMP-2 440
MMP-7 373
MMP-9 1100
MMP-10 408
MMP-11 700
MMP-13 359
TIMP-1 655
T1MP-2 335
TIMP-3 201
TIMP-4 226
c-Met 320
ER-a 432
p-actin 204
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Table 23  Primer sequences and reaction conditions used for semi-quantitative RT-PCR 
alongside expected product sizes.
Target gene. Primer Sequence
Conditions 
(annealing 
temperate - cycle 
number)
MMP-1 F 5’-GTC ACA CCT CTG ACA TTC AC-3’
56°C 33 cycles
MMP-1 R 5’-CAC CTT CTT TGG ACT CAC AC-3’
MMP-2F 5’-CTC GAA TCC ATG ATG GAG AG-3*
58°C 34 cyclesMMP-2R 5’-CAG CTG TCA TAG GAT GTG CC-3’
MMP-7F 5’-ACA GGC TCA GGA CTA TCT CA-3’
55°C 30 cycles
MMP-7R 5’-AGT TCC CCA TAC AAC TTT CC-3’
MMP-9F 5’-AGA CCT GAG AAC CAA TCT CAC-3’ 56°C 33 cyclesMMP-9R 5’-GGC ACT GAG GAA TGA TCT AA-3’
TAG-MMP-
10F 5’-CAC TCT ACA ACT CAT TCA CAG AGC T-3’ 56°C 33 cyclesTAG-MMP-
10R 5’-CTT GGA TAA CCT GCT TGT ACC TCA T-3’
MMP-1 IF 5’-CCG CCT TCT ACA CCT TTC GC-3’
56°C 33 cycles
MMP-11R 5’-AGC CTT CCA GAG CCT TCA CC-3’
MMP-13F 5’-GAT GAT ACT TCC CAC ACC AC-3’ 56°C 33 cyclesMMP-13R 5’-CTG CTC TTT TGT CTC CTG TC-3’
TIMP1F 5*-TTG TTG CTG TGG CTG ATA G-3’ 55°C 23 cyclesTIMP1R 5’-CGG AAG AAA GAT GGG AGT G-3’
TIMP2F 5*-ATC AGG GCC AAA GCG GTC AGT GAG-3’ 61°C 23 cyclesTIMP2R 5’-ATC TTG CAC TCG CAG CCC ATC TGG-3’
TIMP3F 5’-TTC CCA TTG TGG TCA CGC CAT TTG-3’ 55°C 30 cyclesTIMP3R 5’-GGG AAC TTG TGT AGG TTG GTC AGG-3’
TIMP4F 5’-GTG CCG TCA ACA TGC TTC ATA CAG-3’ 58°C 30 cyclesTIMP4R 5’-ATC TGT GCA ACT ACA TCG AGC CCT-3’
ER-oF 5’-GGA GAC ATG AGA GCT GCC AAC-3’ 55°C 27 cyclesER-oR 5*-CCA GCA GCA TGT CGA AGA TC-5’
c-MetF 5’-AAG CCA GAT TCT GCC GAA CCA ATG G-3’ 55°C 27 cyclesc-MetR 5’-CCA AGA TTA GCT ATG GTG AGG TCT CC-3’
f}-actinF 5’-GGA GCA ATG ATC TTG ATC TT-3’ 55°C 27 cycles3-actinR 5’-CCT TCC TGG GCA TGG AGT CCT-3’
Primers were designed according to the general guidelines outlined in table 2.4 
(Taylor et al., 1991); expected product sizes are detailed in table 2.5.
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All primer sequences were cross-checked using an online database 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) to ensure sequence specificity 
(Altschul et al., 1997). All PCR primers were synthesized by Invitrogen. 
Primer stock solutions (20pM) in RNAse-free H2O were prepared and stored at 
-20°C until required.
2.5.6 Polymerase Chain Reaction (PCR)
2.5.6.1 Reaction Mixtures and Thermocycling Conditions
PCR reactions were performed in a total volume of 25 pi (i.e. 0.5 pi cDNA and 
24.5 pi of master mix solution). The master mix contained 2pl dNTP mix 
(0.625mM of dGTP, dCTP, dATP and dTTP), 2.5pl PCR buffer (lOx; see 
buffer appendix), 0.625pi forward primer (20pM), 0.625pi reverse primer 
(20pM), 0.2 pi Taq polymerase enzyme (5U/pl) and 18.6pl sterile RNAse free 
H2O to check for contamination. Each PCR reaction included a negative control 
in which cDNA was replaced by the same amount of RNAse-free H2O to check 
for contamination. The reaction mixture was briefly vortexed and pulsed in a 
microcentrifuge before being placed in a PTClOO-thermal cycler with the 
heated lid programmed at 100°C. The PCR cycling parameters employed are 
outlined in table 2.6; annealing temperature and cycle number varied for each 
target gene. Amplification of the house-keeping gene p-actin was performed in 
parallel on the same set of cDNA samples used for target gene amplification 
and used as an equal loading control.
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Table 2.6 Thermocycler program conditions for PCR amplification.
Step Temperature Duration Cycle number
1
Denaturing
Annealing
Extension
95°C
dependent on target gene 
72°C
2 minutes
1 minute
2 minutes
lx
2
Denaturing
Annealing
Extension
94°C
dependent on target gene 
72°C
1 minute 
30 seconds 
1 minute
dependent on target gene
3 Denaturation 94°C 1 minute lx
4 Final
Extension 60°C 7 minutes lx
5 Short-term
storage 12°C 00
2.S.6.2 Gel electrophoresis and Visualisation of cDNA PCR products
PCR cDNA products were essentially electrophoresed as described before 
(section 2.5.3). 15pi PCR product were combined with sample loading buffer 
(5pl; see buffer appendix) and resolved alongside a DNA molecular weight 
marker (Hyperladder™ IV lOO-lOOObp; 5 pi). cDNA products were visualised 
and photographed as before, and images scanned using a Bio-Rad GS-690 
Imaging Densitometer (Bio-Rad Laboratories Ltd, HERTS, UK) connected to a 
computer running Molecular Analyst Version 1.5 (Bio-Rad). Densitometry was 
measured as ‘adjusted volume Optical Density x mm2’ and raw data was 
subsequently normalised using P-actin.
2.6 Analysis of Protein Expression and Activation
SDS polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) and 
Western Blotting (Towbin et al., 1979) were used to both identify and quantify 
the expression of specific proteins and to determine their activity levels where 
appropriate. Protein expression and activation analysis was performed on 
WTMCF-7 and FAS-R cell lines under basal conditions and following growth 
factor and inhibitor treatment.
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2.6.1 Cell Lysis
Cells were seeded into 60mm culture dishes at a density of 5xlOscells/dish and 
cultured until log-phase growth; at this point treatments were added for the 
desired duration where appropriate.
Cell monolayers were gently washed twice with ice-cold PBS and then lysed 
by the addition of ice-cold Triton-XlOO lysis buffer containing protease and 
phosphatase inhibitors (see buffer appendix). 150-200pl lysis buffer were 
added per dish, the volume depending on dish size and cell confluency. Lysates 
were collected using a cell scraper and transferred to 1.5ml-microcentrifuge 
tubes; these were then incubated on ice for 20 minutes. Cell lysates were 
subsequently centrifuged (13,000rpm, 15 min, 4°C). The resultant supernatants 
were aliquotted and stored at -20°C until required.
2.6.2 Cell Supernatant Collection
In an attempt to detect MMPs potentially secreted into the culture medium, 
protein expression analysis was also carried out on cell supernatants; this 
required collection and concentration of the cell culture medium. As above, 
ceils were seeded into 60mm dishes and treated where appropriate. Cell 
supernatants were then removed from the dishes, transferred to 15ml-centrifuge 
tubes and immediately centrifuged (Jouan C312 (Thermo Fisher Scientific Inc., 
MA, USA); 4000rpm, 5 min) to pellet debris and clarify the medium. As 
above, the resultant supernatants were aliquotted and stored at -20°C until 
required.
2.63 Protein Concentration Assay
Determination of the total soluble protein concentration of cell lysates was 
carried out using the detergent-compatible Bio-Rad Dc Protein Assay Kit (Bio- 
Rad Laboratories Ltd, UK), a modified version of the assay described by 
Lowry etal. (1951).
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First, BSA protein concentration standards ranging from 0 to 1.45mg/ml were 
prepared (see appendix), their absorbance analysed at 750nm using a 
spectrophotometer (see section 2.5.2) and a BSA standard curve generated. 
Then, lysates were diluted with Triton-XlOO lysis buffer (1:5; final volume 
50pl). Test samples were prepared by adding 0.25ml Reagent A (containing 
5 pi Reagent S) and 2ml Reagent B to each diluted lysate in a 
spectrophotometer cuvette. Test samples were gently vortexed, incubated at RT 
for 15 minutes for full colour development and absorbances analysed as before. 
Based on the BSA standard curve and the absorbance values the total soluble 
protein content of the lysates was calculated.
2.6.4 SDS-PAGE Analysis
Whole cell extracts were separated by size using the discontinuous
polacrylamide gel electrophoresis method by Laemmli (Laemmli, 1970). This
comprised a 7-8% (w/v) acrylamide/bis-acrylamide resolving gel (pH 8.8) and
a 4% (w/v) acrylamide/bis-acrylamide stacking gel (pH 6.8), the acrylamide
percentage of the resolving gel varying depending on the molecular weight of
the protein of interest (higher acrylamide percentage being used to separate
lower molecular weight proteins). All SDS-PAGE was performed using the
Bio-Rad Mini-Protean® III apparatus powered by a Powerpac Basic™ power
pack (both Bio-Rad Laboratories Ltd, HERTS, UK) following manufacturer’s
instructions. Acrylamide gel solutions were prepared according to the recipes
in tables 2.7 and 2.8 and carefully dispensed between the glass plates of the
Bio-Rad gel casting apparatus. Immediately after pouring the resolving gel it
was overlaid with 0.05% (w/v) SDS in H2O to level the interface between
resolving and stacking gel. The gel was then allowed to set for 30 minutes at
RT. Once set, the SDS solution was discarded and the stacking gel rinsed with
distilled H2O before being overlaid with the resolving gel. A 10-well comb
(1.5mm width) was inserted and the resolving gel allowed to set for 30 minutes
at RT. The gels were then positioned in the electrophoresis tank and SDS-
PAGE running buffer (lx, see buffer appendix) poured into the inner and outer
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reservoirs of the tank. Once immersed, the comb was gently removed from the 
gels and the resultant wells rinsed out with SDS-PAGE running buffer.
Cell lysates containing 40pg total soluble protein per sample were diluted with 
3x Laemmli sample loading buffer (see buffer appendix), denatured/reduced at 
100°C in a dry heating block (Techne DB-2A Dri-Block) for 5-10 minutes 
(depending on the sample volume) and pulsed before being loaded into the 
wells of the stacking gel. Samples were run alongside a protein molecular 
weight marker (Precision Plus Protein™ All Blue Standards l-250kDa; 5 pi) 
and, where appropriate, a MMP-2/-9 Immunoblotting Standard (Biomol®) 
International, LP, Exeter, UK). Gels were electrophoresed at 150V constant 
voltage until the Laemmli sample loading buffer had migrated the desired 
distance down the gel (approximately 1-1.5 hours).
Table 2.7 Recipe for stacking geL
5% (w/v) 
For 10ml:
Final concentration 
in gel
Acrylamide/bis-acrylamide 
30% solution (ratio 29:1) 1.65ml
5% (w/v)
H20 5.7ml -
Tris (0.5M, pH 6.8) 2.5ml 125mM
SDS (10% solution in H20) lOOpl 0.1% (w/v)
APS (10% solution in H20) 50pl 0.5% (w/v)
TEMED 20pl 0.2% (v/v)
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Table 2.8 Recipe for resolving gel.
8% (w/v) gel 
(70-200kDa) 
For 10ml:
10% (w/v) gel 
(20-100kDa) 
For 10ml:
Final concentration 
in gel
Acrylamide/bis-acrylamide 
30% solution (ratio 29:1)
2.7ml 3.3ml 8 or 10% (w/v)
H20 4.6ml 4ml -
Tris (1.5M, pH 8.8) 2.5ml 2.5ml 375mM
SDS (10% solution in H20) lOOpl lOOpl 0.1% (w/v)
APS (10% solution in H20) lOOpl lOOpl 0.1% (w/v)
TEMED 40pl 40pl 0.4% (v/v)
2.6.5 Western Blotting
Western Blotting involves the electrophoretic transfer of size-fractionated 
proteins from a gel matrix to a solid membrane support. Proteins were 
transferred from SDS-PAGE gels to a nitrocellulose membrane using the 
equipment described above.
Following SDS-PAGE gel plates were separated, the stacking gel discarded 
and the resolving gel rinsed in Western Blot transfer buffer (see buffer 
appendix) to remove excess SDS. Two sheets of grade 3 filter paper and one 
sheet of Protran B85 nitrocellulose membrane (pore size 0.45 pm) per gel were 
cut to size and, together with two fibre pads, pre-soaked in Western Blot 
transfer buffer for 30 minutes. A Western Blot cassette was then assembled as 
outlined in figure 2.1 and a universal plastic tube gently rolled over the surface 
of the ‘gel-sandwich’ to expel trapped air bubbles which might interfere with 
the protein transfer.
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subsequently removed by washes in TBS-Tween (0.05% (v/v) Tween-20 in 
lxTBS, see appendix) (3x5 minutes) and membranes incubated with blocking 
buffer (5% Western Blocking Reagent (v/v) in lxTBS-Tween) on a rotor- 
shaker for 1 hour at RT to prevent non-specific binding of the primary antibody 
(1°AB).
Following blocking, membranes were washed in TBS-Tween and incubated 
with a 1°AB specific to the protein of interest. l°ABs were diluted in TBS- 
Tween containing 5% (v/v) Western Blocking Reagent and 0.05 (w/v) sodium 
azide. 1°AB concentration and incubation conditions varied depending on the 
protein of interest and were optimised individually, see table 2.9 for details. 
After exposure to the 1°AB, membranes were washed in TBS-Tween at RT (3 
x 10 minutes) and incubated with Horse Radish Peroxidase (HRP)-conjugated 
anti-rabbit-or anti-mouse-antibody (1:20,000 dilution for p-actin; 1:10,000 or 
1:5,000 dilution for all other antibodies) for 1 hour at RT. Following repeated 
TBS-Tween washes (3 x 10 minutes) chemiluminescence was performed to 
visualise the presence and, where appropriate, phosphorylation status of the 
protein of interest in each sample (Kricka et al., 1991). Chemiluminescence 
was detected using a commercial kit containing the luminol/peroxide-based 
enhanced chemiluminescence (ECL) reagents Supersignal™ West Pico, Dura 
or Femto (Mattson and Bellehumeur, 1996); the choice of reagent (in 
descending order) being dictated by signal strength.
Membranes were then transferred to an autoradiography cassette and incubated 
with the appropriate ECL reagent (500pl per membrane) for 5 minutes at RT. 
HRP-mediated oxidisation of the substrate luminol in the presence of peroxide 
generates an excited state molecule. The subsequent decay to a lower energy 
state molecule is accompanied by the emission of light; this light is detected 
using x-ray film. Exposure times vary from several seconds to overnight, 
depending on signal strength. Following detection of the protein of interest 
membranes were washed in TBS-Tween (3 x 10 minutes) and re- 
immunoprobed for p-actin and the detection procedures described above were 
repeated.
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White cassette wall (anode)
Teflon sponge pad
Filter paper
Nitrocellulose membrane
1- 4. ^  " -• » I SDS-PAGE gel Current
Filter paper
Teflon sponge pad
Black cassette wall (cathode)
Figure 2.1 Schem atic diagram o f the electrophoretic transfer sandwich.
The individual components o f  the electrophoretic transfer sandwich were assembled in the 
above order and the Western Blot cassette closed and inserted into the transfer apparatus.
Following its assembly the cassette was inserted into the transfer apparatus 
with the nitrocellulose membrane nearest the anode to ensure deposition of the 
negatively charged SDS-coated proteins from the gel matrix onto the 
membrane. Both the transfer apparatus and an ice-pack were then placed in the 
transfer tank filled with ice-cold Western Blot transfer buffer, the tank placed 
onto a magnetic stirrer plate and the transfer allowed to proceed at 100V 
constant voltage for 1 hour under gentle stirring.
2.6.6 Immunoprobing of Western Blots
Following transfer, cassettes were dismantled, gels discarded and membranes 
washed in lxTris buffered saline (TBS, see buffer appendix) ( 3 x 5  minutes). 
Membranes were briefly stained with Ponceau S solution (0.1% (w/v) in 5% 
acetic acid) to ascertain equal protein transfer to the membrane, the stain
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X-ray films were developed using an X-O-graph Compact X2- x-ray developer 
(X-O-graph Imaging System, Tetbury, UK) and the resultant signals scanned 
and analysed using a Bio-Rad GS-690 Imaging Densitometer as described in 
section 2.5.62.
Variation in sample protein loading was corrected by normalising all signal values 
using the signal value of p-actin which does not vary significantly and is thus 
used as an internal loading control (Liao et al., 2000).
71
Chapter Two -  Materials and Methods
Table 2.9 Details of antibodies used for immunoprobing.
Target Source Dilution Incubationconditions Supplier
Catalogue
number
MMP-9 Rabbit 1:2000 O/N 4°C + 2h RT Biomol #SA-106
MMP-9 Mouse 1:2000 O/N 4°C + 2h RT Labvision #MS-569-P0
MMP-9 Rabbit 1:2000 O/N 4°C + 2h RT
Stratech
Scientific #RB-1539-P0
MMP-2 Mouse 1:1000 O/N 4°C + 2h RT Labvision #MS-804-P0
MMP-2 Mouse 1:2000 O/N 4°C + 2h RT
Stratech
Scientific #MS-567-P0
MMP-2 Rabbit 1:2000 O/N 4°C + 2h RT Santa Cruz SC-10736
MMP-1 Mouse 1:400 O/N 4°C + 2h RT
Stratech
Scientific #MS-801-P0
MMP-1 Rabbit 1:2000 O/N 4°C + 2h RT Biomol #SA-102
CD44s Mouse 1:2000 O/N 4°C + 2h RT
Stratech
Scientific #MS-668-P0
ERK 1/2 
Y202/Y204 Rabbit 1:1000 O/N 4°C Cell Signalling #9101
T-ERK 1/2 Rabbit 1:1000 O/N 4°C Cell Signalling #9102
AKTS473 Rabbit 1:1000 O/N 4°C Cell Signalling #9271
T-AKT Rabbit 1:1000 O/N 4°C Cell Signalling #9272
T-c-MET Mouse 1:2000 O/N 4°C Zymed #18-7366
c-Met
Y1349 Rabbit 1:1000 O/N 4°C Cell Signalling #3121
c-Met
Y1234 Rabbit 1:1500 O/N 4°C Upstate #07-211
P-actin Mouse 1:20,000 2h RT Sigma A2228
T = Total
O/N = Overnight
Y = Phosphorylation on tyrosine
S = Phosphorylation on serine
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2.7.1 Cell-conditioned Medium Collection
As described before cells were seeded into 60mm culture dishes at a density of 
5xlOscells/dish and cultured until log-phase growth; at this point treatments 
were added for the desired duration where appropriate. However, when 
growing cultures for zymographic analysis of MMP expression cells were 
cultured in the lowest possible culture medium volume (1ml per dish) to 
increase the MMP concentration in the supernatant. Also, cells were cultured 
in Defined Cell Culture Medium (DCCM) to eliminate contamination with 
exogenous constitutively expressed MMPs contained in the SFCS of routine 
culture medium. Cell-conditioned medium was collected, processed and stored 
as described in section 2.6.2.
2.7.2 Substrate Gel Electrophoresis
Clarified supernatants were separated according to their specific molecular 
weight and electrical charge using a modified version of the discontinuous 
polyacrylamide gel electrophoresis method described in 2.6.4 (Laemmli, 
1970); and zymography was essentially performed according to Hauck (2001). 
While the stacking gel was prepared as detailed in section 2.6.4, a substrate, 
either gelatin (1% gelatin in resolving gel solution) or casein (1% casein in 
resolving gel solution), was incorporated into the resolving gel (see table 
2.10).
Prior to loading samples were combined with an appropriate amount of non­
reducing sample loading buffer (lx; see buffer appendix), vortexed, pulsed and 
incubated for 30 minutes at RT to allow coating of the proteins with SDS. 
Following incubation, samples were applied to the gel as described in 2.6.4 
alongside the protein molecular weight marker and the MMP-2/-9 
Immunoblotting Standard detailed above. A standard volume of 40pl was 
loaded for each sample and densitometric values were subsequently corrected 
based on protein concentration values obtained for these samples. Gels were 
electrophoresed at 70V for 4 hours at 4°C to prevent spontaneous enzyme 
activation.
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2.7 Zvmographv
Numerous methods have been developed to measure the expression and 
activity levels of proteolytic enzymes in tissues and biological fluids (Cheng et 
al.y 2008). Zymography, a technique now routinely used for the detection of 
MMPs in complex biological samples (Snoek-van Beurden and Von den Hoff, 
2005), was first pioneered by Granelli-Pipemo and Reich (1978), and 
subsequently described by Heussen and Dowdle (1980) as a method for 
detecting plasminogen activators in gelatine substrate slab gels. Zymographic 
analysis involves the electrophoretic separation of proteins under denaturing 
but non-reducing conditions through an SDS-polyacrylamide gel containing a 
co-polymerised protease substrate such as gelatin (Lombard et al.9 2005, 
Hattori et al., 2002). Upon electrophoresis, resolved proteins are renatured in 
non-ionic detergent which removes the SDS, and susbsequently incubated in a 
buffer system which supplies the chloride and zinc ions the enzymes require to 
be active. It is thought that zymogen forms of MMPs are activated through this 
process of gentle denaturation and renaturation; and they can therefore be 
detected in zymograms along with the active forms based on their different 
molecular weights (Kleiner and Stetler-Stevenson, 1994). Following 
Coomassie Blue staining, MMPs are visualised as clear zones in which 
proteolytic activity resulted in degradation of the gelatin substrate. 
Zymography has been described as an extremely sensitive technique, and 
Leber and Balkwill (1997) reported the detection of less than 10 pg of MMP-2 
on gelatine zymograms which compares favourably with Enzyme-Linked 
ImmunoSorbent Assays (Kleiner and Stetler-Stevenson, 1994). Moreover, 
zymography has been used extensively in the qualitative evaluation of 
proteases present in tumours and cell culture media (Kleiner and Stetler- 
Stevenson, 1994). In this study, gelatin zymography was employed which is 
routinely used for the detection of the gelatinases MMP-2 and MMP-9. Casein 
zymography for the detection of MMP-1 was also performed.
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Table 2.10 Recipe for resolving gel for zymography.
8% (w/v) gel 
For 10ml:
Final concentration 
in gel
Acrylamide/bis-acrylamide 
30% solution (ratio 29:1)
2.7ml 8 % (w/v)
H20 3.6ml -
1% gelatin stock solution 1ml 0.1%
Tris(1.5M, pH 8.8) 2.5ml 375mM
SDS (10% solution in H20) lOOpl 0.1% (w/v)
APS (10% solution in H20) lOOpl 0.1% (w/v)
TEMED 40pl 0.4% (v/v)
2.73 Staining and Destaining
Following electrophoresis, gels were washed in the detergent Triton X-100 
(2.5% in H2O) three times for a total of 1 hour to allow renaturation of the 
MMP proteins contained in the gel matrix before overnight incubation in 
activation buffer (see buffer appendix) at 37°C to allow digestion of the 
gelatine substrate by the enzymes. Upon overnight incubation, gels were 
briefly rinsed in distilled H2O. A stain stock solution (0.2%) was prepared by 
dissolving 1 PhastBlue® tablet (GE Healthcare, UK) in 80ml of distilled H2O, 
adding 120ml methanol, and stirring until all dye was dissolved. The solution 
was then filtered through Whatman filter paper to remove undissolved stain 
particles. A stain working solution was prepared by adding a certain volume of 
stain stock solution to an equal amount of glacial acetic acid (0.2% in H2O). 
Gels were incubated in stain working solution (200ml per gel) on a rotor- 
shaker for 6 hours and then washed in destain solution (see buffer appendix) 
until clear bands against a dark blue background appeared. Gels were placed on 
a light-box and photographed using a Polaroid GelCam camera (GRI, Rayne, 
UK). Images were subsequently scanned in and analysed using a Bio-Rad GS-
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690 Imaging Densitometer (Bio-Rad Laboratories Ltd, HERTS, UK) connected 
to a computer running Molecular Analyst Version 1.5 (Bio-Rad). Densitometry 
was measured as ‘adjusted volume Optical Density x mm2’.
2 .8  C ell In v a s io n  A ssay
A modified version of the Boyden chamber assay (Albini et al., 1987) was 
used to determine the ability o f WTMCF-7 and FAS-R to invade an artificial 
matrix under both basal conditions and following growth factor and inhibitor 
treatment.
Briefly, the assay consists o f a hollow plastic chamber with a porous 
membrane at the lower end. This invasive chamber, coated with a gel matrix 
designed to mimic the ECM, resides in another chamber filled with medium. 
Cells seeded into the insert invade through the pores to the other side of the 
membrane; and at the assay endpoint, the number of invading cells is 
quantified.
Assays were performed using Coming Standard Transwell® inserts (8 pm pore 
size; 6.5mm diameter (figure 2.2)).
Upper compartment
-  Mkroporou* membrane
-  lowtrr fompartment
Figure 2.2 Schem atic diagram o f a Corning Standard Transwell®  insert.
Diagram o f  a Coming Standard Transwell® insert resting in a well o f  a 24-well-plate. During 
migration and invasion assays the cells that are here depicted as resting on the upper side o f  the 
microporous membrane, traverse through the pores and attach to the bottom o f  the insert. 
Figure acquired from
http://catalog2.coming.com/Lifesciences/media/pdf/transwell_guide.pdf
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The inner membrane of the inserts was coated using BD Matrigel™ Basement 
Membrane Matrix, a solubilised biologically active basement membrane 
prepared from the Engelbreth-Holm-Swarm mouse sarcoma containing laminin 
and collagen IV as its major components. 50pl of a 1 in 3 dilution of BD 
Matrigel™ Basement Membrane Matrix in ice-cold wRPMI (without 
supplements) was pipetted unto the porous membrane of each insert, the inserts 
placed in a 24-well plate and the plate incubated at 37°C for 2 hours until the 
gel matrix had set.
Cells were harvested by trypsinisation as described previously and then seeded 
into the inserts at a density of 5x10s cells/ml in EM ± Faslodex (10'7M) ± 
treatments (200pl). All conditions were performed in duplicate inserts. EM ± 
Faslodex (10’7M) ± treatments (650pl) was pipetted into the wells of the plate 
containing the respective inserts and the plate incubated at 37°C in a 5% CO2 
atmosphere for 48 hours.
Following incubation, the supernatants of the inserts were discarded; and non- 
invasive cells and gel matrix removed by gently wiping the inside of the insert 
membrane with a cotton swab. Those cells that had invaded the gel matrix and 
the pores of the membrane and adhered to the outside of the insert were fixed 
in 3.7% formaldehyde in PBS for 10 minutes, washed with PBS and left to dry 
for 5 minutes. The membranes were then excised from the inserts using a 
scalpel blade and mounted (cells pointing upwards) onto microscope slides in 
duplicate using VectorShield® hard-set mounting medium which contains the 
nuclear stain DAPI. Microscope slides were stored in the dark at 4°C. To 
determine the number of invading cells the number of DAPI-stained nuclei of 
each membrane in 5 non-overlapping fields of view at 20 x magnification was 
recorded using a Leica DM-IRE2 fluorescent microscope (Leica Microsystems 
Imaging Solutions Ltd, Cambridge, UK) connected to a Hamamatsu C4742-96 
digital camera (Hamamatsu Photonics UK Ltd, HERTS, UK) and a 
PowerMAC G5 computer (Apple Computer Inc., CA, USA) running 
Improvision® OpenLab V4.04 software (Improvision®, Coventry, UK). Data
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was presented as mean cell count/membrane. Also, general observations were 
made, recording the appearance of the nuclei following different treatments.
2.9 Cell Migration Assay
Analysis of migratory capacity of WTMCF-7 and FAS-R cells under basal 
conditions and following growth factor and inhibitor treatment was carried out 
using the Transwell® inserts described for the invasion assay (figure 2.2); 
however, for this assay the outer side of the membrane of the inserts was 
coated with the chemo-attractant fibronectin. The lower sides of the inserts 
were coated by pipetting 250pl fibronectin solution (lOpg/ml in wRPMI 
without supplements) into the wells of a 24-well-plate and placing the 
Transwell® inserts into the wells such that the membrane undersides were 
submerged in the solution. The plate was then incubated at 37°C; 2 hours later 
the inserts were rinsed with PBS and left to dry.
Cells were harvested and seeded into wells as described in section 2.8 and 
cultured for 24 hours.
Following incubation, the supernatants of the inserts were discarded; and non- 
migratory cells removed by gently wiping the inside of the insert membrane 
with a cotton swab. Those cells that had migrated through the pores of the 
membrane and adhered to the outside of the insert were fixed in 3.7% 
formaldehyde in PBS for 15 minutes, washed with PBS and then stained with 
crystal violet (0.5% in H2O) for 20 minutes. Following several sequential 
washes in PBS to remove excess crystal violet dye, inserts were left to dry 
before being photographed and analysed using an Olympus BH-2 phase 
contrast microscope attached to an Olympus DP-12 digital camera system 
(both Olympus, Oxford, UK). For each membrane, the number of cells in 5 
non-overlapping fields of view at 10 x magnification was recorded; and data 
was presented as mean cell count/field.
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2.10 Scatter Assay
The extent to which HGF/SF induced dispersion of compact WTMCF-7 and 
FAS-R cell colonies and the effect of inhibitors on the scatter response was 
determined using scatter assays.
Cells were harvested by trypsinisation as described previously and seeded into 
the wells of a 12-well plate at a density of 0.2x105 cells/ml in EM ± Faslodex 
(10‘ M) (1 ml/well; seeding density had been optimised empirically). The plate 
was then incubated at 37°C in a 5% CO2 atmosphere until cells had attached 
and formed discrete colonies (approximately 3 days, depending on cell type). 
Upon colony formation, medium was replaced and HGF/SF (20ng/ml) and 
inhibitors added where appropriate. 24 hours later, medium was aspirated and 
cells fixed by the addition of 3.7% formaldehyde in PBS (1 ml/well). Scatter 
response was assessed visually and selected representative colonies were 
photographed using a Leica DM-IRE2 inverted microscope (see section 2.4).
2.11 Immunofluorescence
Expression and localisation of MMP-1, MMP-2 and MMP-9 was investigated 
using immunofluorescence microscopy. As with Western blotting, the choice 
of MMP family members to be further studied at protein level was dictated by 
both which family members had primarily been linked to invasive behaviour in 
the literature and also by which MMPs had previously been successfully 
detected using immunofluorescent analysis by other investigators.
Since the location of MMPs can be both intracellular and extracellular, i.e. on 
the cell membrane; both permeabilised and non-permeabilised cells were set up 
for immunofluorescence analysis.
WTMCF-7 and FAS-R cells were cultured on thin coverslips until log-phase 
growth was reached. After the removal of cell culture medium, cells were first 
washed gently with PBS, then fixed with 3.7% formaldehyde in PBS 
(lOOpl/coverslip) for 15 minutes at room temperature, followed by a further 
washing with PBS. Permeabilisation buffer (see buffer appendix) was added to
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one set of coverslips (lOOpl/coverslip) for 10 minutes before cells were washed 
and blocked by the addition of 10% normal goat serum in immunofluorescence 
buffer (see buffer appendix) (lOOpl/coverslip) at room temperature for 15 
minutes. The other set of coverslips containing the non-permeabilised cells was 
blocked immediately following formaldehyde fixation. After blocking, cells 
were washed with PBS and incubated with the appropriate primary antibody 
(MMP-1, MMP-2 or MMP-9 primary antibody (table 2.9)) in a 1:50 dilution in 
immunofluorescence buffer (see buffer appendix) (lOOpl/coverslip) for 1 hour 
at room temperature in a humidified chamber. After 3 consecutive PBS 
washes, cells were then incubated with the appropriate secondary Alexa-488- 
conjugated antibody (1:1000 dilution in immunofluorescence buffer; 
lOOpl/coverslip) for 1 hour in a dark chamber. Cells were subsequently washed 
with PBS and incubated with Phalloidin-594 (lOOpl/coverslip) to stain actin 
filaments for 15 minutes. Cells were then mounted onto microscope slides 
using VectorShield® soft-set mounting medium containing the nuclear stain 
DAPI; and nail varnish was used to seal the edges of the coverslips. Slides 
were kept in the dark until they were analysed on a Leica fluorescence 
microscope (section 2.8) using an oil immersion lens at 63x magnification. 
Relevant controls (secondary antibody only; a secondary antibody from a 
different species) were used to avoid any chances of cross staining and false 
positive results.
2.12 Statistical Analysis
Where possible, statistical significance of data generated from comparisons 
between cell lines or from comparisons between treated and control cells was 
analysed using independent two-tailed Student’s t-test and ANOVA (ANalysis 
Of VAriance) with post-hoc tests (Dunnett’s t-test and Tamhane’s T2 test). 
These analyses were performed using the statistical analysis program SPSS 
V12.0.2 (SPSS Inc., Illinois, USA).
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3 Characterisation of the Adverse Phenotype of FAS-R 
Cells
Introduction and Aims
As is the case with tamoxifen, resistance can also develop to long-term 
faslodex treatment resulting in disease relapse and increased patient mortality 
(Cheung et al., 2006, Robertson et al, 2005). Clarification of the molecular 
changes underlying development of resistant growth is therefore urgently 
needed in order to inhibit, or at least delay, the emergence of such a state. To 
this end, a faslodex-resistant xenograft model (Massarweh et al., 2006) as well 
as several faslodex-resistant cell lines (Frogne et a l , 2009, Shaw et al., 2006, 
Liu et al., 2006, Sommer et al., 2003, Brunner et al., 1997, Lykkesfeldt et al., 
1995) including our in-house cell model (Nicholson and Johnston, 2005) have 
been established. The majority of studies using the above models have 
primarily focused on the cellular growth component of faslodex resistance, 
investigating the changes in the cell signalling system that enable resistant cells 
to circumvent the growth-inhibitory effect of faslodex treatment.
In contrast, one of the aims of this study was to determine whether, and how, 
acquisition of faslodex resistance in vitro affects cellular phenotype with 
respect to aggressive behaviour. Previous investigations using models of 
acquired tamoxifen resistance have revealed that acquisition of an endocrine- 
insensitive state is accompanied not only by oestrogen-independent growth but 
also by altered cell-cell and cell-matrix adhesive interactions which promote an 
aggressive in vitro phenotype as demonstrated by migration and invasion 
assays (Hiscox et al., 2006, Hiscox et al., 2004). In order to determine whether 
acquisition of faslodex resistance gives rise to a similar phenomenon, FAS-R 
cells were further characterised with particular emphasis on their in vitro 
aggressive behaviour.
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3.1 Results
3.2.1 FAS-R Cells Display an Aggressive Invasive In Vitro Phenotype 
compared to WTMCF-7 Cells
Cell counting experiments were performed to compare the growth rates of 
WTMCF-7 and FAS-R cells. As figure 3.1A demonstrates, FAS-R cells 
displayed comparable growth rates until approximately day 9 under control 
conditions, i.e. in the absence of faslodex. After this point, however, FAS-R 
cell growth rates increased until they were noticeably higher compared to 
WTMCF-7 growth rates at day 11. Furthermore, WTMCF-7 cell growth rates 
were significantly inhibited in the presence of faslodex whilst FAS-R cell 
growth was unaffected. The effect of E2 and tamoxifen on WTMCF-7 and 
FAS-R cell growth was also examined. In the wildtype, growth rates were 
virtually unchanged only until day 4; with the growth-promoting effect of E2 
and the inhibitory action of tamoxifen becoming obvious by day 6 and peaking 
at day 11 (figure 3.1B). In FAS-R cells, however, E2 and tamoxifen had no 
effect on growth rates whatsoever (figure 3.1C).
Development of tamoxifen resistance was accompanied by morphological 
changes; hence WTMCF-7 and FAS-R cell morphology was studied using 
differential interference contrast microscopy in order to see whether 
development of faslodex resistance changed the appearance of FAS-R cells. A 
Leica DM-IRE2 inverted microscope with a Hoffman condenser was used to 
photograph live cells; representative images are shown in figure 3.2. While 
WTMCF-7 cells grew in distinct, tightly packed colonies FAS-R cells were 
spiky and smaller in size, lacked cell-cell contacts, and thus had a predilection 
for growth in a looser, disorganised fashion, overall displaying a more de­
differentiated, angular morphology reflective of EMT (Kang and Massague, 
2004, Thiery, 2003). Closer inspection of individual cells suggested membrane 
ruffling and potential filopodia and lamellipodia formation.
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Figure 3.1 Growth o f  W TM CF-7 and FAS-R cells.
WTMCF-7 and FAS-R cells were seeded in EM ± Faslodex (10'7M) at a density o f  
30,000 cells/well and cell counts were performed on days 1, 4, 6, 8 and 11 using a 
Beckman Coulter™ Multisizer II. Cell numbers at each time point were determined in 
triplicate and the experiment repeated 3 times; a representative graph displaying mean 
cell counts ± S.D. is shown above (A).
WTMCF-7 (B) and FAS-R (C) cells were also seeded in EM ± tamoxifen (10'7M) and 
EM ± E2(10*7M). Cell counts were performed on days 1, 4, 6, 8 and 11 as before; 
representative graphs displaying mean cell counts ± S.D. are shown on the following 
page (B and C).
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Figure 3.2 Basal morphology o f W TM CF-7 and FAS-R cells.
WTMCF-7 (A) and FAS-R (B) cells were cultured in EM ± Faslodex (10'7M) until log- 
phase growth was reached. Representative images o f  live cells were captured at 20x 
magnification using a Hamamatsu C4742-96 digital camera attached to a Leica DM- 
1RE2 inverted microscope with a Hoffman condenser.
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To elucidate the mechanisms underlying endocrine insensitivity Tenovus 
Centre for Cancer Research had previously established a tamoxifen-resistant 
breast cancer cell model (Knowlden et al., 2003). Studies with this in-house 
model revealed that acquisition of an endocrine-resistant state in these cells 
was accompanied by transition to a more aggressive phenotype displaying 
significantly increased motile and invasive behaviour in vitro (Hiscox et al, 
2004). In order to establish whether acquisition of faslodex resistance had 
resulted in a similar augmentation of metastatic potential, the intrinsic 
migratory and invasive capabilities of FAS-R cells were assessed using in vitro 
migration and invasion assays respectively.
As representative images of Transwell® insert membranes in figure 3.3A 
illustrate, an increased number of cells (stained purple) traversed the pores 
(smaller clear circles) of the fibronectin-coated membrane in the FAS-R cell 
population as compared to WTMCF-7 cells. This increase in migratory 
capacity compared to WTMCF-7 cells was confirmed by quantitation of the 
assay. Data obtained from three independent experiments revealed a 1.6-fold 
increase in the migration rate of basal FAS-R cells as compared to that of basal 
WTMCF-7 cells (figure 33B).
A similar trend was observed for the invasive capacity of FAS-R cells. As 
representative images of DAPI-stained cell nuclei of the insert membranes in 
figure 3.4A show, an increased number of cells invaded the matrigel-coated 
membrane in the FAS-R cell population as compared to the WTMCF-7 cell 
population. Quantitation of the assay confirmed the increase in invasive 
behaviour in FAS-R cells as compared to their wild-type counterpart. Results 
of three independent experiments showed that basal FAS-R cell invasion was 
8.2-fold greater than that of basal WTMCF-7 cells (figure 3.4B).
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Figure 3.3 Basal migration of W TM CF-7 and FAS-R cells.
The migratory capacities o f  WTMCF-7 and FAS-R cells were determined using in vitro  
cell migration assays as described in section 2.9. Crystal-violet-stained cells were 
photographed at 20x magnification using an Olympus BH-2 phase contrast microscope; 
representative images are shown above (A). Quantification was by counting the number 
o f  migratory cells in 5 non-overlapping fields o f  view; data (mean cells/field o f  view) 
are presented as % o f  WTMCF-7 ± S.D. (B). As can be seen, FAS-R cells display an 
increased migration rate compared to WTMCF-7 cells.
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Figure 3.4 Basal invasion o f  W TM CF-7 and FAS-R cells.
The invasive capacities o f  WTMCF-7 and FAS-R cells were determined using in vitro  
cell invasion assays as described in section 2.8. DAPI-stained cell nuclei were visualised 
and photographed at 20x magnification using a DM-IRE2 fluorescent microscope 
connected to a Hamamatsu C4742-96 digital camera; representative images are shown 
above (A). Quantification was by counting the number o f  invasive cells in 5 non­
overlapping fields o f  view; data (mean cells/field o f  view) are presented as % o f  
WTMCF-7 ±  S.D. (♦ p<0.001 vs. WTMCF-7) (B). As can be seen FAS-R cells display a 
significantly increased invasion rate compared to WTMCF-7 cells.
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ER positivity and oestrogen signalling through the ER have been reported to 
suppress acquisition of a more motile and invasive phenotype (Hiscox et al., 
2007, Platet et al., 2004, Rochefort et al., 1998). Conversely ER negativity, an 
important clinical feature of 30% of breast cancer patients on presentation and 
also apparent in some ER-positive carcinomas at the time of tamoxifen relapse 
(Gee et al., 2005), heralds a more proliferative and aggressive phenotype and 
consequently, poor prognosis (Nicholson et al., 1993). In order to establish 
whether the aggressive phenotype of FAS-R cells was accompanied by ER 
negativity, ERa gene and protein expression studies were performed. ERa gene 
expression profiles of FAS-R and WTMCF-7 cells generated using Asymetrix 
cDNA array technology clearly show markedly lower ERa mRNA levels in 
FAS-R cells as compared to in WTMCF-7 cells (figure 3.5; [data provided 
courtesy of J. Gee and R. McClelland]). This finding was corroborated by 
semi-quantitative PCR (figure 3.6A).
ERa protein levels were measured using Western Blotting and showed FAS-R 
cells to be ERa-negative as opposed to their ERa-positive wild-type 
counterparts (figure 3.6B). Immunocytochemical analysis further confirmed 
the ERa-negative status of FAS-R cells; as can be seen in figure 3.6C, intense 
nuclear staining was observed in WTMCF-7 cells whereas virtually no staining 
could be detected in FAS-R cells.
Collectively the above results demonstrate that loss of ERa in FAS-R cells 
results in the development of an adverse phenotype characterised by increased 
growth rate, altered morphology and augmented intrinsic in vitro aggressive 
behaviour.
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Figure 3.5 ERa gene expression profiles o f W TM CF-7 and FAS-R cells generated  
using Affym etrix cDNA array technology.
WTMCF-7 and FAS-R cells were cultured in EM ± Faslodex (10‘7M) until log-phase 
growth was reached. Total RNA was extracted as described in section 2.5.1. Total RNA 
samples were DNase 1-treated to eliminate any genomic DNA contamination and 
subsequently purified using the QIAGEN RNeasy mini kit. Following RNA 
quantification and qualitation by denaturing agarose gel electrophoresis, samples were 
processed and hybridised to Asym etrix GeneChip® Human Genome U133A arrays 
(Central Biotechnology Services, Cardiff University, Cardiff, UK). Hybridised arrays 
were scanned and analysed using Microarray Suite 5.0 software (Affymetrix). Internal 
control gene expression analysis was used to confirm data quality. Comparative gene 
expression analysis was performed on median-normalised, log-transformed data using 
Genesifter software (www.genesifler.net). The gene expression profile depicted above 
(presented as mean signal intensity o f  the ERa transcript o f  WTMCF-7 and FAS-R 
cells) shows higher ERa expression in WTMCF-7 cells compared to FAS-R cells. Data 
was provided courtesy o f  J. Gee and R. McClelland.
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Figure 3.6 ERa mRNA and protein expression levels in W TM CF-7 and FAS-R  
cells.
RT-PCR analysis revealed higher ERa expression levels in WTMCF-7 cells as 
compared to FAS-R cells (A), as already indicated by prior Affymetrix gene expression 
analysis (previous page, figure 3.5). At protein level, the ERa status o f  FAS-R cells as 
compared to WTMCF-7 cells was found to be negative as shown by WB (B) and 
immunohistochemical staining (C) (see next page).
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4 MMP Expression and Role in Invasiveness of FAS-R 
Cells
4.1 Introduction and Aims
As established in the previous chapter, acquisition of faslodex resistance in 
WTMCF-7 cells resulted in increased cell motility and overall aggressive 
behaviour. Although clearly a significant observation, the molecular changes 
underlying this phenotypical change remain largely unknown.
Tumour cell invasion and metastasis is a multi-step process which involves 
proteolytic degradation of the ECM, alteration of cell-cell and cell-matrix 
attachments and migration through the basement membrane (Kleiner and 
Stetler-Stevenson, 1999, Liotta et al., 1980b). The metastatic potential of 
various tumours had been correlated to the ability of the tumour cells to 
degrade basement membrane collagen early on (Liotta et al., 1980a, Liotta et 
al., 1980b), and since several in vivo and in vitro studies have demonstrated the 
importance of MMPs in the invasive process. Numerous studies on clinical 
specimens have revealed increased MMP expression in virtually all 
malignancies compared to normal tissue (Konstantinopoulos et al., 2008); 
furthermore, augmented MMP proteolytic activity has been associated with 
acquisition of an invasive phenotype, advanced stage metastatic disease and 
poor prognosis (Konstantinopoulos et a l, 2008).
Based on the widely acknowledged role of MMPs in invasion, this study aimed 
to investigate whether aberrant MMP and TIMP expression regulation might 
contribute to the molecular changes that promote development of an aggressive 
phenotype in faslodex resistance.
4.2 Results
4.2.1 The Role of Differential MMP Expression in FAS-R Cell Invasion
As demonstrated in chapter 3, FAS-R cells are more invasive as compared to 
WTMCF-7 cells. In order to be able to demonstrate a role for MMP proteolytic
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activity in FAS-R cell invasion, invasion assays were carried out in the 
presence of a broad-spectrum inhibitor, the premise being that decreased 
invasion following MMP inhibition would indicate an involvement of MMPs 
in FAS-R cell invasion.
A range of concentrations were used, with 40pM being chosen as the optimum 
concentration (figure 4.1). Growth curves performed in parallel confirmed the 
MMP inhibitor to be non-toxic to the cells at that concentration (figure 4.2). 
Under these conditions, a significant reduction in FAS-R cell invasion was 
observed (figure 4.1). This suggested that MMPs might play a role in the 
adverse phenotype displayed by FAS-R cells.
After the initial comparison between invasive capacities of WTMCF-7 and 
FAS-R cells (section 3.2.1; figure 3.4), all further invasion studies focused 
solely on FAS-R cells; the poor intrinsic invasiveness of WTMCF-7 cells 
unfortunately rendering inhibition studies unfeasible.
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Figure 4.1 The effect o f broad-spectrum  M M P inhibition on invasion rates o f  FAS- 
R cells.
MMP inhibition was achieved by using a broad-spectrum MMP inhibitor at a range o f  
doses (20, 30 and 40pM ). The effect o f  MMP inhibition on the invasive capacities o f  
FAS-R cells was determined using in vitro  cell invasion assays as described in section 
2.8. DAPI-stained cell nuclei were visualised and photographed at 20x magnification 
using a DM-IRE2 fluorescent microscope connected to a Hamamatsu C4742-96 digital 
camera. Quantification was by counting the number o f  invasive cells in 5 non­
overlapping fields o f  view; data (mean cells/field o f  view) are presented as % o f  control 
± S.D. (* p<0.001 vs. FAS-R control). As can be seen MMP inhibition at 40pM  
significantly reduced the invasive capacity o f  FAS-R cells.
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Figure 4.2 The effect o f MMP inhibitor III on FAS-R cell growth.
FAS-R cells were seeded in EM ± MMP inhibitor III (40pM ). Cell counts were 
performed as before on day 1, 4, 6 and 8. Cell numbers at each time point were 
determined in triplicate and the experiment repeated 3 times; a representative graph 
displaying mean cell counts ± S.D. is shown above. As can be seen, MMPI III did not 
affect FAS-R cell growth.
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4.2.2 Differential Expression of MMPs and TIMPs in Basal Endocrine- 
Sensitive and Endocrine-Resistant Breast Cancer Cells
Next, the MMP and TIMP profiles of FAS-R cells as compared to WTMCF-7 
cells under basal conditions were established; the choice of MMP enzymes to 
be studied being governed by which family members had primarily been 
associated with invasion in the literature. Serum-starved WTMCF-7 and FAS- 
R cells were probed for mRNA expression of MMP-1, MMP-2, MMP-7, 
MMP-9, MMP-10, MMP-11, and MMP-13 as well as for mRNA expression of 
TIMP-1 to TIMP-4 by RT-PCR (figure 4.3). MMP-7 was the only gene 
undetected in both cell lines (data not shown). WTMCF-7 cells expressed all 
the other MMPs listed above with the exception of MMP-2; furthermore, 
expression of individual MMP family members was variable. Interestingly, 
high levels of MMP-2 were detected in FAS-R cells, along with modest 
expression of MMP-11 and MMP-13. Whilst WTMCF-7 cells expressed all 
four TIMP family members, only TIMP-2 to TIMP-4 were detected in FAS-R 
cells. FAS-R cells displayed lower TIMP-2 mRNA levels compared to 
WTMCF-7 cells while TIMP-3 expression was modestly increased in FAS-R 
cells. To establish whether this differential MMP gene expression observed at 
mRNA expression level was also apparent at protein level, gelatin zymography 
was performed on the conditioned supernatants of basal serum-starved 
WTMCF-7 and FAS-R cells. As outlined in section 2.7, this method allows 
detection of secreted active and latent forms of gelatinases, MMP-9 and MMP- 
2. A commercially available MMP-2/MMP-9 standard was included in each 
experiment as in internal assay control. It also served to ascertain whether the 
proteins detected were of the correct molecular weight and hence allowed them 
to be clearly identified as MMP-2 and MMP-9.
Adjusting the amount of supernatant loaded for both samples according to cell 
numbers allowed direct comparison of the MMP secretion levels of basal 
WTMCF-7 and FAS-R cells. As figures 4.4A and 4.4C show only one protein 
was detected; using the standard this was identified to be the latent form of 
MMP-9 (92kDa) on the basis of its molecular weight.
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Figure 4.3 Basal M M P and TIM P mRNA expression levels in W TM CF-7 and FAS- 
R cells as determ ined by sem i-quantitative RT-PCR.
WTMCF-7 and FAS-R cells were cultured in EM ± Faslodex (10‘7M) until log-phase 
growth was reached, serum-starved in DCCM O/N and lysed. Then gene expression 
analysis was performed as outlined in section 2.5 for MMP-1, MMP-2, MMP-9, MMP- 
10, M M P-11 and MMP-13 and for TIMP-1 to TIMP-4 using specially designed primers. 
Data was normalised using p-actin and presented as mean expression levels ± S.D. (n=3) 
(A-K). Representative images (A-K) are shown above and on following pages.
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Figure 4.4 Basal M M P-9 and M M P-2 protein expression levels in W TM CF-7 and 
FAS-R cells as determined by zym ography.
WTMCF-7 and FAS-R cells were cultured until log-phase growth was reached and then 
transferred to DCCM and serum-starved for 24h. Cell-conditioned supernatants were 
collected and processed as described in section 2.6.2. Supernatants were then subjected 
to zymographic analysis as detailed in section 2.7. A commercial MMP-2/-9 standard 
was run alongside test samples as an internal assay control. Data was normalised using 
protein concentration values obtained from respective cell lysates and presented as mean 
expression levels (n=2). Representative images are shown above. Latent MMP-9 was 
detected in WTMCF-7 cells but not FAS-R cells while latent MMP-2 was not detected 
in either cell type (A and E). In order to confirm the MMP nature o f  the protein detected, 
gels were incubated with the chelating agent EDTA (10pM ) (B), with the serine 
proteinase inhibitor PMSF (ImM ) (C) and a broad-spectrum MMP inhibitor (40pM ) 
(D). Incubation with both EDTA and the inhibitor abolished latent MMP activity (B and 
D) while incubation with PMSF did not (C and F).
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Also, MMP-9 expression was restricted to WTMCF-7 cells. So while MMP-2 
was not detected in either cell line, latent MMP-9 was only expressed by 
WTMCF-7 cells.
Biochemical validation of the MMP nature of the protein observed was carried 
out by standard confirmatory tests. The catalytic action of MMPs is dependent 
on both the presence of a zinc ion in the active site and stabilisation of the 
enzyme by calcium ions, therefore incubation with an agent such as EDTA that 
chelates divalent cations leads to loss of MMP activity; this has been 
demonstrated by several investigators (Murphy and Crabbe, 1995, Knowiden et 
al, 1995). Hence EDTA incubation was performed to confirm the MMP nature 
of the protein detected. As figure 4.4B illustrates, incubation in activating 
buffer containing EDTA (10pM) resulted in complete loss of MMP activity, 
proving that the clear band had been caused by proteolytic activity of latent 
MMP-9.
Incubation was also performed in the presence of the serine protease inhibitor 
PMSF to further confirm specific MMP presence rather than general protease 
activity. Since presence of the band was unaffected by PMSF (figure 4.4C) it 
was concluded that the protease detected was not a serine protease.
Moreover, incubation was additionally carried out in the presence of the broad- 
spectrum MMP inhibitor, MMP inhibitor III, which had previously been shown 
to reduce invasiveness of faslodex-resistant cells. Incubation in activating 
buffer containing MMP inhibitor III (40pM) resulted in complete loss in MMP 
activity (figure 4.4D).
As gelatin zymography only permits gelatinase detection, and also to further 
corroborate the above observations, Western Blot analysis of MMP protein 
expression in basal WTMCF-7 and FAS-R cells was carried out. Both cell 
lysates and cell-conditioned supernatants were subjected to immunoblotting 
using antibodies specific to MMP-2, MMP-9, and MMP-1. However, none of 
the three MMPs were detectable; neither in the lysate nor the supernatants
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despite the use of at least two different antibodies for each of the three 
proteases.
Since the presence of MMP-2 and MMP-9 could not be established by Western 
Blot analysis, immunofluorescent detection of the proteases was attempted. 
However, as before, neither MMP-2 and MMP-9 nor MMP-1 was detectable 
with the antibodies employed.
4.23 The Effect of Matrix on MMP and TIMP Expression in WTMCF-7 
and FAS-R Cells
The data presented so far suggests only modest expression of most MMPs and 
TIMPS in FAS-R cells. However, during migration and invasion assays, cells 
are in prolonged contact with fibronectin and the reconstituted basement 
membrane, matrigel. Fibronectin is an ECM component integral to adhesion 
and migration processes while matrigel is a basement membrane preparation 
rich in laminin, collagen IV and many other ECM proteins. Since these ECM 
components are akin to the in vivo environment, they stimulate complex 
cellular behaviour in vitro and have been reported to increase MMP and TIMP 
expression (Balduyck et al., 2000, Bafetti et al., 1998). Therefore, matrigel and 
fibronectin coating was chosen to simulate the in vivo cell environment in the 
following experiments. Thus, WTMCF-7 and FAS-R cells were grown on 
these different matrices (plastic, matrigel and fibronectin) before mRNA and 
protein levels were analysed using RT-PCR and zymography, respectively, to 
determine the effect of cell environment on MMP and TIMP expression 
(figures 4.5 and 4.6). In the case of matrigel, both a thin gel layer and a thick 
gel matrix were employed where cells would predominantly either rest on top 
of the gel layer or invade the matrix; the rationale being that exposure to 
differing cell environments which reflect separate aspects of the in vivo tumour 
microenvironment environment may result in different MMP expression 
profiles. In WTMCF-7 cells both culture on thin and thick matrigel layers did 
not result in increased MMP and TIMP expression levels, but instead markedly 
decreased the expression levels of MMP-1, MMP-9 and MMP-10 (figure 4.5).
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Figure 4.5 M M P and TIM P mRNA expression levels o f  W TM CF-7 and FAS-R cells 
grown on different matrices as determined by sem i-quantitative RT-PCR.
WTMCF-7 and FAS-R cells were cultured on plastic, matrigel and fibronectin under 
serum-free conditions in DCCM until log-phase growth was reached. In the case o f  
matrigel, both a thin and a thick coating method were employed. The effect o f  different 
matrices on MMP-1, MMP-2, MMP-9, MMP-10, M M P-11 and MMP-13 and TIMP-1 to 
T1MP-4 expression was determined using gene expression analysis as outlined in section 
2.5. Data was normalised using p-actin and presented as mean expression levels (n=2) 
(A-K.). Representative images (A-K) are shown above and on following pages.
1 0 7
Chapter Four  -  Results
J
CL
c!S
io>00
'£H
E
<L>
00
' £C3
E
Q8fl
g(O(S
WTMCF-7
uIS■S -S .5
u
i
a.
00 -J8fi
g
FAS-R
MMP-9
u>_a>
£ 1
cB<u2
0 -
plastic
. I  I
matrigel thin matrigel thick fibronectin
I WTMCF-7 
I FAS-R
D
J
Cl
e
IS
<uoo
CJ
o8cOI—
-C
WTMCF-7
Ja.
c
IS
4>
00
o
0  6  c:
1  
IS
FAS-R
MMP-10
p>_a>
£ iI s
cea■
2 L I
I WTMCF-7 
I FAS-R
plastic matrigel thin matrigel thick fibronectin
Figure 4.5 continued.
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As was observed throughout the course of this study the expression of MMP-2 
in WTMCF-7 cells was detectable in some sample sets but not in others; this 
suggested that levels are exceedingly low and at detection threshold. Low 
levels of MMP-2 were detected under control conditions; and culture on both 
matrigel layers seemed to reduce its expression. Culture on both matrigel layers 
furthermore distinctly lowered TIMP-2 and TIMP-4 expression.
Similarly, culture on fibronectin did not cause a marked increase in MMP and 
TIMP expression levels. In fact, a noticeable decrease in mRNA expression 
levels of MMP-9, MMP-11, and TIMP-4 was observed on culture on 
fibronectin as compared to culture on plastic.
Basal characterisation of MMP expression has already shown that MMP 
expression levels in FAS-R cells are lower than those observed for WTMCF-7 
cells, with the exception of MMP-2. This trend continued on culture on matrix. 
MMP -9, which was not expressed in basal FAS-R cells, remained undetected 
on culture on matrigel and fibronectin while the expression levels for MMP-13 
following culture on matrix remained almost unchanged. Only MMP-2 and 
MMP-11 showed an upregulation in expression levels following culture on 
matrigel compared to plastic, whilst MMP-1 and MMP-10 gene expression 
seemed to be induced by matrigel. Whilst MMP-10 was undetected in FAS-R 
cells previously (section 4.2.2; figure 43D), expression was observed in these 
samples. It may be that this apparent inconsistency is due to the fact that 
expression levels of MMP-10 in basal FAS-R cells are extremely low and 
hence just at detection threshold.
In conclusion, with the exception of MMP-2, all MMPs displayed lower 
expression in FAS-R cells despite culture on different matrices. Similarly, 
culture on matrix did not distinctly alter TIMP-1 to TIMP-4 expression in FAS- 
R cells. Collectively these results suggested that cell environment did not 
significantly increase or decrease MMP or TIMP expression levels, 
respectively.
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Zymographic analysis was used to corroborate the above results with respect to 
MMP-9 at protein level (figure 4.6). Unlike before, where the amount of 
supernatant assayed for each sample had been adjusted according to cell 
numbers, for this experiment and subsequent zymographic studies the same 
volume (50pl) was assayed for all samples, and data subsequently normalised 
using protein concentration values obtained from respective cell lysates as 
these were required for downstream assays. As can be seen from figure 4.6C, 
the MMP-9 protein expression profile of FAS-R cells correlated directly to the 
mRNA expression profile. This confirmed that culture on matrix induced 
neither the active nor the latent form of the MMP-9 protein in FAS-R cells. 
Zymography also showed that MMP-2 protein remained undetected following 
culture on matrix despite MMP-2 being expressed at mRNA level.
4.2.4 Role of Growth Factor Signalling in Endocrine-Resistant Growth 
and in MMP and TIMP Expression and Invasion
Basal MMP expression of FAS-R cells has been determined previously (figure 
43). In the in vivo setting, however, cells are exposed to a plethora of growth 
factors, which activate various signalling pathways thus altering expression 
levels of target genes. Furthermore, it is now widely acknowledged that breast 
cancer progression involves complex interactions between steroidal and growth 
factor signalling pathways, and several studies have demonstrated the 
importance of aberrant growth factor signalling in the development of 
endocrine therapy resistance (Nicholson and Johnston, 2005, Nicholson et al., 
2005). Signalling studies carried out on our in-house cell models have 
demonstrated an important role for deregulated growth factor signalling in 
endocrine-resistant growth and invasive behaviour. More specifically, our 
TAM-R and double-resistant TAM/TKI-R cell model systems have revealed 
that endocrine-resistant growth and invasion in these cells is driven by EGFR 
and its ligands EGF and TGF-a and by IGF-1R and its ligand IGF-II, 
respectively (Knowlden et al., 2003, Jones et al., 2004).
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Figure 4.6 M M P-2 and M M P-9 protein expression levels o f W TM CF-7 and FAS-R  
cells grown on different m atrices as determined by zym ography.
WTMCF-7 (A) and FAS-R cells (C) were cultured on plastic, matrigel and fibronectin 
under serum-free conditions in DCCM until log-phase growth was reached. In the case 
o f  matrigel, both a thin and a thick coating method were employed. Cell-conditioned 
supernatants were collected and processed as described in section 2.6.2. Supernatants 
were then subjected to zymographic analysis as detailed in section 2.7 to determine the 
effect o f  different matrices on MMP-2 and MMP-9 protein expression. A commercial 
MMP-2/-9 standard was run alongside test samples as an internal assay control. Data 
was normalised using protein concentration values obtained from respective cell lysates 
and presented as mean expression levels (n=2) (B). Representative images are shown 
above (A and C).
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The protein expression profile and signalling activity of these RTKs in FAS-R 
cells has been investigated previously (figure 4.7; [data provided courtesy of J. 
Gee and J. Knowlden]). While both EGFR and IGF-1R are expressed in FAS-R 
cells, phospho-EGFR and phospho-IGF-lR levels are very low compared to 
their wildtype counterpart, suggesting their signalling activity to be only 
modest. It is therefore unlikely that these two RTKs should play a vital role in 
the invasive behaviour of FAS-R cells.
However, parallel studies employing Affymetrix cDNA array technology had 
recently revealed a distinct increase in c-Met mRNA levels in FAS-R cells as 
compared to in WTMCF-7 cells (figure 4.8A; [data provided courtesy of J. 
Gee and R. McClelland]). This pro-invasive RTK is another receptor 
commonly overexpressed in a wide variety of malignancies. Therefore, 
analysis of c-Met mRNA and protein levels of FAS-R cells was undertaken to 
confirm that c-Met expression was altered in our endocrine-resistant cells. As 
can be seen in figure 4.8B, RT-PCR analysis corroborated the microarray­
generated mRNA profile for c-Met. Protein expression levels of the receptor 
were estimated using Western Blotting. Whilst WTMCF-7 cells did not express 
the c-Met receptor protein, expression of the pro-invasive RTK was detected in 
FAS-R cells (figure 4.9A). This overexpression was further confirmed by 
immunocytochemical analysis as can be seen in figure 4.9B.
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Figure 4.7 Com parison o f EGFR and 1GFR signalling activity in W TM CF-7 and 
FAS-R cells.
Western blot analysis o f  total and phosphorylated levels o f  EGFR (A) and 1GF-1R (B) 
proteins in WTMCF-7 and FAS-R cells (data provided courtesy o f  J. Gee and J. 
Knowlden).
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Figure 4.8 c-M et mRNA expression levels in W TM CF-7 and FAS-R cells.
mRNA expression levels o f  c-Met were increased in FAS-R cells as compared to WTMCF-7 cells as 
shown by Affymetrix cDNA array analysis (A (data provided courtesy o f  J. Gee and R. McClelland)) and 
RT-PCR (B).
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Figure 4.9 c-M et protein expression levels in W TM CF-7 and FAS-R cells.
Protein expression levels o f  c-Met were increased in FAS-R cells as compared to WTMCF-7 
cells as shown by Western Blotting (A) and immunohistochemical staining (B (Hiscox et al., 
2006)).
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While FAS-R cells displayed high levels of membranous c-Met expression 
with predominant staining at intercellular junctions, only very faint staining 
was observed in WTMCF-7 cells. Taken together, these data demonstrated 
distinct overexpression of the pro-invasive RTK c-Met by FAS-R cells.
In order to prove that this receptor was functional, the effect of HGF/SF 
stimulation (20ng/ml for 5 minutes) on c-Met phosphorylation was examined 
by Western Blot analysis. While no c-Met phosphorylation was observed in the 
wildtype, HGF/SF clearly activated both phosphorylation sites, Y1349/1356 
and Y1234/1235, in FAS-R cells (figure 4.10).
Accompanying this activation was an augmentation of the motile capacities of 
FAS-R cells as demonstrated by scatter and migration assays: as figure 4.11 
illustrates, exposure to exogenous HGF/SF (20ng/ml) elicited a strong scatter 
response in FAS-R cells while virtually no colony dispersion was observed in 
WTMCF-7 cells. Similarly, as demonstrated in figure 4.12, FAS-R cell 
migration rates were significantly increased in the presence of exogenous 
HGF/SF (20ng/ml) (6.23-fold) whilst the response of WTMCF-7 cells was 
only modest in comparison (2.42-fold).
As outlined above, the RTKs EGFR, IGF-1R and c-Met are of paramount 
importance to endocrine-resistant cell growth; this warranted further 
investigation to determine whether they played a role in the invasive behaviour 
of FAS-R cells. Invasion assays were therefore performed in the presence of 
their respective ligands EGF, TGF-a, IGF-II and HGF/SF. While both the 
EGFR ligands EGF and TGF-a and the IGF-1R ligand IGF-II did not 
significantly increase the invasive capacity of FAS-R cells, HGF/SF treatment 
resulted in a 2.3-fold increase in FAS-R cell invasion (figure 4.13).
Excitingly, when invasion assays were carried out in the presence of the broad- 
spectrum MMP inhibitor used earlier (again at 40pM), a significant reduction 
in HGF/SF-augmented invasive rates was observed (figure 4.14). This finding 
strongly implicated MMP function in HGF/SF-enhanced invasive behaviour.
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Figure 4.10 HGF/SF activates c-M et receptor phosphorylation in FAS-R cells.
Serum-starved subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF 
(20ng/ml) for 5 minutes. Cell lysates were obtained, subjected to SDS-PAGE analysis and 
probed with antibodies specific for phospho-c-Met Y 1349/1356 and Y1234/1235 and total 
c-Met as outlined in section 2.6. As can be seen, HGF/SF activated both c-Met 
phosphorylation sites in FAS-R cells.
121
Chapter Four  -  Results
WTMCF-7 control
FAS-R control
WTMCF-7 + HGF/SF
>
FAS-R + HGF/SF
Figure 4.11 Colony dispersion in W TM CF-7 and FAS-R cells following HGF/SF  
challenge as determined by scatter assays.
WTMCF-7 (A) and FAS-R cells (B) were seeded in EM ± Faslodex (10 7M) and 
allowed to form discrete colonies prior to 24h HGF/SF (20ng/ml) challenge in DCCM. 
The extent to which HGF/SF induced colony dispersion was determined using cell 
scatter assays as described in section 2.10. Scatter response was assessed visually and 
selected colonies were photographed using a Leica DM-IRE2 inverted microscope; 
representative images are shown above. As can be seen, HGS/SF induced extensive 
colony dispersion in FAS-R cells (B).
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Figure 4.12 The effect o f HGF/SF on migration rates o f  W TM CF- and FAS-R cells.
The effect o f  HGF/SF treatment (20ng/ml) on the migratory capacities o f  WTMCF-7 
and FAS-R cells was determined using in vitro  cell migration assays as described in 
section 2.9. Crystal-violet-stained cells were photographed at 20x magnification using 
an Olympus BH-2 phase contrast microscope; representative images are shown above 
and on the following page (A and C). Quantification was by counting the number o f  
migratory cells in 5 non-overlapping fields o f  view; data (mean cells/field o f  view) are 
presented as % o f  WTMCF-7 ± S.D. (*p<0.001 vs. WTMCF-7 control) and as % o f  
FAS-R cells ± S.D. (*p<0.005 vs. FAS-R control) (B and D). As can be seen HGF/SF 
caused a significant increase in the migratory capacity o f  FAS-R cells.
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Figure 4.13 The effect o f growth factor treatm ent on invasion rates o f FAS-R cells.
The effect o f  EGF (lOng/ml) (A), TGF-a (lOng/ml) (B), IGF-II (lOng/ml) (C) and 
HGF/SF (20ng/ml) (D) treatment on the invasive capacities o f  FAS-R cells was 
determined using in vitro  cell invasion assays as described in section 2.8. DAPI-stained 
cell nuclei were visualised and photographed at 20x magnification using a DM-IRE2 
fluorescent microscope connected to a Hamamatsu C4742-96 digital camera. 
Quantification was by counting the number o f  invasive cells in 5 non-overlapping fields 
o f  view; data (mean cells/field o f  view) are presented as %  o f  control ± S.D. As can be 
seen on the following page HGF/SF clearly increased the invasive capacity o f  FAS-R 
cells (D).
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Figure 4.14 The effect o f broad-spectrum  M M P inhibition on H GF/SF-modulated  
invasion rates o f  FAS-R cells.
MMP inhibition was achieved by using a broad-spectrum MMP inhibitor (40pM ). The 
effect o f  MMP inhibition on HGF/SF-modulated invasive capacities o f  FAS-R cells was 
determined using in vitro  cell invasion assays as described in section 2.8. DAPI-stained 
cell nuclei were visualised and photographed at 20x magnification using a DM-IRE2 
fluorescent microscope connected to a Hamamatsu C4742-96 digital camera. 
Quantification was by counting the number o f  invasive cells in 5 non-overlapping fields 
o f  view; data (mean cells/field o f  view) are presented as % o f  control ± S.D. (*p<0.001 
vs. FAS-R control **p<0.001 vs. FAS-R + HGF/SF). As can be seen, MMP inhibition 
significantly reduced HGF/SF-modulated invasion rates o f  FAS-R cells.
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Following assessment of the contribution of the above RTKs to the regulation 
of invasive behaviour, the effect of their respective ligands on MMP and TIMP 
expression was studied. Serum-starved subconfluent WTMCF-7 and FAS-R 
cells were treated with TGF-a (lOng/ml), EGF (lOng/ml), HGF/SF (20ng/ml), 
IGF-II (lOng/ml) and TP A (lOOnM) overnight and subsequently probed for 
mRNA expression of MMP-1, MMP-2, MMP-7, MMP-9, MMP-10, MMP-11 
and MMP-13 as well as for mRNA expression of TIMP-1 to TIMP-4 by RT- 
PCR (figure 4.15). TPA-treated samples served as positive controls for MMP 
and TIMP expression. The gene expression data shown in graphs and gel 
photos in figure 4.15 has been summarised in tables for each individual target 
gene in the appendix (see p. 247).
EGF and TGF-a clearly augmented MMP-1, MMP-9, MMP-10, TIMP-1 and, 
to a lesser extent, TIMP-4 expression in WTMCF-7 cells suggesting that 
expression regulation of these genes underlies the EGFR signalling pathway 
(figure 4.15). Conversely, in FAS-R cells all the above genes (with the 
exception of MMP-10 at this early time-point) were upregulated by HGF/SF, 
suggesting that in these cells expression regulation of these genes underlies the 
c-Met signalling pathway instead. Moreover, while EGF and TGF-a also 
increased TIMP-1 and TIMP-4 expression in FAS-R cells, a much more 
distinct upregulation was observed upon HGF/SF stimulation. These results 
seem to imply a switch in MMP and TIMP expression regulation from the 
EGFR pathway in WTMCF-7 cells to the HGF/SF/c-Met signalling axis in 
FAS-R cells. The only exception to this was in the form of MMP-2, the 
expression of which seemed to be upregulated in the presence of EGF but 
suppressed following HGF/SF treatment in FAS-R cells. MMP-7 was 
undetectable in both cell types. The apparent inconsistency of sudden MMP-9 
detection in basal FAS-R cells is thought to be due to mRNA levels at 
detection threshold that are detected in some samples but not in others.
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Figure 4.15 M M P and TIM P mRNA expression levels o f W TM CF-7 and FAS-R cells 
following growth factor challenge as determ ined by sem i-quantitative RT-PCR.
Serum-starved subconfluent WTMCF-7 and FAS-R cells were treated with TGF-a (lOng/ml), 
EGF (lOng/ml), HGF/SF (20ng/ml), IGF-II (lOng/ml) and TPA (lOOnM) for 16 hours. The effect 
o f  these growth factors on MMP-1, MMP-2, MMP-9, MMP-10, M M P-11 and MMP-13 and 
TIMP-1 to TIMP-4 expression was determined using gene expression analysis as outlined in 
section 2.5. Data was normalised using p-actin and presented as mean expression levels (n=2) (A- 
K). Representative images (A-K) are shown above and on following pages.
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Again, zymography was used to corroborate the above results at protein level 
(figure 4.16). As explained above, data was normalised using protein 
concentration values obtained from respective cell lysates. Analysis of MMP-9 
protein expression by this method confirmed the observations made at mRNA 
level, with the EGFR ligands EGF and TGF-a augmenting expression in the 
wild-type whilst HGF/SF significantly increased MMP-9 secretion in FAS-R 
cells. As before, only latent MMP-9 was identified while MMP-2 remained 
undetectable. This further supported the hypothesis of regulatory pathway 
switching from EGFR signalling in the wildtype to HGF/SF/c-Met signalling 
in FAS-R cells.
Treatment of WTMCF-7 and FAS-R cells with the c-Met ligand HGF/SF for 
16 hours caused a marked upregulation in MMP-1 and MMP-9 mRNA levels 
and also significantly increased secretion of latent MMP-9. In view of the 
widely accepted role for the HGF/SF/c-Met signalling axis and MMP 
proteolytic activity in invasive cancer in general and the reduction in HGF/SF- 
augmented FAS-R cell invasion following MMP activity inhibition in 
particular, these findings warranted further investigation. The effect of HGF/SF 
treatment (20ng/ml) on MMP expression in FAS-R cells as compared to 
WTMCF-7 cells was thus further analysed at two more time-points, namely 
24h and 4 days, to mirror duration of migration and invasion assays, 
respectively (figure 4.17).
Up to this point, TIMP mRNA levels have been analysed alongside MMP 
expression profiles as it was considered that it was the balance between MMPs 
and their specific inhibitors that ultimately determined overall proteolytic 
behaviour. However, the data resulting from TIMP expression analysis proved 
inconclusive. Furthermore, in light of the multi-faceted and paradoxical role 
ascribed to TIMP family members in carcinogenesis and metastasis it was 
recognised that putting findings into context with regard to these MMP 
inhibitors would be beyond the scope of this project, and analysis of TIMP 
expression was accordingly discontinued at this point.
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Figure 4.16 M M P-9 protein expression levels o f  W TM C F-7 and FAS-R cells 
following growth factor challenge as determ ined by zym ography.
Serum-starved subconfluent WTMCF-7 (A) and FAS-R cells (C) were treated with 
TGF-a (lOng/ml), EGF (lOng/ml), HGF/SF (20ng/ml) and IGF-II (lOng/ml) for 16h. 
Cell-conditioned supernatants were collected and processed as described in section 
2.6.2. Supernatants were then subjected to zymographic analysis as detailed in section 
2.7 to determine the effect o f  growth factor challenge on MMP-2 and MMP-9 protein 
expression. Data was normalised using protein concentration values obtained from 
respective cell lysates and presented as mean expression levels (n=2) (B and D). 
Representative images are shown above (A and C).
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Figure 4.17 M M P mRNA expression levels o f W TM CF-7 and FAS-R cells following  
HGF/SF challenge as determined by sem i-quantitative RT-PCR.
Serum-starved subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF 
(20ng/ml) for 24h and 4 days respectively. The effect o f  HGF/SF on MMP-1, MMP-2, 
MMP-9, MMP-10, M M P-11 and MMP-13 expression was determined using gene 
expression analysis as outlined in section 2.5. Data was normalised using p-actin and 
presented as mean expression levels ± S.D. (n=3) (A-G). Representative images (A-G) 
are shown above and on following pages.
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As before, HGF/SF addition induced MMP-1 and MMP-9 in FAS-R cells at 
both 24h and 4 days (figure 4.17). Interestingly, at these two later time-points 
HGF/SF treatment also resulted in induction of MMP-10 mRNA expression in 
FAS-R cells, another MMP that was augmented following EGF and TGF-a 
treatment in the wildtype and that therefore presumably underlies control of the 
EGFR signalling pathway in those cells while being governed by the 
HGF/SF/c-Met axis in FAS-R cells. This further confirmed the pathway- 
switching hypothesis brought forward earlier. While MMP-1, MMP-9, and 
MMP-10 induction was seen at both time-points, the effect of HGF/SF 
treatment for all three proteins was more pronounced at 24h. As observed 
before, HGF/SF addition again resulted in downregulation of MMP-2 mRNA 
levels in FAS-R cells; this downregulation was more also prominent at the 
earlier time-point of 24h. A similar trend was observed for MMP-13 expression 
in FAS-R cells.
Again, zymography was used to screen WTMCF-7 and FAS-R cells for 
expression of latent and active forms of MMP-9 and MMP-2 (figure 4.18). 
MMP-2 remained undetected in all samples; this confirmed previous findings 
and was consistent with the above observations that HGF/SF downregulated 
MMP-2 gene expression in FAS-R cells. In the case of MMP-9, the protein 
expression profile obtained by zymography correlated directly to the mRNA 
expression profile and revealed induction of secretion of MMP-9 at both time 
points upon HGF/SF treatment of FAS-R cells. Moreover, HGF/SF did not 
induce secretion of active MMP-9, and MMP-9 expression levels of basal and 
HGF/SF-treated WTMCF-7 cells were higher than those detected in FAS-R 
cells for all samples.
Western Blot detection of MMP-9, MMP-2, and MMP-1 in basal WTMCF-7 
and FAS-R cells had been attempted earlier without much success. Since 
stimulation with HGF/SF resulted in such a distinct upregulation of MMP-1 
mRNA levels and MMP-9 protein secretion it was hoped that Western Blot 
detection of MMPs in HGF/SF-treated FAS-R cells would yield a positive
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Figure 4.18 MM P-2 and M M P-9 protein expression levels o f W TM CF-7 and FAS- 
R cells following HGF/SF challenge as determ ined by zym ography.
Serum-starved subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF 
(20ng/ml) for 24h and 4 days respectively. Cell-conditioned supernatants were collected  
and processed as described in section 2.6.2. Supernatants were then subjected to 
zymographic analysis as detailed in section 2.7 to determine the effect o f  HGF/SF 
challenge on MMP-2 and MMP-9 protein expression. Data was normalised using protein 
concentration values obtained from respective cell lysates and presented as mean 
expression levels ± S.D. (n=3) (B). A representative image is shown above (A).
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signal. However, as figure 4.19 illustrates, MMP-9 protein was only visible in 
the TPA-treated TAM/TKI-R sample and in the MMP-2/MMP-9 standard (A), 
whilst MMP-2 was only visible in the standard (B) and MMP-1 was not 
detected at all (C). It was therefore concluded that the commercially available 
antibodies were unsuitable for MMP detection in our model systems and 
Western Blot analysis of MMP expression was accordingly discontinued. 
Casein zymography for the expression analysis of MMP-1 protein was 
performed but the enzyme could not be detected, suggesting MMP-1 protein 
levels to be either just below detection threshold or absent altogether.
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Figure 4.19 MM P-2 and M M P-9 protein expression levels o f W TM CF-7 and FAS-R cells 
as determ ined by Western Blotting.
Serum-starved subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF 
(20ng/ml) for 24h. Serum-starved TAM/TK.I cells were treated with TPA (lOOnM) for 24h. 
Cell-conditioned supernatants were collected and processed as described in section 2.6.2 and 
then subjected to SDS-PAGE analysis as outlined in section 2.6 and probed with at least 2 
different antibodies specific for MMP-9, MMP-2 and MMP-1 respectively. A commercial 
MMP-2/-9 standard was run alongside test samples as an internal assay control. To improve 
chances o f  MMP-2 and-9 detection, cell-conditioned supernatants were concentrated 
following collection (B and C). As can be seen latent MMP-9 was only detected in the TPA- 
treated TAM/TKI-R cells and standard (A and B); latent MMP-2 only in the standard (C).
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pathways by many investigators (Jinnin et al., 2005, Tanimura et al., 2003, 
Tanimura et al., 2002, Kermorgant et al., 2001, Zeigler et al., 1999, Zhang et 
al., 2004). The aim of the present study therefore was to establish whether 
ERK1/2 and PI3K signalling play a role in HGF/SF-mediated MMP-1/-9 and - 
10 expression and in the aggressive behaviour of FAS-R cells.
5.2 Results
5.2.1 The Role of ERK1/2 signalling in HGF/SF-mediated MMP 
Expression and in the aggressive Phenotype of FAS-R Cells
In order to establish whether c-Met signals through the ERK1/2 pathway in our 
cell model as hypothesised, ERK1/2 phosphorylation levels following 
stimulation with HGF/SF were measured by Western Blotting. Subconfluent 
serum-starved WTMCF-7 and FAS-R cells were treated with HGF/SF 
(20ng/ml) for 5 minutes and subsequently immunoprobed for phospho- 
ERK1/2. As can be seen in figure 5.1, phospho-ERKl/2 expression was 
markedly increased in FAS-R cells, proving ERK1/2 to be a target of c-Met in 
these cells; no noticeable increase was seen in WTMCF-7 cells.
To be able to identify a possible role for ERK1/2 signalling in HGF-mediated 
MMP expression and in the adverse FAS-R cell phenotype, ERK1/2 signalling 
was blocked using the pharmacological MEK-1 inhibitor PD98059. The 
effectiveness and use of this compound is well documented in the literature and 
has also been demonstrated in in-house studies (Knowlden et al., 2003). A dose 
response in which WTMCF-7 and FAS-R cells were treated with a range of 
doses of PD98059 (5, 10, 30 and 50pM) for 24h was performed in order to 
determine the optimum dose for ERK1/2 inhibition (figure 5.2). Optimum 
inhibition without cytotoxic effects to both cell models was achieved at 50pM; 
all further experiments with PD98059 were hence carried out at this 
concentration. In contrast to figure 5.1, ERK phosphorylation was detected in 
basal FAS-R cells. This apparent discrepancy is due to deliberate overexposure 
which permitted identification of the optimum dose of PD98059 to be used.
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5 Regulation of HGF/SF-induced MMP Expression and 
its Role in the aggressive Phenotype of FAS-R Cells
5.1 Introduction and Aims
The pivotal role of MMP proteolytic activity in in vitro and in vivo tumour cell 
invasion has long been acknowledged. Equally well established is the role of 
aberrant HGF/SF-c-Met signalling in both the acquisition of an aggressive 
cancer cell phenotype in vitro and in promoting tumour progression and 
metastatic disease in solid tumours in vivo. Moreover, many in vitro studies 
have established a clear link between MMPs and c-Met signalling, whereby 
HGF/SF-induced protease activity through matrix degradation and facilitation 
of invasion promotes the adverse cell phenotype associated with c-Met receptor 
overexpression. As the findings of this project have shown, the same 
mechanism appears to be operative in FAS-R cells.
As the data presented so far illustrates, FAS-R cells display an aggressive 
phenotype and express MMPs which are thought to contribute to the 
aforementioned adverse behaviour. Furthermore, these resistant cells display c- 
Met receptor overexpression and an enhanced sensitivity to exogenous 
HGF/SF which promotes colony dispersion and invasion. Moreover, HGF/SF 
was shown to promote MMP-1, MMP-9 and MMP-10 expression, whilst 
HGF/SF-enhanced invasive capability was reduced following inhibition of 
proteolytic activity of MMPs using a broad-spectrum inhibitor.
Having established that MMPs contribute to the augmented invasive behaviour 
of FAS-R cells, the aim was to clarify the molecular mechanisms underlying 
the regulation of MMP expression by HGF/SF by identifying the signalling 
components which control MMP expression downstream of c-Met.
Whilst the precise signalling pathways downstream of c-Met that mediate each 
of the diverse biological effects of HGF/SF remain somewhat obscure, 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) and phosphoinositide-3 
kinase (PI3K) have been demonstrated to be the two main target candidate
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Figure 5.1 HGF/SF enhances ERK1/2 signalling in W TM CF-7 and FAS-R cells.
Serum-starved subconfluent WTMCF-7 (A) and FAS-R cells (B) were treated with 
HGF/SF (20ng/ml) for 5 minutes. Cell lysates were obtained, subjected to SDS-PAGE 
analysis and probed with antibodies specific for phospho-ERK 1/2 and total ERK1/2 as 
outlined in section 2.6. HGF/SF stimulation resulted in enhanced ERK1/2 in FAS-R 
cells (B).
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Figure 5.2 PD98059 dose response to establish optim um  dose for ERK 1/2 
inhibition in W TM CF-7 and FAS-R cells.
Serum-starved subconfluent WTMCF-7 (A) and FAS-R cells (B) were treated with a 
range o f  doses o f  PD98059 (5, 10, 30 and 50pM ) for 24h. Cell lysates were obtained, 
subjected to SDS-PAGE analysis and probed with antibodies specific for phospho-ERK 
1/2 and total ERK 1/2. As can be seen, the optimum dose for ERK 1/2 inhibition was 
established to be 50pM.
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Next, a time course of WTMCF-7 and FAS-R cells ± PD98059 ± HGF/SF was 
performed to examine the stimulatory effect of HGF/SF on ERK 1/2 
phosphorylation and the inhibitory effect of PD98059 on HGF/SF-enhanced 
ERK 1/2 signalling over time and to identify the optimum time point to study 
these events (figure 5.3). With the exception of the control sample and the 
sample treated with PD98059 alone, cells were either treated with only 
HGF/SF for 5, 30, 60 minutes and 24h or pre-treated with PD98059 for 30 
minutes before additionally being stimulated with HGF/SF for the above 
lengths of time. Samples were then immediately lysed and subsequently 
immunoprobed for phospho-ERKl/2. As can be seen in figure 5.3, HGF/SF- 
enhanced ERK 1/2 phosphorylation in FAS-R cells was sustained over 24h. 
Moreover, inhibition of this phosphorylation by PD98059 was most 
pronounced at 24h; further Western Blot analysis was therefore carried out at 
this time point.
Following these optimisation studies, WTMCF-7 and FAS-R cells ± HGF/SF 
(20ng/ml) ± PD98059 (50pM) were grown in parallel for 24h for MMP gene 
and protein expression analysis by RT-PCR and zymography, respectively, and 
for ERK 1/2 and AKT phosphorylation level determination by Western 
Blotting.
As observed during the optimisation studies, HGF/SF treatment resulted in 
increased ERK 1/2 phosphorylation in FAS-R cells (figure 5.4) which was 
effectively blocked by PD98059, re-confirming ERK 1/2 to be a target of c- 
Met. As before, ERK1/2 phosphorylation levels in WTMCF-7 cells were 
overall higher compared to FAS-R cells.
Lysates were simultaneously immunoprobed for phospho-AKT to ensure that 
treatment with PD98059 did not interfere with the PI3K/AKT signalling 
pathway. As can be seen in figure 5.5, AKT phosphorylation levels of 
PD98059-treated samples were unchanged for both WTMCF-7 and FAS-R 
cells.
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Figure 5.3 Time course with HGF/SF and PD98059 in W TM CF-7 and FAS-R cells.
Subconfluent WTMCF-7 and FAS-R cells were serum-starved 24h prior to treatments. 
Out o f  10 dishes, one set o f  5 dishes was pre-treated with PD98059 (50pM) for 30 
minutes with the exception o f  the control sample. Following this pre-treatment the 
remaining 4 dishes were treated with HGF/SF (20ng/ml) for 5, 30, 60 minutes and 24h 
respectively. With the exception o f  another control sample the second set o f  5 dishes 
was also treated with HGF/SF (20ng/ml) for 5, 30, 60 minutes and 24h respectively. At 
the end o f  each time point, cell lysates were obtained immediately which were then 
subjected to SDS-PAGE analysis and probed with antibodies specific for phospho-ERK 
1/2 and total ERK 1/2 as outlined in section 2.6. Densitometry was performed on the 
resulting signal and all signal values were normalised using p-actin. Data is presented as 
mean expression levels (n=2) (B and D). Representative images (A and C) are shown 
above and on the next page.
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Figure 5.4 The effect o f PD98059 on HGF/SF-m ediated ERK 1/2 phosphorylation in 
W TM CF-7 and FAS-R cells as determined by W estern Blotting.
Serum-starved subconfluent WTMCF-7 and FAS-R cells ± HGF/SF (20ng/ml) ± PD98059 (50pM ) 
were incubated for 24h. Cell lysates were obtained, subjected to SDS-PAGE analysis and probed 
with antibodies specific for phospho-ERK 1/2 and total ERK 1/2 as outlined in section 2.6. 
Densitometry was performed on the resulting signal and all signal values were normalised using p- 
actin. Data is presented as mean expression levels ± S.D. (n=3) (B). Representative images are 
shown above (A). As can be seen PD98059 decreased HGF/SF-modulated ERK 1/2 
phosphorylation in FAS-R cells.
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Figure 5.5 Effect o f PD98059 on AKT phosphorylation in W TM CF-7 and FAS-R cells as 
determ ined by W estern Blotting.
Serum-starved subconfluent WTMCF-7 and FAS-R cells ± HGF/SF (20ng/ml) ± PD98059 
(50pM ) were incubated for 24h. Cell lysates were obtained, subjected to SDS-PAGE analysis and 
probed with antibodies specific for phospho-AKT and total AKT as outlined in section 2.6. 
Densitometry was performed on the resulting signal and all signal values were normalised using 
p-actin. Data is presented as mean expression levels ± S.D. ( (n=3) (B). Representative images are 
shown above (A). As can be seen, PD98059 did not affect AKT phosphorylation levels.
1 54
Chapter Five  -  Results
Next, RT-PCR was employed to reveal the effect of ERK 1/2 inhibition upon 
HGF/SF- controlled MMP gene expression. As before, HGF/SF induced or 
enhanced MMP-1, MMP-9 and MMP-10 expression in FAS-R cells (figure 
5.6). Interestingly, PD98059 treatment reduced HGF/SF-mediated MMP 
expression for all three genes, confirming the assumption that the HGF/SF/c- 
Met complex regulates MMP-1, MMP-9 and MMP-10 expression via ERK 1/2. 
Zymographic analysis revealed PD98059 treatment to distinctly decrease 
MMP-9 protein secretion (figure 5.7), further confirming the role ERK 1/2 in 
HGF/SF-mediated MMP expression. As before, HGF/SF markedly upregulated 
MMP-9 protein secretion, corroborating earlier data.
In order to establish whether ERK 1/2 signalling was also implicated in the 
adverse phenotype of FAS-R cells, scattering, migration and invasion assays 
were performed in the presence of PD98059. As observed before, HGF/SF 
greatly enhanced the motile, migrative and invasive capabilities of FAS-R cells 
(figures 5.8; 5.9 and 5.10); this again validated earlier findings. Importantly, 
ERK 1/2 inhibition dramatically reduced HGF/SF-enhanced scattering (figure 
5.8) and migration rates (figure 5.9) in FAS-R cells, suggesting a role for 
ERK 1/2 signalling in the motile behaviour of these cells. Invasion assays, 
however, revealed an increase in HGF/SF-augmented invasion following 
PD98059 treatment (figure 5.10); leaving the involvement of ERK1/2 in the 
FAS-R invasive cell phenotype inconclusive.
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Figure 5.6 Effect o f ERK 1/2 inhibition on H GF/SF-m odulated M M P mRNA  
expression levels o f W TM CF-7 and FAS-R cells as determ ined by RT-PCR.
ERK 1/2 inhibition was achieved using the inhibitor PD98059 (50pM ). As PD98059 
was solubilised in DMSO, a DMSO control was also included. Serum-starved 
subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF (20ng/ml) ±  
PD98059 for 24h. The effect o f  ERK 1/2 inhibition on HGF/SF-modulated MMP-1, 
MMP-9 and MMP-10 expression was determined using gene expression analysis as 
outlined in section 2.5. Data was normalised using p-actin and presented as mean 
expression levels ± S.D. (n=3) (B, D and F). Representative images are shown above 
and on following pages (A, C, E and G).
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Figure 5.7 Effect o f ERK 1/2 inhibition on HGF/SF-m odulated M M P-9 protein 
expression levels o f W TM CF-7 and FAS-R cells as determ ined by zym ography.
ERK 1/2 inhibition was achieved using the inhibitor PD98059 (50pM ). Serum-starved 
subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF (20ng/ml) ±  
PD98059 for 24h. Cell-conditioned supernatants were collected and processed as 
described in section 2.6.2. Supernatants were then subjected to zymographic analysis as 
detailed in section 2.7 to determine the effect o f  ERK 1/2 inhibition on HGF/SF- 
modulated MMP-9 protein expression. Data was normalised using protein concentration 
values obtained from respective cell lysates and presented as mean expression levels ±  
S.D. (n=3) (B). A representative image is shown above (A).
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Figure 5.8 The effect o f  ERK 1/2 inhibition on HG F/SF-induced colony dispersion in 
W TM C F-7 and FAS-R cells as determ ined by scatter assays.
ERK 1/2 inhibition was achieved using PD98059 (50pM ). WTMCF-7 (A ) and FAS-R cells (B) 
were seeded in EM ± Faslodex (10*7M) and allowed to form discrete colonies prior to 24h 
treatment with HGF/SF (20ng/m l) ± PD98059 (50pM ) in DCCM. The extent to which ERK 1/2 
inhibition reduced HGF/SF-induced colony dispersion was determined using cell scatter assays as 
described in section 2.10. Scatter response was assessed visually and selected colonies were 
photographed using a Leica DM-IRE2 inverted microscope; representative images are shown 
above and on the following page. As can be seen ERK 1/2 inhibition reduced HGF/SF-induced 
colony dispersion in FAS-R cells (B).
1 6 0
Chapter Five  -  Results
—
B FAS-R control FAS-R + HGF/SF
FAS-R + PD FAS-R + HGF/SF + PD
Figure 5.8 continued.
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Figure 5.9 Effect o f  ERK 1/2 inhibition on H G F/SF-m odulated m igration o f  
W T M C F-7 and FAS-R cells.
ERK 1/2 inhibition was achieved using the inhibitor PD98059 (50pM ). The effect o f  
ERK 1/2 inhibition on HGF/SF-modulated migration o f  WTMCF-7 and FAS-R cells 
was determined using in vitro  cell migration assays as described in section 2.9. Crystal- 
violet-stained cells were photographed at 20x magnification using an Olympus BH-2 
phase contrast microscope; representative images are shown above and on the following  
page (A  and C). Quantification was by counting the number o f  migratory cells in 5 non- 
overlapping fields o f  view; data (mean cells/field o f  view ) are presented as % o f  basal 
WTMCF-7 ± S.D (*p<0.001 vs. WTMCF-7 control **p<0.001 vs. WTMCF-7 + 
HGF/SF) and as % o f  basal FAS-R ± S.D  (*p<0.005 vs. FAS-R control) (B and D). As 
can be seen ERK 1/2 inhibition significantly reduced HGF/SF-modulated migration o f  
FAS-R cells (C and D).___________________________________________
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Figure 5.10 Effect o f  ERK 1/2 inhibition on HGF/SF-m odulated invasion o f FAS-R  
cells.
ERK 1/2 inhibition was achieved using the inhibitor PD98059 (50pM ). The effect o f  
ERK 1/2 inhibition on HGF/SF-modulated invasion in FAS-R cells was determined 
using in vitro  cell invasion assays as described in section 2.8. DAPI-stained cell nuclei 
were visualised and photographed at 20x magnification using a DM-IRE2 fluorescent 
microscope connected to a Hamamatsu C 4742-96 digital camera. Quantitation was by 
counting the number o f  invasive cells in 5 non-overlapping fields o f  view; data (mean 
cells/field o f  view) are presented as %  o f  control ±  S.D. (*p<0.001 vs FAS-R control). 
As can be seen, ERK 1/2 inhibition increased HGF/SF-modulated invasion o f  FAS-R  
cells.
16 4
Chapter Five  -  Results
5.2.2 The Role of PI3K/AKT signalling in HGF/SF-mediated MMP 
Expression and in the aggressive Phenotype of FAS-R Cells
In order to be able to implicate PI3K/AKT signalling in the above processes, 
the same experiments as described in section 5.2.1 were performed with the 
AKT-specific inhibitor LY294002, the effectiveness of which is widely 
acknowledged and has been established in previous in-house studies 
(Hutcheson et al., 2007, Jordan et a l , 2004).
Assessment of AKT protein levels by Western Blotting following HGF/SF 
stimulation of WTMCF-7 and FAS-R cells revealed a marked increase in AKT 
phosphorylation in the latter (figure 5.11), confirming PI3K/AKT to be a 
signalling component downstream of the HGF/SF/c-Met complex in FAS-R 
cells.
To determine whether the PI3K/AKT pathway is involved in HGF-mediated 
MMP expression and promotes the adverse FAS-R cell phenotype, signalling 
was inhibited by way of LY294002. A dose response in which WTMCF-7 and 
FAS-R cells were treated with a range of doses of LY294002 (5, 10, 15, 20, 25 
and 30 pM) for 24h was performed to establish the optimum dose for AKT 
inhibition (figure 5.12). Optimum inhibition was achieved at lOpM LY294002 
in FAS-R cells. Moreover, higher concentrations proved cytotoxic to both cell 
models, hence all further studies were carried out using a dose of lOpM.
The next step was to perform a time course of WTMCF-7 and FAS-R cells ± 
LY294002 ± HGF/SF to assess the stimulatory effect of HGF/SF on phospho- 
AKT levels and to determine how LY294002 inhibited HGF/SF-augmented 
PI3K/AKT signalling over time with the aim of identifying the optimum time 
point to study these events (figure 5.13). Samples were set up as described in 
section 5.2.1 with LY294002 instead of PD98059. Whilst HGF/SF-enhanced 
AKT phosphorylation had peaked at 60 minutes in FAS-R cells, the largest 
increase in WTMCF-7 cells was observed after 24h. LY294002-mediated 
inhibition of this phosphorylation peaked at 5 minutes but was still visible at 
24h in both cell types.
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Figure 5.11 H G F/SF enhances AKT signalling in W T M C F-7 and FAS-R cells.
Serum-starved subconfluent WTMCF-7 (A) and FAS-R cells (B) were treated 
HGF/SF (20ng/m l) for 5 minutes. Cell lysates were obtained, subjected to SDS- 
PAGE analysis and probed with antibodies specific for phospho-AKT and total AKT 
as outlined in section 2.6. HGF/SF stimulation resulted in enhanced AKT signalling 
particularly in FAS-R cells.
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Figure 5.12 LY294002 dose response to establish optimum dose for P13K inhibition 
in WTMCF-7 and FAS-R cells.
Serum-starved subconfluent WTMCF-7 (A) and FAS-R cells (B ) were treated with a 
range o f  doses o f  LY294002 (5, 10, 15, 20, 25 and 30pM ) for 24h. Cell lysates were 
obtained, subjected to SDS-PAGE analysis and probed with antibodies specific for 
phospho-AKT and total AKT as outlined in section 2.6. As can be seen, the optimum 
dose for PI3K inhibition was established to be lOpM.
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Figure 5.13 T im e cou rse w ith H G F/SF and LY 294002 in W T M C F-7 and FAS-R  
cells.
Subconfluent W TM CF-7 and FAS-R cells were serum-starved 24h prior to treatments. 
Out o f  10 dishes, one set o f  5 dishes was pre-treated with LY 294002 (10pM ) for 30 
minutes with the exception o f  the control sample. Follow ing this pre-treatment the 
remaining 4 dishes were treated with HGF/SF (20ng/m l) for 5, 30, 60 minutes and 24h 
respectively. With the exception o f  another control sample the second set o f  5 dishes 
was also treated with HGF/SF (20ng/m l) for 5, 30, 60 minutes and 24h respectively. At 
the end o f  each tim e point, cell lysates were obtained immediately which were then 
subjected to SD S-PA G E analysis and probed with antibodies specific for phospho-AKT  
and total AKT as outlined in section 2.6. Densitometry was performed on the resulting 
signal and all signal values were normalised using p-actin. Data is presented as mean 
expression levels (n= 2) (B and D). Representative images are shown above and on the 
follow ing page (A and C).
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Figure 5.13 continued.
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This made it possible to choose the 24h time point for further analysis, which 
was desirable as it was consistent with the experiments carried out earlier for 
the ERK 1/2 signalling investigation, and also because at a very early time point 
only insufficient MMP mRNA and protein may have accumulated posing 
problems for downstream assays.
Upon completion of these preliminary studies, WTMCF-7 and FAS-R cells ± 
HGF/SF (20ng/ml) ± LY294002 (lOpM) were grown in parallel for 24h for 
MMP gene and protein expression analysis by RT-PCR and zymography, 
respectively, and for AKT and ERK 1/2 phosphorylation level determination by 
Western Blotting.
As observed during the optimisation studies, HGF/SF caused augmented AKT 
phosphorylation in FAS-R cells (figure 5.14) which was effectively inhibited 
using LY294002; re-confirming PI3K/AKT to be a target of c-Met signalling. 
As seen before, AKT phosphorylation levels overall were higher in WTMCF-7 
cells as compared to FAS-R cells.
To ensure that LY294002 treatment did not impact on ERK 1/2 signalling, 
lysates were simultaneously immunoprobed for phospho-ERKl/2; as expected, 
ERK 1/2 phosphorylation levels were virtually unaltered for both cell models 
(figure 5.15).
RT-PCR was employed to determine the effect of AKT inhibition upon 
HGF/SF- controlled MMP gene expression. As before, HGF/SF induced or 
enhanced MMP-1, MMP-9 and MMP-10 expression in FAS-R cells (figure 
5.16). As expected, LY294002 treatment decreased HGF/SF-augmented MMP- 
9 gene expression in both cell types. Conversely, LY294002 was seen to 
increase HGF/SF-augmented MMP-1 and MMP-10 expression in FAS-R cells, 
suggesting these genes to be negatively controlled by the PI3K/AKT pathway. 
Overall, however, the data confirmed an involvement of this signalling 
pathway in HGF/SF/c-Met regulated MMP expression in our faslodex-resistant 
cell model.
170
Chapter Five  -  Results
WTMCF-7 FAS-R
p-AKT
T-AKT
P-actin
■ WTMCF-7 
□ FAS-R
Figure 5.14 The effect o f  LY294002 on H G F/SF-m ediated PI3K phosphorylation in 
W T M C F-7 and FAS-R cells as determ ined by W estern Blotting.
Serum-starved subconfluent WTMCF-7 and FAS-R cells ±  HGF/SF (20ng/m l) ±  
LY 294002 (lO pM ) were incubated for 24h. Cell lysates were obtained, subjected to 
SDS-PAGE analysis and probed with antibodies specific for phospho-AKT and total 
AKT as outlined in section 2.6. Densitometry was performed on the resulting signal and 
all signal values were normalised using p-actin. Data is presented as mean expression 
levels ± S.D. (n=3) (B). Representative images are shown above (A). A s can be seen 
LY294002 decreased HGF/SF-modulated AKT phosphorylation.
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Figure 5.15 Effect o f  L Y 294002 on ERK 1/2 phosphorylation in W TM C F-7 and 
FA S-R  cells as determ ined by W estern Blotting.
Serum-starved subconfluent WTMCF-7 and FAS-R cells ± HGF/SF (20ng/m l) ±  
LY 294002 (lO pM ) were incubated for 24h. Cell lysates were obtained, subjected to 
SDS-PAGE analysis and probed with antibodies specific for phospho-ERK 1/2 and total 
ERK as outlined in section 2.6. Densitometry was performed on the resulting signal and 
all signal values were normalised using p-actin. Data is presented as mean expression  
levels ± S.D . (n=3) (B). Representative images are shown above (A). As can be seen, 
LY 294002 did not affect ERK 1/2 phosphorylation levels.
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Figure 5.16 Effect o f  PI3K  inhibition on H G F/SF-m odulated  M M P m RNA  
expression  levels o f  W T M C F-7 and FAS-R cells as determ ined  by RT-PCR.
PI3K inhibition was achieved using the inhibitor L Y 294002 (10pM ). Serum-starved 
subconfluent W TM CF-7 and FAS-R cells were treated with HGF/SF (20ng/m l) ± 
L Y 294002 for 24h. The effect o f  PI3K inhibition on HGF/SF-modulated MM P-1, 
M M P-9 and M M P-10 expression was determined using gene expression analysis as 
outlined in section 2.5. Data was normalised using p-actin and presented as mean 
expression levels ± S.D. (n=3) (B, D and F). Representative im ages are shown above 
and on follow ing pages (A , C, E and G).
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Figure 5.16 continued.
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Zymographic analysis demonstrated LY294002 treatment to virtually abolish 
MMP-9 protein secretion (figure 5.17), further validating the role of 
PI3K/AKT signalling in HGF/SF-mediated MMP expression in FAS-R cells. 
As before, HGF/SF clearly upregulated MMP-9 protein expression in both cell 
models, corroborating earlier data.
In order to determine whether PI3K/AKT signalling was also implicated in the 
adverse phenotype of FAS-R cells, scattering, migration and invasion assays 
were performed in the presence of LY294002. As seen in earlier assays, 
HGF/SF greatly enhanced the motile, migrative and invasive capabilities of 
FAS-R cells (figures 5.18, 5.19 and 5.20, respectively) whilst only increasing 
migration rates in the WTMCF-7 cells and having no impact at all on their 
motile behaviour (figures 5.18 and 5.19); corroborating earlier findings. 
Excitingly, PI3K/AKT inhibition not only reduced colony dispersion (figure 
5.18) and migration (figure 5.19) but also clearly decreased invasion rates of 
FAS-R cells (figure 5.20); confirming a role for the PI3K/AKT pathway in 
promoting the aggressive phenotype of FAS-R cells.
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Figure 5.17 Effect o f PI3K inhibition on H G F/SF-m odulated M M P-9 protein  
expression levels o f  W TM C F-7 and FAS-R cells as determ ined by zym ography.
PI3K inhibition was achieved using the inhibitor LY294002 (lOpM ). Serum-starved 
subconfluent WTMCF-7 and FAS-R cells were treated with HGF/SF (20ng/m l) ±  
LY294002 for 24h. Cell-conditioned supernatants were collected and processed as 
described in section 2.6.2. Supernatants were then subjected to zymographic analysis as 
detailed in section 2.7 to determine the effect o f  PI3K inhibition on HGF/SF-modulated 
MMP-9 protein expression. Data was normalised using protein concentration values 
obtained from respective cell lysates and presented as mean expression levels ± S.D. 
(n=3) (B). A representative image is shown above (A).
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Figure 5.18 The effect o f PI3K inhibition on HGF/SF-induced colony dispersion in W TM CF-7  
and FAS-R cells as determ ined by scatter assays.
PI3K inhibition was achieved using the inhibitor LY294002 (lOfiM). WTMCF-7 (A) and FAS-R cells 
(B ) were seeded in EM ± Faslodex (10*7M) and allowed to form discrete colonies prior to 24h 
treatment with HGF/SF (20ng/m l) ± LY294002 (lOpM ) in DCCM. The extent to which PI3K 
inhibition reduced HGF/SF-induced colony dispersion was determined using cell scatter assays as 
described in section 2.10. Scatter response was assessed visually and selected colonies were 
photographed using a Leica DM-1RE2 inverted microscope; representative images are shown above 
and on the following page. As can be seen, PI3K inhibition caused a modest decrease in HGF/SF- 
induced colony dispersion in FAS-R cells (B).
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Figure 5.18 continued.
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Figure 5.19 Effect o f  PI3K inhibition on HG F/SF-m odulated migration of  
W TM CF-7 and FAS-R cells.
PI3K inhibition was achieved using the inhibitor LY294002 (lOpM ). The effect o f  PI3K 
inhibition on HGF/SF-modulated migration o f  WTMCF-7 and FAS-R cells was 
determined using in vitro  cell migration assays as described in section 2.9. Crystal- 
violet-stained cells were photographed at 20x magnification using an Olympus BH-2 
phase contrast microscope; representative images are shown above and on the following 
page (A and C). Quantification was by counting the number o f  migratory cells in 5 non­
overlapping fields o f  view; data (mean cells/field o f  view) are presented as % o f  
WTMCF-7 ±  S.D. (*p<0.00l vs. WTMCF-7 control **p<0.00l vs. WTMCF-7 vs 
WTMCF-7 + HGF/SF) and as % o f  FAS-R cells ± S.D. (*p<0.005 vs. FAS-R control) 
(B and D). As can be seen PI3K inhibition reduced HGF/SF-modulated migration o f  
FAS-R cells (C and D). 1 8 0
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Figure 5.20 Effect o f PI3K inhibition on H G F/SF-m odulated invasion o f  FAS-R  
cells.
PI3K inhibition was achieved using the inhibitor LY294002 (lOpM ). The effect o f  PI3K 
inhibition on HGF/SF-modulated invasion in FAS-R cells was determined using in vitro  
cell invasion assays as described in section 2.8. DAPl-stained cell nuclei were visualised  
and photographed at 20x magnification using a DM-1RE2 fluorescent microscope 
connected to a Hamamatsu C4742-96 digital camera. Quantification was by counting the 
number o f  invasive cells in 5 non-overlapping fields o f  view; data (mean cells/field o f  
view) are presented as % o f  control ± S.D. (*p<0.001 vs. FAS-R control). As can be 
seen PI3K inhibition reduced HGF/SF-modulated invasion o f  FAS-R cells.
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‘An expert is a person who has made all the mistakes 
that can be made in a very narrow field. ”
Niels Bohr (1885-1962)
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6.1 Discussion
The selective oestrogen receptor modulator tamoxifen has been the gold standard 
endocrine therapy for ER-positive breast cancer for more than 25 years; 
however, patients with ER-positive disease that are initially responsive to this 
treatment eventually develop endocrine resistance (Osborne, 1999). Treatment 
with the selective oestrogen receptor downregulator faslodex has been proved to 
be effective upon progression on tamoxifen or aromatase inhibitors; and the pure 
anti-oestrogen is now approved as a second-line agent in postmenopausal 
women (Howell, 2006). Faslodex displays several superior qualities compared to 
tamoxifen. It binds the ER with a much higher affinity, downregulating ER 
protein and suppressing oestrogen-regulated genes more strongly, and thus 
inhibiting ER-driven cell proliferation more potently. It is furthermore devoid of 
any agonist activity and hence associated with a far more favourable side effect 
profile (Howell, 2006). Sadly, faslodex resistance can develop as a result of 
long-term therapy, presenting a further setback in the pharmacotherapeutic 
management of breast cancer (Cheung et a l , 2006, Robertson et aL, 2005, 
Buzdar, 2004). Consequently, elucidation of the mechanisms underlying 
resistance to faslodex and rapid identification of novel targets to control 
faslodex-resistant tumour growth is imperative.
Preliminary studies using our faslodex-resistant cell model have revealed that 
development of resistance is associated with the acquisition of an adverse cell 
phenotype in vitro, as exemplified by enhanced migratory and invasive 
capabilities. The objective of this study was to establish the role of MMP 
proteolytic activity in this process, and further to identify the principal growth 
factor signalling pathway driving this aggressive behaviour. Confirmation of the 
involvement of specific MMP family members and identification of a dominant 
receptor tyrosine kinase would permit their precise targeting using selective 
MMP and tyrosine kinase inhibitors and may eventually result in successful 
suppression of FAS-R invasion.
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MCF-7 parental cells are ER-positive; and were sensitive to estradiol whilst the 
anti-oestrogens tamoxifen and faslodex had an inhibitory effect on their growth. 
In contrast, FAS-R cells derived by chronic exposure of WTMCF-7 cells to 
faslodex, were insensitive to estradiol, faslodex and tamoxifen. This was due to 
an apparent loss of the ER. Clinically, loss of ER is associated with poorly 
differentiated tumours and higher histological grade, limited treatment strategies 
and hence poor prognosis and decreased overall survival (Putti et al., 2005, 
Kuukasjarvi et al., 1996, Pichon et al., 1996, Kinne et al., 1987, Pari et al., 1984, 
Maynard et al., 1978). The main criticism regarding the FAS-R cell model 
employed in this study is that the cells might stem from an ER-negative 
outgrowth of the original ER-positive WTMCF-7 population. This would mean 
the model was de novo resistant to faslodex instead of having subsequently 
acquired resistance to the anti-oestrogen as described in section 2.2.5. However, 
the status of ER protein expression and endocrine responsiveness in the earlier 
stages of the FAS-R model are reversible after as little as one week of anti­
hormone withdrawal, proving these changes to be of a reversible nature. It is 
therefore clear that the FAS-R model used does not stem from clonal selection of 
an ER-negative population.
Numerous faslodex-resistant breast cancer cell models have been established to 
elucidate the mechanisms underlying resistance to the pure anti-oestrogen. These 
cell lines vary in their culture conditions and the observations made with respect 
to ER protein and mRNA expression levels (summarised in table 6.1).
Whilst the FAS-R cell model employed in this investigation was established 
using 10*7M faslodex, varying concentrations of faslodex and additional medium 
supplementation with E2 and insulin have been described. Sommer et al. (2003), 
for example, argued that a model cultured in the presence of E2 was more 
physiologically relevant as this reflected the E2 levels present in the human body 
during anti-oestrogen administration. A more differentiated approach was 
adopted by Shaw et al. (2006) who emphasise that loss of response to oestrogen 
following oestrogen deprivation is an event distinct from the development of 
anti-oestrogen resistance. Shaw et al. (2006) therefore advocated the
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development of cell lines that allow the study of loss of response to faslodex in 
isolation from loss of response to oestrogen. They hence developed faslodex- 
resistant cell lines from both the original oestrogen-maintained parental cell line 
and a long-term oestrogen-deprived MCF-7 cell line which had been established 
12 months earlier. The oestrogen-maintained faslodex-resistant cells were 
considered the most physiologically relevant model. These cells were 
additionally supplemented with insulin; insulin supplementation was moreover 
described by Lykkesfeldt et al. (1995) and Jensen et al (1999).
Whilst our FAS-R model is characterised by loss of ER protein and reduced ER 
mRNA levels, this observation was not shared across all faslodex-resistant cell 
lines (table 6.1). ER negativity and decreased ER mRNA expression was 
reported by Sommer et al (2003) and by Shaw et al (2006) in their oestrogen- 
maintained model. Dramatic reduction in ER protein levels was observed by Liu 
et al (2006), whilst a 3-fold reduction was seen by Lykkesfeldt et al (1995) and 
Jensen et al. (1999). In contrast, ER protein was found to be expressed in a 
model described by Brunner et al (1997) and in the long-term oestrogen- 
deprived faslodex-resistant cell line developed by Shaw et al. (2006).
A ‘one size fits all’ model seldom stands the test of time when trying to simulate 
the complex in vivo tumour microenvironment. Hence, the existence of several 
resistant cell lines is of significant advantage, each recreating different scenarios 
of resistance development to faslodex in the clinic. For example, oestrogen- 
deprived conditions mirror the post-menopausal state whilst the presence of 
oestrogen recreates the environment of the pre-menopausal state. Overall, results 
obtained from the studies using the above models are all equally valid and 
collectively may throw light onto different facets of the mechanisms underlying 
the emergence of clinical resistance to faslodex.
In contrast to the studies carried out by other investigators which focused solely 
on the effect of acquired faslodex resistance and functional ER loss or 
downregulation on proliferation, the present study addresses the impact of these 
events on invasion, thus informing on a novel aspect of endocrine resistant cell 
behaviour.
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Faslodex
concentration E2 present Insulin present ERa protein expression ERa mRNA expression
Nicholson et al (2005) 10*7M no no absent reduced
Lykkesfeldt et al. (1995)/ 
Jensen et al. (1999) 10'7M no yes reduced by 33% present*
BrQnner et al. (1997) lO^M no no present* present*
Sommer et al. (2003) lO^M yes no absent reduced
Shaw et al. (2006) a) 10*7M yes yes absent absent
Shaw et al. (2006) b) io*7m no no reduced by 10.5% low
Liu et al. (2006) lO^M no no dramatically reduced reduced by 33%
Table 6.1 Culture conditions and ERa-status of faslodex-resistant breast cancer celi models compared to that of parental cells.
* authors only commented on presence of ERa mRNA and protein; changes in expression levels between resistant and parental cells were not specified
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Having characterised FAS-R cells with respect to their aggressive phenotype, the 
next step was to determine and compare their MMP and TIMP expression profile 
to that of the parental cells to establish whether differential expression of these 
proteins may play a role in FAS-R invasion.
Profiling of WTMCF-7 cells revealed both MMP and TIMP family members to 
be widely expressed at modest levels, with the exception of MMP-7 which was 
absent. Interestingly, when the mRNA expression pattern for these MMPs and 
TIMPs observed for WTMCF-7 cells was compared to that reported by other 
investigators, several differences were observed. Balduyck et al (2000), for 
example, reported detection of TIMP-1, TIMP-2 and TIMP-3 only. TIMP-1, 
TIMP-2 and TIMP-3 expression was also described by Kousidou et al (2004) 
who additionally observed MMP-2, MMP-9 and MMP-11 expression under 
serum-free conditions. Expression of MMP-1 was observed by Bachmeier et al
(2005) and Bartsch et al (2003); the latter also found MMP-11 to be present in 
WTMCF-7 cells under serum-free conditions. There were also several instances 
where MMPs and TIMPs detected in MCF-7 cells in this study were not 
observed by the above investigators. Bartsch et al (2003), for example, could 
not detect MMP-9 or MMP-10. Similarly, Bachmeier et al (2005) reported 
absence of MMP-9 mRNA expression. Furthermore, MMP-1 expression was not 
observed by Kousidou et al (2004). Balduyck et al (2000) did not detect any of 
the MMPs we found to be expressed in MCF-7 cells; and furthermore only 
reported presence of TIMP-4 mRNA transcripts.
The observed discrepancies in the MMP and TIMP expression patterns may 
possibly be attributed to differences in the degree of sensitivity of the RT-PCR 
systems employed, the passage number of the cells investigated and variations in 
the culture conditions of each cell line, in particular the presence or absence of 
serum. Indeed, zymographic analysis of serum alone in preliminary studies 
revealed considerable MMP-9 expression; hence all further experiments for 
MMP expression analysis described in this investigation were performed under 
serum-free conditions (i.e. culture in DCCM) to eliminate false-positive results.
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Serum furthermore contains several growth factors, the influence of which on 
MMP expression is well known (Birkedal-Hansen, 1995); further emphasising 
the importance of serum-free conditions. Also, since increasing cell density has 
been demonstrated to downregulate MMP and TIMP expression (Bachmeier et 
al, 2005), great care was taken to harvest cells as soon as 60-70% confluency 
had been reached.
Whereas initial profiling included all four TIMP family members, analysis of 
TIMP expression was discontinued during the course of this study. As indicated 
previously, the role of these inhibitors in cancer is complex and paradoxical, 
with not only inhibitory but also stimulatory effects on carcinogenesis and 
tumour progression demonstrated in cell and animal models which 
overexpressed TIMPs (Kahlert et al., 2008). Furthermore, TIMPs have been 
identified as poor prognostic indicators in several human cancers (reviewed by 
Jiang et al., 2002). Considering that the data arising from early experiments 
analysing TIMP expression proved inconclusive, and based on the above reports, 
it seemed appropriate to focus solely on MMP expression for the remainder of 
the investigation.
With the exception of MMP-2 which was expressed in FAS-R cells only and 
TIMP-4, mRNA expression of all other MMPs and TIMPs was lower compared 
to the wildtype or absent altogether. Although MMP-2 had been detected at gene 
level, FAS-R cells did not secrete MMP-2 protein; and MMP-9 protein was not 
found to be expressed either. In contrast, latent MMP-9 expression was detected 
in WTMCF-7 cells.
Considering that FAS-R cells expressed neither MMP at protein level, the 
observation that FAS-R invasion was reduced in the presence of a broad- 
spectrum inhibitor seems slightly surprising. However, since gelatinase 
zymography only permits detection of gelatinases, other MMPs such as MMP-11 
and MMP-13 which were expressed in FAS-R cells at mRNA level might, 
unknown to us, also be expressed at protein level. It is therefore likely that the 
observed reduction in FAS-R cell invasion following blanket MMP inhibition
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was due to abrogation of proteolytic activities of family members not assayed 
for.
Detection of MMP expression in the conditioned supernatant of matrigel-coated 
inserts of invasion assays has been described by Balduyck et al (2000). As 
mentioned earlier, cells to be assayed for MMP expression were cultured under 
serum-free conditions to avoid detection of MMPs originating from the serum 
component of the medium. However, when invasion assays were attempted 
under serum-free conditions, the experiments had to be aborted due to cell death. 
MMP expression analysis from the upper chamber of transwell inserts from 
HGF/SF-stimulated invasion could therefore not be performed.
As these findings illustrate, an obvious limitation of the work presented herein 
was the lack of more detailed MMP protein expression data. Attempts to 
corroborate observations from zymographic analysis with Western Blotting and 
immunofluorescence techniques were not successful. Interestingly, the obstacles 
encountered herein in the protein detection of MMPs were the subject of a 
comprehensive review by Lombard, Saulnier and Wallach (2005), which 
suggested that the inherent problems associated with MMP activity analysis have 
been reported by many investigators. Since the commencement of this study, 
several highly evolved methods for MMP protein detection have been described, 
such as solid phase activity assays (Lauer-Fields et al., 2004), energy-based 
multiplexed assays (Kim et al, 2008) and quantum dot nanosensors (Xia et a l , 
2008). Application of these novel techniques to future studies of this nature may 
yield more detailed results on MMP protein expression and activity levels.
The clinical significance of MMP-9 in breast cancer progression is well 
established. MMP-9 has been correlated with metastatic progression and reduced 
survival in breast cancer patients by many investigators and, as outlined below, 
some suggest MMP-9 could even be used as a prognostic marker. As delineated 
in section 1.6.5, it was not until recently that the host-protective nature of certain 
MMPs was recognised and that individual family members were accordingly
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assigned ‘anti-target’ or ‘target’ status. Despite the fact that some of the early 
studies that implicated MMP-9 in metastatic progression preceded this 
realisation of the host-protective functions of ‘anti-target’- MMPs, their findings 
are corroborated by several very recent reports. Ranuncolo et al. (2003), for 
example, determined that plasma MMP-9 activity was significantly increased in 
breast cancer compared to benign mammary pathologies and healthy controls. 
The investigators therefore concluded that MMP-9 activity might be useful as a 
marker in the prognosis of breast cancer patients. This study coincided with the 
recent findings of Quaranta et al. (2007) who assessed the prognostic value of 
MMP-9 amongst other markers. Moreover, the prognostic value of MMP-9 in 
patients with lymph node-negative breast carcinoma was described by Li et al. 
(2004) who found it to be an unfavourable prognostic factor for relapse-free 
survival. These observations coincided with a recent study by Wu et al. (2008) 
which confirms the prognostic significance of MMP-9 serum and tissue 
expression in breast cancer. The investigators found serum MMP-9 levels to be 
significantly higher in breast cancer compared to in benign breast disease and 
healthy tissue. Furthermore, high MMP-9 serum levels and tissue expression 
were associated with higher tumour grade whilst high tissue expression 
correlated with reduced relapse-free and overall survival. These findings are in 
accordance with the previous studies and further support the usefulness of MMP- 
9 as a biomarker for predicting progression and prognosis in breast cancer. Also, 
as mentioned in the introduction, MMP-9 was one of the 70 genes associated 
with short interval to distant metastases in a ‘poor prognosis’ signature of 
primary breast carcinomas (van't Veer et al., 2003, van de Vijver et al., 2002). 
Intriguingly, enhanced expression and activation of MMP-9 amongst other 
MMPs at the tumour periphery of invasive breast carcinomas was revealed by 
Bachmeier et al. (2005). In addition, Incorvaia et al. (2007) suggested that 
MMP-9 be considered as a target in breast cancer metastasising to bone whilst 
Thanakit et al. (2005) reported that MMP-9 enhanced breast carcinoma cell 
invasion and was linked to lymph node metastases in high-grade breast 
carcinoma patients. Finally, a recent study by Shah et al. (2009) reported
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elevated MMP-9 activity levels in malignant breast tissue compared to adjacent 
normal tissue, reconfirming the above findings from earlier studies.
The clinical relevance of MMP-9 and the fact that growth factor-stimulated 
FAS-R cells secrete MMP-9 suggests that development of faslodex resistance in 
breast cancer patients may be accompanied by elevated MMP-9 expression and 
activity. It would therefore be of considerable interest to measure MMP-9 
proteolytic activity in tissue samples of individuals with faslodex-resistant breast 
tumours.
Having discovered a potential role for MMP-9 activity in the adverse phenotype 
of FAS-R cells, the next step was to investigate the possible existence of a 
dominant receptor tyrosine kinase pathway driving this aggressive behaviour. As 
delineated in section 4.2.4, FAS-R cells were subsequently found to express 
elevated c-Met mRNA and protein levels. These observations were particularly 
interesting in light of the well-established association between clinical c-Met 
overexpression and poor prognosis and reduced survival rate in breast cancer 
(Kang and Massague, 2004, Elliott et al, 2002, Edakuni et a l , 2001, Camp et 
al, 1999, Tsarfaty et al, 1999, Ghoussoub et al, 1998). Moreover, some studies 
have suggested c-Met as a potential prognostic factor for breast cancer patients, 
replacing more traditional markers such as Her-2 and EGFR (Lengyel et al, 
2005, Tolgay Ocal et a l, 2003). These findings further underline the potential 
clinical relevance of dominant c-Met signalling in FAS-R cells which will be 
considered in more detail later in this chapter.
Whilst HGF/SF treatment of FAS-R cells resulted in MMP-9 secretion, 
scattering and markedly increased migration and invasion rates, neither 
scattering nor increased invasion were seen in WTMCF-7 cells. However, 
WTMCF- cells did display a modest increase in ERK and AKT phosphorylation 
and an enhanced migratory response and augmented MMP-9 secretion on 
treatment with HGF/SF which was unexpected considering neither total nor 
phosphorylated c-Met could be detected in these cells. However,
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immunocytochemical analysis had revealed some c-Met expression also in the 
wildtype. Taken together, this indicated that some albeit very low c-Met activity 
must exist in these cells after all. In fact, as demonstrated by Hiscox et al
(2006), phosphorylated c-Met protein was detectable in WTMCF-7 cells 
following stimulation with HGF/SF at the much higher concentration of 
80ng/ml. Whilst such modest signalling activity is unlikely to account for the 
response observed, this apparent discrepancy might be accounted for by receptor 
transactivation events. The fact that c-Met communicates with various secondary 
receptors supports this hypothesis. Indeed, a recent study in several mammary 
carcinoma cell lines revealed that EGFR played a significant role in HGF/SF- 
mediated biological responses (Bonine-Summers et a l , 2007); and it is thought 
that a similar mechanism, possibly involving a different secondary receptor, 
might potentially be operating in HGF/SF-treated WTMCF-7 cells.
Whereas WTMCF-7 and FAS-R cells treated with HGF/SF both secrete similar 
levels of MMP-9, HGF/SF only enhanced FAS-R cell invasive rates with 
WTMCF-7 invasion levels remaining unchanged (data for WTMCF-7 invasion 
not shown). Whilst these results appear rather paradoxical at first, a closer look 
at the processes and machinery governing extracellular MMP activation and cell 
surface localisation seems to offer potential explanations.
The majority of MMPs are secreted as inactive zymogens and subsequently 
activated extracellularly by proteases including other members of the MMP family 
and serine proteases. MT1-MMP, for example, has been shown to play a pivotal 
role in the cell-surface activation of MMP-2 (Sato et a l , 1994). Potentially, a 
similar mechanism might operate in HGF/SF-stimulated FAS-R cell invasion with 
regard to MMP-9. In an effort to establish a possible link gene expression profiling 
of MT1-MMP using RT-PCR analysis in HGF/SF-treated FAS-R cells compared 
to HGF/SF-treated WTMCF-7 cells was attempted but conclusive data could not 
be obtained. Furthermore, establishment of the gene and protein expression 
profiles of all potential activating proteases unfortunately lay outside the scope of 
this project. Nevertheless, it is thought that
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the increase in invasion following HGF/SF treatment of FAS-R cells but not of 
WTMCF-7 cells despite similar MMP-9 secretion may be partially due to 
differential MMP-9 activation.
Furthermore, in addition to zymogen activation, cell surface localisation of MMPs 
is critical in order to achieve the localised matrix degradation thought to be central 
to the invasive process. Molecules such as the hyaluronic acid receptor, CD44, 
function as cell surface docking receptors that localise secreted MMPs to the 
invasion front. CD44-mediated cell surface localisation of active MMP-9 has been 
demonstrated in keratinocytes (Yu and Stamenkovic, 2000), and it is thought that 
such a mechanism might also operate in FAS-R cells. Intriguingly, FAS-R cells 
have been shown to express elevated levels of CD44 mRNA and protein, as 
demonstrated by gene expression analysis using Asymetrix arrays and RT-PCR 
and immunocytochemistry, respectively (R. McClelland, N. Jordan, M. Harper; 
unpublished data); these observations lend further weight to the above hypothesis. 
In summary, HGF/SF-mediated elevation in FAS-R cell invasion only may 
potentially be due to differential MMP-9 activation and cell surface localisation of 
MMP-9 via elevated expression of activating proteases and cell surface docking 
receptors respectively.
The phenomenon of HGF/SF-induced cell scattering, migration and invasion has 
been firmly established in a variety of cell types. Equally well acknowledged is the 
fact that HGF/SF-mediated motile and aggressive behaviour is accomplished 
through stimulation of MMP expression and activity. Indeed, this has been 
demonstrated for a wide range of epithelial cancer models including colon 
adenocarcinoma (Tanimura et al., 2003, Kermorgant et al., 2001), prostate 
carcinoma (Fujiuchi et al., 2003, Tanimura et al., 2003), hepatocellular carcinoma 
(Abiru et a l, 2002, Tanimura et al, 2002), nasopharyngeal cancer (Zhou et al,
2008), oral squamous cell carcinoma (Hanzawa et a l, 2000), ovarian cancer (Zhou 
and Wong, 2006) and, importantly, breast adenocarcinoma (Tanimura et al,
2003), validating the findings of this study. Evidently, HGF/SF-
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mediated invasion via MMP proteolytic activity is a mechanism common to all 
major carcinomas and therefore represents a promising broad-spectrum therapeutic 
target with considerable potential.
Early investigations into the signalling components mediating HGF-induced 
motile behaviour downstream of c-Met in MDCK (Madin-Darby Canine Kidney) 
cells using the pharmacological inhibitors PD98059, LY294002 and wortmannin 
revealed involvement of both ERK1/2 and PI3K pathways (Potempa and Ridley, 
1998, Royal et al., 1997, Royal and Park, 1995). Since then, a distinct role for 
ERK1/2 and PI3K signalling in HGF/SF-stimulated aggressive behaviour has been 
observed in and is now widely acknowledged for many cancer cell lines. 
Importantly, these cancer cell models display differential requirements for ERK1/2 
and PI3K activity in their response to HGF/SF. Requirement of ERK1/2 signalling 
only was detected in the hepatocarcinoma cell line HepG2 (Abiru et al., 2002) and 
the stomach adenocarcinoma cell line TMK1 (Tanimura et al., 1998). Conversely, 
sole dependency on the PI3K pathway was seen in the small cell lung cancer cell 
line NCI-H69 (Maulik et a l, 2002), the hepatocarcinoma cell lines Hep3B and 
Huh-7 (Nakanishi et al., 1999), in ovarian cancer cells (Zhou and Wong, 2006), in 
the colonic carcinoma cell line Caco-2 (Kermorgant et al., 2001) and in 
nasopharyngeal cancer cells (Zhou et al., 2008). Significantly, contribution of both 
pathways to HGF/SF-induced motility, as witnessed in our FAS-R cell model, was 
reported for the mammary carcinoma cell line 184B5 (Day et al., 1999). Clearly, 
carcinoma types vary in their dependence upon either pathway for mediating 
response to HGF/SF stimulation, with an apparent dual signalling activity 
operational in some breast cancer models.
Furthermore, it appears that HGF/SF-induced invasion in FAS-R cells involves 
MMP-9, a mechanism also described in colonic cancer (Kermorgant et al., 2001), 
ovarian cancer (Zhou and Wong, 2006), nasopharyngeal cancer (Zhou et al., 2008) 
and a murine model of breast carcinoma (Zhang et al., 2004).
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The present study is limited by the fact that the observations described were made 
in one faslodex-resistant breast cancer model only. Repeating these experiments in 
other ER-positive mammary carcinoma cell lines with acquired resistance to 
faslodex will inform on whether the mechanism observed for FAS-R cells applies 
to breast cancer models in general. Targeting the described invasion mechanism 
using siRNA approaches to both c-Met and MMP-9, neutralising antibodies to c- 
Met, HGF/SF and MMP-9 or c-Met antagonists could further confirm the role of 
these targets in the aggressive behaviour arising as a consequence of faslodex 
resistance. Eventual translation of these 2D cell models into orthotopic mouse 
models will hopefully corroborate the existence of the invasion strategy proposed 
in this thesis in vivo.
Given that the aggressive behaviour displayed by FAS-R cells is driven by 
elevated c-Met signalling activity, c-Met may present a potential therapeutic 
target in such cancers. In direct contrast to the problematic development of MMP 
inhibitors, the advancement of selective and broad-spectrum c-Met and HGF/SF 
inhibitors has been a success, with several compounds showing promising 
activity in clinical trials (see table 1.5). For example, the humanised monovalent 
antagonistic anti-c-Met antibody, one-armed 5D5 (MetMAb, Genentech), was 
recently evaluated in Phase I clinical studies and found to be safe and well- 
tolerated (Salgia et al., 2008). Similarly, phase I dose escalation studies with the 
non-ATP-competitive highly selective c-Met TKI ARQ197 (ArQule) 
demonstrated the compound to be well-tolerated; moreover, no dose-limiting 
toxicity was observed (Garcia et al, 2007). Moreover, early clinical trials with 
the ATP-competitive c-Met TKI XL 184 (Exelixis) have indicated promising 
antitumour activity in the absence of toxicity with a >50% response rate and a 
1 0 0 % disease control rate in a study involving patients with medullary thyroid 
cancer (Salgia et al, 2007, Salgia et al, 2008).
This is an exciting development particularly in light of the findings presented 
herein, as follow-on in vivo studies further establishing the role of c-Met
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signalling in faslodex-resistant breast cancer will be able to directly avail 
themselves of these agents which were not available at the commencement of 
this project.
Having identified a role for c-Met signalling in FAS-R cells in vitro, it is now 
necessary to establish whether this mechanism of elevated c-Met activity 
following acquisition of faslodex resistance can be detected in clinical samples 
of patients having undergone long-term faslodex therapy, thus ascertaining it is 
also functional in vivo. At present, faslodex is still very much ‘the new kid on the 
block’; thus tumour biopsies of patients relapsed on faslodex are rare and current 
treatment regimes with faslodex only short-term. However, once the exact 
positioning of faslodex within the endocrine treatment sequence and an optimal 
dosing regime has been established, appropriate clinical samples should be more 
readily available. The outcome of such studies in the future is awaited with great 
interest.
Excitingly, recent data emerging from in-house studies has shown that elevated 
c-Met expression is witnessed as early as 2 days after exposure of WTMCF-7 
cells to faslodex (S. Hiscox and J.Gee, personal communication) suggesting that 
switching to c-Met signalling is an extremely early event occurring whilst cells 
are still in the drug-responsive phase. Studies must now be initiated to determine 
whether this observation is reflected in vivo. If recapitulated in the clinic, this 
would support the initiation of anti-invasive therapy with c-Met inhibitors right 
at the outset and in direct conjunction with commencement of faslodex therapy 
as opposed to later, after establishment of resistance to faslodex has already 
taken place.
Combined therapy of endocrine agents with signal transduction inhibitors (STIs) 
is an important concept in the clinical management of breast carcinoma, and is 
based on the observation that enhanced signal transduction pathways are one of 
the principal adaptive changes accounting for endocrine-resistant growth 
(Nicholson and Johnston, 2005).
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In vitro data by (Gee et al., 2003) indicated that combined therapy of tamoxifen 
with the EGFR TKI gefitinib provided greater anti-proliferative and pro- 
apoptotic effects than tamoxifen monotherapy, leading to the hypothesis that 
combined endocrine/TKI therapy would prove a more effective strategy than 
either monotherapy, crucially delaying the emergence of tamoxifen resistance 
arising from ER/EGFR cross-talk. Recently, several investigators have reported 
back from clinical trials investigating this hypothesis in vivo (Johnston et al.,
2009). Significantly, tamoxifen/gefitinib combination as first-line therapy in ER- 
positive patients was found to improve progression-free survival, confirming the 
observations made by Gee et al. (2003) at in vitro level and providing proof-of- 
concept. Should faslodex combined with c-Met inhibitors be shown to delay 
faslodex resistance development in WTMCF-7 cells in vitro in future studies, 
clinical trials should then be initiated to investigate whether these synergistic and 
additive effects are repeated in the clinic, potentially providing the rationale for 
combined faslodex and c-Met inhibitor treatment. As mentioned in section 
1.3.3.3, combinations of fulvestrant with small molecule inhibitors or 
monoclonal antibodies such as gefitinib or bevacizumab respectively are already 
showing promising results in phase II trials (Robertson, 2007) (see table 1.2), 
indicating the feasibility of such a combined approach.
Based on the role of MMP-9 activity in the c-Met-driven aggressive behaviour
of FAS-R cells, targeting of this particular facet of c-Met signalling may provide
additional anti-invasive effects in vitro. If such an approach should prove
effective in vitro, and if the same mechanism should be proven to be functional
in patients who progressed on faslodex, this eventually may indicate additional
treatment with a specific and highly selective MMP-9 inhibitor.
The observation that emergence of faslodex resistance was accompanied by c-
Met overexpression was of particular interest in view of the fact that c-Met
signalling has recently been implicated in acquired resistance to other cancer
therapeutics. Engelman et al. (2007; 2008) and Bean et al. (2007), for example,
reported that c-Met signalling was involved in the emergence of acquired
resistance to the EGFR TKIs gefitinib and erlotinib in non-small-cell lung cancer
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patients. Furthermore, Mueller et al (2008) demonstrated a role for combined c- 
Met/c-src signalling in acquired resistance to gefitinib in the breast cancer cell 
line SUM 229.
Most significantly, however, c-Met signalling was found to play a role in 
acquired resistance to the targeted agent trastuzumab (Herceptin™) in both 
Her2-overexpressing breast cancer cell lines and Her2-overexpressing tumours 
(Shattuck et al., 2008). This report provides a second example of the role of c- 
Met signalling in loss of response to therapy in breast cancer cell lines and is 
hence in accordance with the findings presented in this thesis. Analysis of a 
publicly available microarray dataset (http://caarraydb.nci.nih.gov/caarray/) 
revealed that c-Met receptor transcript levels were elevated in trastuzumab- 
resistant tumours. In a direct parallel to the observation of rapid c-Met 
upregulation in faslodex-naive WTMCF-7 cells after just 48h exposure to the 
drug, the Her-2 overexpressing breast cancer cell lines SKBR3 and BT474 
displayed a significant increase in c-Met protein expression within 48h of 
trastuzumab treatment (Shattuck et al., 2008). As becomes apparent from these 
studies, c-Met signalling is emerging as a generic ‘escape hatch" for cancer cells 
facing inhibition of their primary dominant signalling pathway, emphasising the 
value of c-Met as a therapeutic target in a wide range of malignancies and 
illustrating the great impact effective c-Met therapeutics will have on delay or 
even prevention of resistance if given upfront in combination with endocrine 
agents or STIs.
Whilst the accrual of the advantageous mutation, namely c-Met receptor 
overexpression, occurs specifically in the epithelial cancer cell, the ligand 
activating c-Met signalling is derived from the stromal compartment. HGF/SF 
production by the stroma in turn is stimulated through secretion of HGF/SF- 
inducers such as interleukin-1(3, basic fibroblast growth factor, platelet-derived 
growth factor, transforming growth factor-a and prostaglandin E2 by the 
epithelial cancer cells (Matsumoto and Nakamura, 2006). In a perfect example of
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tumour-host conspiracy, this paracrine signalling loop emphasises the 
importance of the tumour microenvironment and identifies the tumour stroma to 
be a key player in breast carcinoma progression and metastasis rather than an 
innocent bystander.
Although our FAS-R cell model in which HGF/SF was added exogenously 
yielded valuable data and made possible the initial discovery of c-Met signalling 
involvement in the invasive phenotype of these cells, such 2D monolayer 
cultures of epithelial cells are inadequate for assessing the role of the tumour 
stroma. Hiscox et al. (2006) addressed this issue by performing co-culture 
studies with HGF/SF-producing MRC5 fibroblasts further highlighting the 
contributory role of the stroma in the development of the aggressive FAS-R cell 
phenotype.
While co-culture models do permit the study of the cancer cell-stroma 
interaction they are only a very basic approximation of the in vivo scenario. 
Thus, although both monolayer and co-culture studies have afforded us 
considerable insight into the role of c-Met signalling, there is a clear need to 
develop more complex and physiologically relevant in vitro models that reflect 
the histological complexity of tumours to further investigate the contribution of 
c-Met signalling to the adverse phenotype of FAS-R cells.
The increasing recognition of the importance of microenvironmental control of 
tumour cell progression has led to the development of multicellular organotypic 
assays as a means of dissecting the role of epithelial-stromal cell cross-talk in 
breast carcinoma progression more accurately (Chioni and Grose, 2008, Holliday 
et al., 2009, Krause et al., 2008, Kenny et al., 2007, Lee et al., 2007, Kim et al.,
2004). Such 3D culture systems allow epithelial cells to organise into structures 
that mimic their in vivo tissue architecture and function and thus reflect the 
signal transduction and heterotypic cell interactions of the physiological tumour 
microenvironment (Weigelt and Bissell, 2008). Chioni and Grose (2008) 
describe an organotypic model in which the stromal component consists of a 
collagen:matrigel (70:30) matrix enriched with human fibroblasts cultured on a
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grid at the air-liquid interface. MDA-MB-231 breast carcinoma cells were then 
seeded onto this artificial stroma and left to invade for 9 days following which 
invasive capacity was assessed through Haematoxylin and Eosin staining of 
sections of the organotypic culture system.
Adoption of such a heterotypic 3D approach in which FAS-R cells are cultured 
on top of a collagen/matrigel matrix enriched with MRC5 fibroblasts would 
permit more accurate analysis of c-Met signalling in a physiologically 
representative context and consequently facilitate the generation of clinically 
relevant data.
In terms of additional therapeutic options the observation that faslodex-resistant 
breast cancer is not a tumour cell autonomous condition but rather a pathology 
involving a dynamic epithelial-stromal cell dialogue reinforces the increasingly 
popular concept of direct targeting of this interaction as a promising strategy in 
the endeavour to control metastatic progression (Aharinejad et al., 2009, Anton 
and Glod, 2009).
As the findings of this thesis demonstrate, ER status correlated inversely with c- 
Met receptor expression in WTMCF-7 and FAS-R cells. Interestingly, this 
inverse correlation has been reported for several other breast cancer cell lines 
(see table 6.2).
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Breast cancer cell 
line
MCF-7
T47D
ZR-75-1
SK-BR-3
FAS-R
MDA-MB-231
M DA-M B-435s
BT20
ER status
ER-positive
ER-negative
c-IMet status
c-Met-negative
c-Met-positive
Reference
Hiscox et al. (2006) 
Beviglia et al., 1997
Beviglia et al., 1997
Beviglia et al., 1997
Beviglia et al., 1997
Hiscox et al. (2006)
Beviglia et al., 1997 
Parr and J iang (2001)
Beviglia et al., 1997
Beviglia et al., 1997
Table 6.2 Inverse correlation o f ER and c-IMet status in breast cancer cell lines.
Whilst oestrogens stimulate breast cancer cell proliferation, the inhibitory effect 
o f oestrogen signalling on motility and invasion through suppression of 
transcription of pro-invasive genes ((Hiscox et al., 2007, Platet et al., 2004, 
Rochefort et al., 1998) and induction o f anti-invasive genes such as E-cadherin 
is well established. Taken together, this indicates that expression of the pro- 
invasive RTK c-Met may be negatively regulated by the ER in clinical samples. 
The relationship between c-Met and ER status was queried using the Oncomine 
clinical transcriptome database (http://www.oncomine.org) which provides 
publicly available data sets on cancer gene expression (Rhodes et al., 2004). 
Analysis of 7 separate data sets from the database using t-test confirmed that 
there was a significant inverse correlation between ER and c-Met mRNA 
expression in clinical breast cancer samples (J. Gee, personal communication; 
table 6.3).
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O ncom ine-reported study Size o f test population p-value
Wang et al., 2005 ER-ve: n = 77 ER+ve: n = 88 p<0.0001
Minn et al., 2005 ER-ve: n = 42 ER+ve: n = 57 p<0.0001
Bittner et al., 2005* ER-ve: n = 78 ER+ve: n =  154 p<0.0001
Chin et al., 2006 ER-ve: n = 43 ER+ve: n = 75 p<0.0001
Desmedt et al., 2007 ER-ve: n = 64 ER+ve: n =  134 p<0.0001
Saal et a l , 2007 ER-ve: n = 60 ER+ve: n = 45 p<0.0001
Finak et al., 2008 ER-ve: n = 10 ER+ve: n = 43 p<0.0001
Table 6.3 Results from O ncom ine database analysis revealing inverse correlation o f ER 
and c-M et mRNA status (J.G ee, personal com m unication).
* database link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109
An inverse correlation between ER status and c-Met mRNA expression was 
furthermore observed in a published study o f patients with invasive ductal 
carcinoma (Greenberg et al., 2003). Moreover, gene expression and tissue 
microarray analysis of human breast cancers revealed that high c-Met expression 
correlated significantly with ER/Her-2 negative tumours and the basal subtype 
(Graveel et al., 2009). These findings are o f considerable interest as they 
collectively suggest a role for c-Met as an important therapeutic target in ER- 
negative disease forms which are associated with aggressive disease, poor 
prognosis and highly limited treatment options. Based on the above 
observations, inhibition of c-Met signalling may be o f significant therapeutic 
benefit in de novo ER-negative disease (possibly including Triple Negative 
Breast Cancer) and in ER-negative disease arising as a consequence of 
progression on tamoxifen and eventually faslodex, potentially controlling disease 
progression and improving patient outlook. The observations arising from this 
thesis are of potentially o f considerable significance since all these disease states 
represent areas of unmet need with regards to targeted therapy strategies.
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6.2 Conclusion
The data presented herein demonstrate that development of faslodex resistance 
in vitro is accompanied by overexpression of c-Met, the activation of which 
augments the aggressive invasive phenotype of FAS-R cells by a mechanism 
likely to involve MMPs. If recapitulated in vivo, these observations would 
suggest the importance of c-Met as therapeutic target in faslodex-resistant 
disease.
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8 Appendix
8.1 Reverse Transcription and PCR -  Buffers and Solutions
8.1.1 lOx PCR buffer
Component Stock concentration For 20ml Final concentration
Tris-HCl 0.5M (ph 8.3) 4ml lOOmM
KC1 1M 10ml 500mM
MgCl2 1M 0.3ml 15mM
Gelatine 2% (w/v) 0.1ml 0.01% (w/v)
Pure H20  (Sigma) - 5.6ml -
8.1.2 50x Tris-Acetate-EDTA (TAE) Buffer
Component For 1L Final concentration
Tris (Base) 242g 2M
Glacial Acetic Acid 57.1ml 1M
EDTA (0.5m; pH 8.0) 100ml 0.05M
• Adjust pH to 8.3 and make up to 1L with distilled H2O.
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8.1.3 Sample Loading Buffer for Agarose Gel Electrophoresis
Component For 10ml Final concentration
Sucrose 6g 60% (w/v)
Bromophenol Blue 0.025g 0.25% (w/v)
• Make up to 10 ml with RNAse-free H2O.
8.2 SDS-PAGE and Western Blotting —Buffers and
Solutions
8.2.1 Cell Lysis Buffer
Component For 100ml Final concentration
Tris Base 0.6 lg 50mM
EGTA 0.19g 5mM
NaCl 0.87g 150mM
Triton X-l 00 1ml 1 % (v/v)
h2o 100ml -
• Adjust pH to 7.5 with HC1 (5M).
• Add protease and phosphatase inhibitors immediately before use.
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8.2.2 Phosphatase and Protease Inhibitors
Inhibitor Stock
concentration
Solvent
Volume added 
to 10ml cell 
lysis buffer
Final 
concentration in 
cell lysis buffer
Sodium
orthovanadate
lOOmM h2o 200pl 2mM
PMSF lOOmM Isopropanol lOOpl ImM
Sodium fluoride 2.5M h2o lOOpl 25mM
Sodium
molybdate
IM h2o lOOpl lOmM
Phenylarsine 20mM Chloroform lOpI 20pM
Leupeptin 5 mg/ml h2o 20|il 10 jig/ml
Aprotinin 2mg/ml h2o 40pl 8pg/ml
8.2.3 BSA Standard Curve for Bio-Rad Dc Protein Assay (50pl)
BSA concentration 
(mg/ml)
BSA (pi) 
(1.45mg/ml stock)
Cell lysis buffer (pi)
0.00 0.0 50.0
0.25 8.5 41.5
0.50 17.5 32.5
0.75 26.0 24.0
1.00 34.5 15.5
1.45 50.0 0.0
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8.2.4 SDS-PAGE Running Buffer
Component For 1L Final concentration
Tris base 3.03g 0.25M
Glycine 14.4g 1.92M
SDS lg 0.1% (w/v)
h2o 1L -
• Adjust pH to 8.3 with HC1 (5M).
8.2.5 Laemmli Sample Loading Buffer
Component 3 x Stock (10ml)
Final concentration
SDS 0.6g 2% (w/v)
Glycerol 3ml 10% (v/v)
Tris base 3.6ml (0.5M) 60mM
h2o Make up to 10ml -
Bromophenol Blue 0.03g 0.01% (w/v)
• Add 23.1 mg di-thiothreitol per ml 3x Laemmli sample loading buffer 
immediately prior to use.
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8.2.6 Western Blot Transfer Buffer
Component For 1L Final concentration
Tris base 3.03g 0.25M
Glycine 14.4g 1.92M
Methanol 200ml 20% (v/v)
h2o 800ml .
8.2.7 Tris-Buffered Saline (TBS)
Component For 1L Final concentration
Tris base 1.21g lOmM
NaCl 5.8g lOOmM
h2o 1L -
• Adjust to pH 7.6 with HC1 (5M).
8.2.8 TBS-Tween (TBS-T)
TBS (see section 8.2.7 above) containing 0.05% (v/v) Tween 20.
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8.3 Zymographv — Buffers and Solutions
8.3.1 Non-reducing sample loading buffer
Same composition as 3x Laemmli sample loading buffer (section 8.2.5) but 
without the addition of di-thiothreitol.
83.2 Activation buffer
Component For 1L Final concentration
Tris base 6g 50mM
Ca2Cl 1.48g lOmM
h2o 1L -
• Adjust to pH 7.6 with HC1 (5M).
833 Stain stock solution
• For a 0.2% stock solution 1 PhastBlue® tablet was dissolved in 80ml of 
distilled H2O and stirred.
• 120ml methanol was added and the solution filtered using Whatman
filter paper to remove undissolved stain particles.
83.4 Destain solution
• 1L destain solution consisted of 100ml glacial acetic acid, 300ml 
methanol and 600ml distilled H2O.
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8.4 Immunofluorescence microscopy -  Buffers and Solutions
8.4.1 Immunofluorescence buffer
PBS containing 1% (w/v) BSA.
8.4.2 Permeabilisation buffer
Immunofluorescence buffer (section 8.4.1) containing 0.2% (v/v) Triton X- 
100.
8.43. Block
Immunofluorescence buffer containing 10% (v/v) normal goat serum.
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8.5 Tabulated summary of PCR data shown in figure 4.15
The changes in expression levels of MMPs and TIMPs in WTMCF-7 and 
FAS-R cells following growth factor challenge shown in figure 4.15 have 
been summarised for each single gene below. Within each of the two cell 
types, expression levels following each treatment were compared to those of 
the control and accordingly categorised as “increased”, “decreased”, “no 
expression” or “no change”.
MMP-1 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased increased decreased increased
FAS-R decreased decreased , no increased increasedexpression
MMP-2
' TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased increased increased noexpression
FAS-R decreased increased decreased decreased decreased
MMP-9 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased increased decreased increased 
FAS-R increased increased increased decreased increased
D MMP-10 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased increased decreased increased
FAS-R noexpression no change increased decreased increased
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E MMP-11 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 decreased decreased decreased decreased decreased
FAS-R decreased decreased decreased decreased increased
F MMP-13 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 decreased decreased decreased decreased increased
FAS-R decreased decreased decreased decreased decreased
G TIMP-1 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased increased increased increased
FAS-R increased increased increased decreased increased
H TIMP-2 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 decreased increased decreased decreased decreased
FAS-R increased increased no change decreased increased
I TIMP-3 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 decreased increased increased decreased decreased
FAS-R decreased decreased decreased decreased decreased
J TIMP-4 TGF-a EGF HGF/SF IGF-II TPA
WTMCF-7 increased increased decreased increased increased
FAS-R increased increased increased increased increased
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